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Chapter 1.1 
I.1 Introduction 
During life the body is challenged by a wide variety of infectious agents. To combat 
and constrain infections with these agents the immune system uses a complex 
network of defence mechanisms. One of these is the ability to respond in a specific 
way (adaptive innnunity) to unique stmctures (antigens) of the agent or its products. 
Interestingly, many agents have developed ways to escape from, or suppress specific 
and non-specific inu11une effector mechanisms. The principle of vaccination, which 
was introduced more than 200 years ago by Edward Jenner (Willis, 1997), utilizes the 
ability of the immune system to develop a specific inu11une and/or memOlY response, 
before the body is exposed to the pathogen, thereby mimicking specific immunity 
induced by infection. 
The immune system 
For the inU11ediate response against many pathogens which enter the body, the ilmate 
immune response is of utmost imp0l1ance (cfBrown et aI., 1994). 
Innate imlllunity can be divided into three major functions: barrier, humoral and 
cellular functions. 
Barrier jilllcliollS include: surface epithelia (divided in: mechanical, chemical and 
microbiologically active barriers), macrophages circulating in blood and lymph, 
filtering and removing non-self particulate matter, natural polyclonal IgA (in external 
body fluids and at mucosal surfaces) to bind to invading pathogens, and massive 
storage of cytokine molecules in the skin released upon contact with penetrating 
substances. 
HUllloral jilllCliolls include: the altemative pathway of complement activation in the 
blood which functions without the interference of antibodies; acute phase proteins in 
the liver; chemoattractants and certain Cy10kines like interferons, interleukins and 
TNF-a. 
Cellular jilllcliollS include: macrophages, dendritic cells, neutrophils, NK cells which 
kill cells harbouring intracellular pathogens and tumor cells, CD5+ B-cells producing 
antibodies to conn11on bacterial products (mainly IgM, T-cell independent, no class 
switching or somatic hypen11utation (Carroll and Prodeus, 1998)), yo-T-cells found in 
mucosal surface epithelia probably recognising alterations in the (infected) epithelium, 
and direct activation of T -cells by certain cell surface molecules for which the ligands 
are not known (Dohel1y et aI., 1992; Welsh et aI., 1997). 
It should be noted that although most of these innate functions are considered non 
specific, they may increase substantially when effector cells of the specific inmume 
sytem are stimulated. In conclusion, numerous cells and factors which are primarily 
involved in adaptive responses can also playa role in ilmate immunity (Skoner et aI., 
1996; Medzhitov and Janeway, 1997). Innate immunity works almost immediately, 
upon contact with what is perceived to be "non-self'. It does not utilize and hence can 
not be influenced by active immunization. However knowledge of this system is 
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particularly imp0l1ant because it may directly influence the outcome of vaccination 
since certain adjuvants may influence the complex interaction between antigen, 
effectors of the specific immune system, and effectors of the iImate immune system 
(Chin and San Gil, 1998). For example antigen processing and presentation is largely 
mediated by cells of the innate innnune system and also localized specific immune 
effector mechanisms take advantage of components of the innate immune system (van 
Rooijen and Sanders, 1997). 
The major characteristics of adaptive immunity are the specific recognition of the 
pathogen, the induction and persistence of memory and the clonal selection of 
monospecific effector lymphocytes (for review see Han et a!., 1997). Furthennore, 
adaptive immunity involves affinity maturation (Rajewsky, 1996) and by definition 
takes longer to develop than innate immunity. Typically, a primaty response will take 
days to weeks to reach its peak, whereas the emergence of a secondaty or memOlY 
response is a matter of days. This branch of the immune system is divided into two 
anns, the humoral and the cellular pat1 between which a close interaction exists. 
The humoral response relies on the production of antibodies by plasma cells derived 
from (differentiated) B-cells. The Fab (fragment antigen binding) pat1 of antibodies 
recognises conformational and linear determinants (B-cell epitopes) of microorganisms 
and vimses. Depending on the immunoglobulin isotype (IgAl,2,D,E,G 1-4,M) 
antibodies can trigger a vast number of effector mechanisms designated to inactivate, 
neutralize andlor remove the microorganism and its products. It should be noted that 
major differences between the presence, properties and effector functions of different 
isotypes exist between different animal species, including man. 
When antibodies bind to antigens their "tail" (Fc part) undergoes confol1national 
changes. Furthennore, binding involves aggregation of antibodies on the pathogen. 
These two phenomena result in recognition of bound (and not free) antibody by 
specific Fc-receptors, with distinct receptors for several effector mechanisms. Effector 
mechanisms thus triggered include: inhibition of infectivity and neutralisation of toxins 
(high affinity IgM, IgG, IgA) opsonisation and enhanced phagocytosis (IgG, IgA), 
release of bactericidal agents by phagocytes (IgG 1,2), classical pathway complement 
activation (IgM, IgG 1,2,3, IgA), antibody dependent cellular cytotoxicity (ADCC, 
IgGl,3), NK activation (IgGl,3), sensitisation of neutrophils (IgG), mast 
cellslbasophils (IgE) and eosinophils (IgG, IgE). A given pathogen (or fragment 
thereof) can be recognised by several antibodies of different specificities and this 
cross-linking will fOl1n a network called an inununecomplex. Immunecomplexes can 
be easily removed from blood and lymph by liver, spleen, kidney and lymph nodes, 
thereby speeding up the elimination process. Furthermore, innnunecomplexes are 
trapped on follicular cells of spleen and lymph nodes which results in the induction and 
persistence of memory which is known to be antigen dependent (van den Eertwegh et 
a!., 1992; Ridge et a!., 1998). It should be noted that antibody binding may also have 
major effects on the conformation of the antigen. This may be an intrinsic part of the 
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mechanism that leads to neutralization but in certain cases also to antibody mediated 
enhancement of infectivity (Siebelink et aI., 1995; Schutten et aI., 1994; Huisman et 
aI., 1998). Such mechanisms have been shown to play an important role in anti-viral 
immunity . 
In cellular responses, T-cells (mainly those of the CD4+ phenotype) play an 
important role in regulating overall B- and T-cell functions. For instance they trigger 
B-cells to produce antibodies through a cognate interaction involving antigen, class II 
MHC and CD40-CD40 ligand (Janeway et aI., 1994; Laman et aI., 1996). Activated 
T-cells (usually those of the CD8+ phenotype) can also be directly involved in the 
elimination of cells infected with intracellular microorganisms. This cellular response 
depends on direct interactions between cytotoxic T-cells (CTL) and cells of the host 
bearing the antigen they recognise. For both pathways it is essential that small peptides 
are liberated, by correct processing in antigen presenting cells, from the target 
substance. The induction of CTL responses requires that the antigens are processed and 
that the resulting peptides (usually 9-mers) are routed via the cytoplasm and associate 
with class I molecules (Bjorkman et aI., 1987; Neefjes and Ploegh, 1992; Yewdell and 
Bennink, 1992; Zhang et aI., 1992). These MHC -peptide complexes are then 
expressed on the surface of the cells where they are recognized by cytotoxic T-cells 
(Townsend et aI., 1986). Live viral vaccines or infection induce good CTL responses 
because synthesis of antigens takes place intracellularly. Inactivated vaccines are 
processed via the the endogenous processing pathway. Although most cells express 
MHC class I, professional antigen presenting cells and most likely dendritic cells are 
involved in the induction ofCTL (Macatonia et aI., 1989). 
In recent years it has become clear that many of the activities of both CD4+ and CD8+ 
T -cells are related to their cytokine profile which allows a division into e.g. Th I versus 
Th2 type responses (Audibert and Lise, 1993; Seder and Paul, 1994; Wood and Seow, 
1996; Mosman and Sad, 1996; Constant and Bottomly, 1997). In mice Thl type 
responses are related to the expression of interleukin-2 (IL-2), interferon-y (IFN-y) 
and lymphotoxin (LT). Th2 type responses are characterised by the expression of IL-4, 
IL-5, IL-6, IL-9, IL-IO and IL-13. Human T-cell subsets produce similar pattems but 
the expression of particular lymphokines like IL-2, IL-5, IL-6, IL-IO and IL-13 is not 
as restricted as it is in mouse T-cells. 
The expression of the lymphokines cOlTelates well with the functions of the individual 
subsets in that Th I are mainly involved in cell mediated inflammatOlY reactions, 
cytotoxicity and DTH reactions. Th2 on the other hand tends to be more involved in 
providing help in antibody responses. Th2 lymphokine profiles are typical for strong 
antibody responses and allergic reactions. Some of the lymphokines that are produced 
by either Thl or Th2 are inhibitOlY for the reciprocal subset. Thl and Th2 originate 
fi'om a single precursor cell that initially produces mainly IL-2 after stimulation with 
antigen but later differentiates in either Thl or Th2 cells. However, depending on the 
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pathogen/antigen studied the effects of individual Th subsets may greatly vary. For 
instance Thl subsets can protect against disease in some situations (Lehmann and 
Alber, 1998; Sjolander et aI., 1998) but actually ameliorate pathology in others (Lucey 
et aI., 1996). At the same time it is well known that Th2 cures disease in most 
helminthic and some viral infections whereas it exacerbates in others (Mossman, 
1996). Therefore it can be assumed, and is generally accepted, that other factors, 
characteristic for the pathogen or dose studied, are also of importance in deciding the 
outcome of both infection and vaccination. In this thesis a comparison between two 
different vaccine modalities is made and in view of the contradictory results (and 
minimal predictive value) described in the studies referenced above, only minimal 
attention is paid to the role of cytokine profiles after inm1Unization and adjuvation 
(Audibett and Lise, 1993). 
Anti-viral immunity 
Specific protection against vimses can be mediated both by antibodies and by CTL 
responses. Antibodies that are generated either in response to infection or after 
immunization can neutralize the virus in several ways. A possible mechanism of vims 
neutralization is the direct blocking of the virus/receptor interaction ( i.e. CD4 binding 
in the case of HIV). Confornlational changes in the antigen can occur due to binding of 
the antibody that changes the target antigen to a non-functional fonn. Antibodies may 
also interfere with post enlly events that prevent multiplication or spreading of the 
vims. Another mechanism by which antibodies help to clear infection is antibody 
mediated cellular cytotoxicity (ADCC). It has been shown ill vitro that virus specific 
antibodies induced by immunization can also enhance infection thus leading to a more 
rapid development of disease instead of protection (Robinson et al.,1989; Siebelink et 
aI., 1995). The same antibodies can be neutralizing or enhancing infectivity depending 
on the phenotype of the vims involved (Schutten et aI., 1994). These enhancing 
antibodies can be a major concern in efficient vaccine development. 
Furthennore maternal antibodies present at the time of infection or immunization may 
interfere with the outcome of vaccination and disease. It has been demonstrated that 
innnunization with live vaccinia virus in the presence of maternal antibodies did not 
interfere with the induction of anti vaccinia virns immunity (Fetmer et aI., 1989). 
Proteins that are expressed in vaccinia vitus however induce lower responses in the 
presence of maternal or passively acquired antibodies as was shown for measles and 
RSV proteins (Murphy et aI., 1988; van BitU1endijk et aI., 1997; Osterhaus et aI., 
1998). In a study in macaques it was shown that passively transfened antibodies 
suppressed both humoral and cellular measles specific inullune responses after 
immunization with attenuated vims or recombinant vaccinia vims expressing F and H 
proteins. An experimental isc011l vaccine containing Hand F proteins was not 
influenced by preexisting measles vims specific antibodies (van Binnendijk et aI., 
1997; Osterhaus et aI., 1998). 
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Because viruses replicate intracellularly cytotoxic CD4/CD8 T-cells are considered 
important for the protection against some viral pathogens. 
Vaccines that aim at protection against viral disease should therefore preferably be able 
to generate specific CTL responses. It has been speculated that the absence of a 
functional T-cell response to measles virus after inununization with an inactivated 
vaccine is responsible for atypical measles syndrome (UytdeHaag et aI., 1994). 
Anti-bacterial immunity 
Protective immune responses against extracellullar bacteria are usually controlled by 
antibodies which may act via several mechanisms. Antibodies can bind to bacterial cell 
surface antigens or toxins and can block attaclunent receptors on host surfaces. A 
second mechanism, termed opsonization, acts via enhancement of phagocytosis by 
macrophages and neutrophils. After ingestion these bacteria are destroyed. Antibodies 
can also kill bacteria directly or indirectly by activating complement. Surface antigens 
are usually the target of these antibodies, except iu the case of toxins. Bacterial 
capsular polysaccharides are weakly immunogenic and can effectively protect bacteria 
by shielding more immunogenic surface structures. The chemical structure of 
polysaccharides has an impact on the virulence of encapsulated bacteria, i.e. some 
polysaccharides make bacteria more virulent than others. This probably relates to the 
interaction with complement, i.e. CPS containing sialic acid (Carroll, 1998). 
To combat infections with intracellular bacteria antibodies are less effective. Once the 
bacterium has invaded cells a specific CTL response is required to kill these cells and 
the bacteria they contain. Another mechanism by which intracellular bacteria can be 
removed is by the production of cytokines that either downregulate bacterial 
replication or enhances the ability of phagocytosing cells to kill ingested bacteria. In 
this thesis, where a meningococcal vaccine candidate is studied, only the fonnation of 
protein specific antibodies that are able to lyse bacteria in the presence of complement 
is studied. This is considered an important mechanism in the development of 
protection against meningococcal disease (for review see Hart and Rogers, 1993). 
Vaccines against infectious diseases 
Since the introduction of the principle of vaccination about 200 years ago by Edward 
Jemler, the use of vaccines against many infectious diseases has led to their control in 
the developed world. Vaccination is amongst the most cost effective ways to control 
infectious diseases. The most striking example is the eradication of smallpox from the 
world, by the end of the seventies, with a vaccination approach that was originally 
introduced by Jenner. Similarly it may be expected that by the year 2000 poliomyelitis 
will effectively be eradicated (Tangennann et aI., 1997) and possibly also measles by 
the year 2010. These tremendous successes have sofar all been achieved with classical 
live attenuated vaccines. 
With the advent of modem immunological and molecular biological techniques other 
principles of vaccination have been developed over the last decades. These include 
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subunit vaccines which make use of only those parts of the infectious agent which 
catTy the B- and T-cell epitopes of the pathogen, relevant for the induction of the 
desired immune response. Those subunits may be purified directly from the agent or 
alternatively be produced by recombinant DNA techniques or peptide synthesis. The 
first registered vaccine for human use, based on one of these principles is the subunit 
hepatitis B vaccine produced in yeast (Hilleman et a!., 1987). Alternatively vectors, 
including viruses and bacteria which express the heterologous subunit antigen can also 
be used to present these antigenic moieties to the immune system (e.g. pOX-, adeno-, 
and herpesviruses, Salmollella spp., MycobacteriulII spp.). It has also been suggested 
that components of the host immune system itself -anti idiotypic or anti clonotypic 
structures- could be exploited as sUITogate antigens, a concept which is based on the 
idiotype network interactions originally described by Jerne (Ierne, 1974). Sofar this 
approach has not led to any practical vaccine candidates. 
Recently a novel approach was introduced exploiting the direct use of nucleic acids , 
encoding the antigen of interest. Generally for vaccines not based on the principle of 
active replication, adjuvants or adjuvant systems are required in order to obtain an 
adequate immune response (Jennings et a!., 1998; Allison, 1997; Audibert and Lise, 
1993; Gupta et a!., 1995). 
In deciding which of the approaches to select for the development or use of a vaccine 
for a particular infectious disease, not only technical feasabilities but also the minimal 
requirements for the induction of protective immunity should be considered. It is 
interesting to note that for some of the infectious diseases for which vaccines are not 
available but most urgently needed today, like AIDS, malaria and tuberculosis, 
cotTelates of protective immunity and immune pathogenesis are still largely unknown. 
General criteria of the "ideal vaccine" against all infectious diseases are therefore 
hard to define. However it may still be stated that the "ideal vaccine" should generally 
meet the following requirements: it should induce a long lasting antibody response 
involving antibodies with the appropriate biological activities. It should induce long 
lasting T-cell responses involving cells with the appropriate phenotypes and effector 
functions. Preferably these antibody and T-cell responses and/or the cotTesponding 
memory responses should also be induced in the presence of pre-existing or matemal 
antibodies. Another important aspect is that for certain pathogens not only systemic 
immunity but also, or rather an effective immunity at the site of entry is required. 
Therefore the induction of mucosal immunity may be a major issue (McGhee et a!., 
1993). Collectively the induced immune responses should lead to a long lasting 
protection against all the antigenic variants of the infectious agent. FurthelTllore, 
production procedures should allow large scale cost effective production, under GMP 
conditions, of a product stable for prolonged periods of storage and transport that can 
be produced at a reasonable price. Finally it should be realized that apart from efficacy 
criteria the most important requirement for a vaccine is its overall safety. 
18 
Chapter I.l 
Routes of administration 
Usually vaccines are injected intramuscularly or subcutaneously to induce a systemic 
immune response. After immunization via this route antigens are taken up by antigen 
presenting cells and these cells migrate to draining lymph nodes and spleen where 
immune responses develop. This route of administration of vaccines is well accepted 
and most studies involving adjuvant research, study this type of administration. Many 
pathogens however enter the host via mucosal surfaces that are in direct contact with 
the extemal environment. Protection against infection with these pathogens should 
therefore preferably occur at these mucosal surfaces, and induction of a mucosal 
immune response should therefore, in some cases, be a target of vaccine development 
(McGhee et aI., 1992 and 1993). The iImnune' response at the mucosal sites takes 
place in a system that is generally termed mucosa associated lymphoid tissue (MALT). 
Protective immune responses against pathogens that invade the upper respiratory tract 
will have to develop in the nasal associated lymphoid tissue (NAL T) and the bronchus 
associated lymphoid tissue (BALT). In close proximity with the intestinal mucosa lies 
the gut associated lymphoid tissue (GALT). Immune responses in the GALT and the 
NALT are initiated by uptake and transcytosis of antigen from the extemal 
environment by M-cells. These M-cells transport antigen to the underlying area where 
macrophages , dendritic cells, B-cells and T-cells can be found. Secretory IgA (sIgA) 
is an important humoral defence mechanism at mucosal surfaces (Lamm, 1997). This 
dimer of IgA is secreted by IgA specific plasma cells and is actively transported to 
external secretions. Cellular responses can also develop in the MALT. Dendritic cells 
(DC) are also important for antigen sampling at mucosal surfaces. In the respiratory 
tract, a submucosal network of DC's functions as a surveillance system to monitor 
inhaled antigens , and cross regulation takes place between DC's, alveolar 
macrophages and T -cells. 
Ample research has been focussed on developing vaccines that can be easily 
administered. Targeting of antigens to the MALT requires special adjuvants or 
formulations. Cholera toxin (CT) and its B subunit (CTB) are widely studied as 
adjuvants to enhance mucosal inunune responses. Mucosal adjuvants should facilitate 
antigen/receptor interaction to target antigens to immune cells in the gut. To generate 
local inunune responses in the gut, live (replicating) vaccine formulations that can be 
administered orally are ideal (e.g. oral polio vaccine). Live vectors have been used to 
express foreign antigens to induce immune responses against these antigens. 
For large scale ilmnunization a technique which employs needle-less jet guns may be 
useful (Foul11ier, 1973; Mathei et aI., 1997; Parent du Chatelet et aI., 1997). These so 
called jet guns inject vaccines subcutaneollsly by a thin, high pressure nozzle which 
can be resterilised at the end of each section. Since no needle is involved that 
penetrates the skin the risks of viral transmission from one recipient to the other are 
much lower but not absent (Brink et aI., 1986). These jet guns have several advantages 
over classical syringes with needles like; absence of risk of accidental puncture; 
possibility to inununize large groups of people rapidly since less manipulation is 
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required. Side effects are slightly higher than those observed with conventional 
techniques. When delivered by jet gun, vaccines were of equivalent or superior 
inmmnogenicity, as compared to the syringe technique (Mathei et aI., 1997). 
Adjuvants and adjuvant systems 
Vaccines based on inactivated pathogens or subunit vaccines generally induce poor 
immune responses inactivated and subunit vaccines are considered to be much safer 
than attenuated vaccines since they contain no infectious agent at all. Limitations of 
these vaccines are that they generally induce lower immune responses than those 
following natural infections or vaccination with attenuated vaccines. There are a 
number of variables which detennine the outcome of immunization like: dose, nature 
of the antigen, immunization schedule, route of administration, immune status of the 
host and the choice of adjuvant that is used. 
An adjuvant is, by definition, a substance which, when given in combination with the 
antigen of interest, leads to a better immunity. However the effects of individual 
adjuvants may differ largely. The most important of these effects are as listed below: 
1) Antigen dose may be lowered to get the same level of immunity/protection. This can 
be an advantage when antigen is a limiting factor for vaccine production. It is of 
economical interest when antigen is relatively expensive as compared with the 
adjuvant. 
2) Maximal level of immullity (plateau) will be higher when the same amount of 
antigen is used. A higher maximal level of inununity is for instance an advantage in 
cases where the antigen alone is not protective, even at high doses, but where the 
combination with an adjuvant leads to protective levels of immunity. 
3) Time to reach a protective level of immunity can be shorter (but also longer) when 
an adjuvant is used. 
4) Number of immunizatiolls can be reduced to reach the same level of immunity. 
5) Duratioll of immunity can be prolonged when an adjuvant is used. Immunity levels 
tend to drop over time, even to a level where they are no longer protective. Booster 
immunizations can be required after some time to maintain a protective level of 
immunity. The use of an adjuvant has advantages if less booster immunizations are 
required. 
6) Nature of immullity can be changed. Adjuvants may change the nature of inunune 
responses. Inactivated antigens are generally poor inducers of cellular immunity but in 
combination with celtain adjuvants this can be overcome. Moreover, adjuvants can 
influence the balance between Thl and Th2 responses and can thus be used to control 
the desired type of inununity. To achieve this goal an extensive knowledge of the 
mechanisms by which adjuvants work is necessalY. 
7) More potent induction of mel/WI)' the induction of protective immunity by 
vaccination in most cases primarily depends on an adequate response at B- and T-cell 
levels after infection. Consequently moieties that enhance the induction of such 
memOlY responses will increase protective immunity of vaccines and therefore may 
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also be considered to be adjuvants. 
Few adjuvants have all of the above mentioned effects, and the effects are largely 
dependent on the mechanisms by which they influence the immune system (for review 
see Cox and Coulter, 1997). 
Adjuvants are a heterogeneous group of compounds or mixtures of compounds. Until 
now approximately 100 different substances have been identified as adjuvants. A 
compendium giving an extensive overview of adjuvants that are cUlTently available on 
the market has been recently published (Vogel and Powell, 1995). Since most 
adjuvants induce considerable side effects, not all substances can be readily applied in 
vaccines (Gupta et aI., 1993). 
As mentioned above different mechanisms play a role in the adjuvanticity of this 
heterogenous group of compounds (for review see Gupta and Siber, 1995; Gupta et aI., 
1993; Cox and Coulter, 1997). These mechanisms are listed below together with 
examples of adjuvants that can be grouped in this way. 
1) Depot forlllation at the site of injection results in the sustained release of the antigen, 
a mechanism that exposes the immune system to the antigen for a prolonged period of 
time. Mineral compounds (e.g. alum), oil based adjuvants (Freund's complete and 
incomplete adjuvant (FCA and IFA», liposomes and biodegradable polymer 
microspheres >IO~lm (so called slow release particles) all result in depot fonnation. 
2) Targeting of antigens to cells involved in the immune system like, antigen 
presenting cells, B- or T-cells. Examples of these are liposomes, oil based adjuvants, 
small «lO~nn), and non ionic block polymer surfactants. Small particles presenting 
antigens are favoured because they may interact easily with the cells of the immune 
system. 
3) /lIIlIIlInostillllliators 01' illllllllnolllodliiators which influence immune cells to secrete 
specific cytokines as a result of which certain effector mechanisms are influenced. 
Compounds that act via this mechanism are FCA, muramyl dipeptide (MDP), 
lipopolysaccharide (LPS), monophosphoryl lipid-A (MPLA), saponins (e.g. Quil-A , 
QS-21), Pertussis toxin (PT) and cytokines. For this thesis LPS and Quil-A will be 
further addressed. 
4)Vehic/e effect which protects the antigen against degradation. 
5) Aggregation of antigens certain modifications of antigens may also lead to enhanced 
immunogenicity. Aggregation of antigens generally results in an increase of their 
immunogenicity larger particle antigens are more efficiently recognized by the immune 
system, easier than soluble proteins (e.g. liposomes). 
Most of the above mentioned mechanisms have been observed for iscom and OMV, 
immunogenic presentation in the framework of this thesis (see below). 
Cytokines by themselves represent another type of adjuvant which acts by modulating 
the innnune system directly. Several researchers have demonstrated that the addition of 
cytokines to antigens is beneficial for the generation of a protective immune response 
(for review see Dong et aI., 1995; chapter II.6 this thesis). Factors complicating the use 
of cytokines as generally applicable adjuvants are species specificity and the fact that 
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the cytokines have to be delivered to the appropriate cell at the right time. Moreover, 
most cytokines exert more than one effect on different cell subsets, both up and down 
regulating the immune response involved. 
Sofar the only registered adjuvant for human application are aluminum salts. LPS 
which has adjuvant activities is intrinsically present in inactivated bacterial vaccines 
derived from gram negative bacteria and thus, although it is not registered as an 
adjuvant, it may playa role in such vaccines. Other adjuvants (QS-21, MPL, iscom) 
are tested in clinical trials but most of them are not considered safe enough for use in 
human vaccines. When adjuvants or adjuvant systems are considered for use in human 
vaccines the adjuvated vaccine should in principle approach the ideal vaccine. 
characteristics iscom OMV 
size 30·40 run 10-150 urn 
structure rigid cage like structure lipid bilayer 
adjuvant Quil-A LPS 
number of antigen minimal 3 required for induction several hunderd copies per 
copies per particle of inunune response particle 
confomlation of as in membraneous environment as in outer membrane of 
antigen bacteria 
viral antigens + -
bacterial antigens + + 
parasite antigens + -
peptide antigens + + 
lipid composition cholesterollPEIPC as in outer membrane of 
bacteria 
toxicity mild haemolytic effect mild pyrogenicity due to 
presence of LPS 
table 1: characteristics of the iscom alld 01\IV anligen presenting structures. +,' tested alld 
immulJogenic. -,' lIot tested 
The adjuvant systems described in this thesis, iscom and bacterial outer membrane 
vesicles (OMY), combine several mechanisms to enhance the itmnunogenicity of the 
incorporated antigens. Both iscom and OMY contain multiple copies of (protein) 
antigens. Iscom contain Quil-A derived glycosides (triterpenoids) as a built-in adjuvant 
in the same particle as the antigen. OMY possesses intrinsic adjuvant activity due to 
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the presence of bacterial LPS. Iscom ( ,,40nm) and OMY (,,10-100 nm) are 
comparable in size. Some of the main characteristics of iscom and OMY are 
summarized in table 1. 
Adjuvant activity of Quil-A 
Quil-A is a crude extract from the bark of Quillaja sapollaria Molilla which shows a 
potent adjuvant activity and is widely used as an adjuvant in veterinary vaccines, 
particularly against foot-and mouth-disease. The adjuvant activity is due to the 
presence ofa mixture oftriterpene glycosides (Dalsgaard, 1978). The structure of Quil-
A saponins has been further characterized and typical structures found in the mixture 
are given in figure I (Higushi et aI., 1987; van Setten et aI., 1995; Kensil et aI., 1995). 
Glucuronic 
Xylose acid 
~o 00: 011 110 0 
"€1 
011 
Galactose 
QuilfaiC acid 
ct#'~ 0 vr-0{ 
II HO H 
011 011 all 
110 011 Xyfose Rhamnose 
Ap!ose 
Fatly acyl uni/s 
011 (3.S.dlflydfoxy.6.melhy!. 
octanoic acid) 
~001l , , . , 
IIJ!:! 
011 
Arabinose 
figure J: Structure ofQS~21. This structure is representative for the triterpene glycoside structure that 
call be found ill the QllilA saponin mixture. The aglycon structure, the eenlral Quillaic acid, is 
glycosylated at positions 3 and 28. The structUJ'e is amphipathic due to the presence of the 
hydrophobic domaills (tl'ilerpelles and fatty acids) alld hydrophilic domains (glycosides). (taken from 
Kel/sil el al., /995) 
Quil-A is palt of the iscom structure and it is generally accepted that Quil-A is 
responsible for the observed adjuvant activity of iscom (Morein et aI., 1984; 
Rimmelzwaan and Osterhaus, 1995; this thesis). 
Quil-A saponins are amphipathic molecules due to the presence of hydrophobic 
domains (triterpene and fatty acids) and hydrophilic domains (glycosides). The 
structure of QS-21, a fraction of Quil-A saponins with high adjuvant activity is given 
in figure I. Crude Quil-A is relatively toxic, probably due to its haemolytic activity. It 
forms micelles in PBS (Morein et aI., 1984; Kersten et aI., 1991) and it is not known 
whether the immuno- active fOllll of Quil-A is monomeric or multimeric. Quil-A 
saponins have been purified to identifY the components that are relevant for adjuvant 
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activity and to separate toxic and innnunostimulating components. Kersten et al. 
(1991) showed by HPLC analysis that crude Quil-A is composed of 24 peaks which 
was later confirmed by Kensil et al. (1991). Individual purified saponins were shown 
to possess different levels of adjuvant activity and iscom fOinling propeliies. A 
fraction tenned QS-21 was isolated that combined potent adjuvant activity, low 
toxicity and availability in relatively high amounts (Kensil et aI., 1995). Many studies 
have been perfOl1lled with QS-21 which enhances both humoral and cellular immune 
responses. The induction of class I restricted CTL against protein antigens is claimed 
using QS-21 as an adjuvant (Newman et aI., 1992; Shirai et aI., 1994). QS-21 has been 
tested in phase I studies. 
In a separate study Quil-A was purified in cl1lde fractions (Behboudi et aI., 1995). This 
preparation could be used for the preparation of functional iscoms and opens 
perspectives for a safer iscom vaccine. 
Adjuvant activity of LPS and LPS derivatives 
The bacterial LPS is a component of the bacterial outer membrane. Moreover, LPS is a 
stl1lctural component of the OMV and, although it is considered a toxic molecule, it is 
at the same time being studied as a possible vaccine adjuvant (Jollllson et aI., 1956). 
The structure of meningococcal LPS is given in figure 2. 
The early findings that the addition of whole cell pertussis vaccine or other gram 
negative bacteria to tetanus or diphtheria toxoid increased immunogenicity of these 
vaccines led to the conclusion that these bacteria possessed adjuvant characteristics. 
The responsible factor for this appeared to be the bacterial LPS which also proved to 
be responsible for the endotoxin activity of bacterial vaccines. Initially LPS-protein 
complexes were held responsible for the adjuvant activity but the nitrogen content 
could be reduced to as low as 0.6 % without loss of adjuvant activity, indicating that 
the protein was not essential for adjuvanticity. Both humoral and cell mediated 
immunity could be elevated markedly by LPS. Chemical modification of Salmollella 
millllesota R595 LPS results in a fOl1ll which contains only one phosphate group, and 
which lacks the sugar chains, the so-called monophosphoryllipid-A (MPLA) (Ribi et 
aI., 1986; cfUlrich and Myers, 1995). MPLA still possesses adjuvant activity but much 
lower toxicity. 
Some bacterial strains, Neisseriae among others, shed vesicular stl1lctures of their 
outer membrane, so called blebs (10-1 OOmn). The biological function of these blebs is 
unknown but it has been speculated that the bacteria use these blebs to fool the 
immune system. Blebs may bind antibodies and complement and in this way some of 
the invading pathogenic bacteria can possibly survive in a hostile environment. These 
blebs contain antigens and LPS that are nonnally present in the outer membrane of the 
bacterium and that could function as a target for protective antibodies. Blebbing can be 
promoted by the addition of deoxycholate (DOC) which results in the massive 
fonnation of OMV and at the same time in the complete inactivation of the bacterium. 
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Outer core Inner core 
HOOC \ p-=t 
o-\::) 
o COOH 
Lipid A 
figure 2: Structure of meningococcal lipopolysaccharide of the L3,7 immllllotype. Fatty acids attached 
to the lipid A part are inserted ill the bacterial outer membrane. The illller core region cOlltaills the 
saccharides L-glycerero-D-mamlO-heptose (Hep 1) alld 2-keto-3-deoxy-D-mmmo-octulosollic acid 
(KDO). The outer core cOllsists of a lacto-N-tetraose unit and a phosphethallo!amine containing 
group. (with permission taken from: T cell recognition of Neisseria mel1illgitidis outer membrane 
proteins (1993) E. IViertz, thesis, Utrecht) 
The LPS content is reduced during down stream processing to a level where residual 
side effects are minimal. This approach is used to develop vaccines based on outer 
membrane protein antigens. 
OMV are probably less suited for the presentation of most viral antigens but they are 
very interesting candidates for the presentation of bacterial antigens. The formation of 
vesicles containing bacterial outer membrane antigens (proteins and LPS) occurs 
spontaneously in some gram negative bacteria. Also the fonnation of large amount of 
OMV can be stimulated by the extraction of bacteria with a detergent, deoxycholate 
which may be beneficial for large scale production of OMY. Experimental vaccines 
described in this thesis are designed to induce responses against outer membrane 
proteins (OMP), that are known to induce bactericidal antibodies, which play an 
important role in the protection against infection and development of disease. 
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The iscom structure as an immune-enhancing moiety: 
experience with viral systems 
I. Claassen (1)(2) and A. Osterhaus (I) 
(I) Laboratory of ImmllIlObiology, and 
(}) Laboratory of COlltrol of Biological Products, Natiol/al lllstitllle of Public Health 
and Em'irOllmelltal Protection, POB I, 3720 BA Bitthoven (The Netherlallds) 
The iscom as an antigen-prcsenling slruclure 
Extensive studies on fundamental mechanisms of 
protection induced by vaccination have led to insight 
into the components necessary for the ind.uction of 
protective immunity. This has enabled vaccine 
researchers to focus on those components which are 
involved in the actual induction of immune responses 
and to exclude irrelevant, immunosuppressive or 
potentially harmful components from vaccines. 
The "ideal" vaccine should meet the following 
requirements: the induction of a long-lasting anti-
body response of biologically active antibodies, which 
should be elicited even in the presence of maternal 
antibodies; functional T-cell responses which com-
prise both major histocompatibility complex (f."tHC) 
c1ass-I- and class-II-restricted cytotoxic T cells (CTL) 
and helper T cells; long-lasting protection against in-
fection with the pathogen. Furthermore, the produc-
tion procedures must be suitable for large-scale 
production and the product must be stable during 
prolonged periods of storage and transport. Last but 
not least, it has to be safe and devoid of any undesira-
ble side effects. New generations of vaccines will 
probably be composed of relevant antigen subunits 
either derived from the pathogen itself or prepared 
via molecular biological or synthetic techniques. 
However, \'accine formulations based on individual 
antigens or subunits bearing one or more B- and 
T-ceH epitopes in a monomeric form have a major 
disadvantage: they are usually poorly immunogenic 
as compared to the original inactivated or attenuat-
ed pathogen. Therefore adjuvants or immune en-
hancers are needed to elicit the desired immune 
response. In general. adjuvants should contribute to 
the requirements stated above for the "ideal" vac-
cine. r-.,'(ost adjuvants however, only contribute to 
some of these, and concerns about undesirable side 
effects have largely prohibited their use in registered 
vaccines for humans. 
In our laboratory, we have been especially in-
terested in evaluating the potential of the immune-
stimulating complex (iscom) as a carrier for viral 
proteins. 
Iscom was first described in 1984 (Morein et al., 
1984). It is a cage-like structure, usually about 30 to 
40 nm in diameter, composed of glycosides present 
in the adjuvant Quil-A, cholesterol, the immunizing 
(protein) antigen and also, in most cases, phos-
pholipids. Although similar structures had been ob-
served before (Horzinek et al., 1973), it was not until 
the work of Morein et al. that their potential as an 
immune-enhancing moiety was recognized. 
Quil-A is a crude extract from the bark of Qui!-
laja sapollaria Molina which has potent adjuvant ac-
tivity and is widely used as an adjuvant in veterinary 
vaccines. The adjuvant activity is due to the presence 
of a mixture of triterpine glycosides (Dalsgaard, 
1978). 
Although antigens of different origin including 
viruses, bacteria and parasites have been incorporated 
into iscoms (table I), in this review, we will mainly 
address data obtained with iscoms containing viral 
antigens. We will discuss the advantages and disad-
vantages of using Quil-A or iscoms as adjuvants. Fur-
thermore, we will postulate a working hypothesis 
with respect to the mechanisms by which the iscom 
exerts its specific adjuvant activity. 
The preparation procedure and structure of the 
iscom have been extensively described earlier 
(Hoglund et af., 1989). Recent studies have generat-
ed detailed information on the structure of the iscom. 
The typical cage-like structure is formed by Quit-
A/cholesterol micelles which are held together by 
hydrophobic forces (Ozel et af., 1989). This struc· 
ture is very stable. Iscoms can resist repeated freeze-
thawing and the structure remains intact upon 
lyophilization. The minimal requirements for the for-
mation of iscoms have been extensively described 
(Lovgren and Morein. 1988). Quit A is a necessary 
constituent of the iscom structure. The size and mor-
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Table I. Characteristics of immune~stimulating complexes containing different antigens. 
Antigen Name Carrier Route Dose Isatypes/ T cells Species Protection Reference 
nature bioI. activity 
Protein BSA sc 0.1-1 ~g Nl Mouse NI Marein et aI., 1990 
OVA or 10-100 ~g DTH,CTL Mouse NI Mowatt et 01., 1991a/b 
sc 0.1-50 ~g DTH,CTL 
Peptide LHRH, Influenza virussc 1 and NI NI Mouse NI Lovgren et 01., 1987 
FMDV 144-159 proteins 3 eg 
Virus 
Herpesviridae HSVI sc 1-15 eg NI NI Mouse ++ Erturk et 01., 1989 
BHVI im 50 ~g VN NI Rabbit. calf ++ Trudel et 01., 1987, 1988 
CMV id 15 ~g G LST Rhesus monkey Wahren et aI., 1987 
Pseudorabies virus 170 ~g VN NI Mouse, pig ++ Tsuda et al., 1991 
EBV sc 2-5 ~g VN LST Tamarin ++ Morgan et aI., 1988 
Hepadnaviridae HBV ip 1-5 ~g NI Mouse NI Howard et 01., 1987 
Togaviridae Rubella V im 100 eg VN NI Rabbit NI Trudel et 01., 1988 
Flaviviridae BVDV sc/im 50 fLg VN NI Sheep ++ Carlson el 01., 1991 
ParamyxoviridaeMV im 2-20 ~g VN/FIIHLl DTH Mouse, monkey + + De Vries et aI., 1988a 
CDV im Dog ++ De Vries et af., 1988b 
im VN Seal ++ Visser et al., 1989 
BRSV im 100 eg NI Guinea pig NI Trudel et af., 1989 
HRSV im/in 3.5 flg G IL2/CTL Mouse NI Trudel et af., 1992 
Rhabdoviridae Rabies virus sc/im 0.3 flg NI NI Mouse/dog ++ Fedaku et af., 1992 
Orthomyxoviridae Influenza virus sc/in 1-10 ~g G,A,M Mouse ++ Lovgren et at., 1988, 1990 
in 5 ~g G,A,M NK/CTL Mouse NI Jones et aI., 1988 
Retroviridae FeLV im 3 eg NI NI Cat ++ Osterhaus et af.. 1989 
BLV sc 0.3-50 ~g NI Mouse/calf NI Merza et aI., 1991 
SIV im Rhesus monkey + + Osterhaus et af., 1992 
HIV-l sc 1 ~g VN CTL Mouse/rhesus NI Takehashi el al., 1990 
NI Mouse NI Pyle el ai., 1989 
Bacteria E. coli, pili sc/im 5-40 flg NI NI Rabbit, pig Nl Nagy et aI., 1990 
B. abortus, porin-OPS sc 1-5 ~g NI Mouse ++ Winter el al., 1988 
Parasites Toxoplasma gondii sc 0.1-10 ~g NI NI Mouse Overness et aI., 1991 
Plasmodium Jalciparum im 40 ~g NI NI Rabbit NI Sjolander et aI., 1991 
Cell Erythrocyte membrane sc/ivag 10·50 flg G/A Mouse Thapar et al., 1991 
antigen ip 
Other Biotin Influenza virussc 1-10 eg Mouse Lovgren et af., 1987 
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NI::: not investigated; LHRH '" luteini7jng.hormone-releasing hormone; FMDV 144.159=peptide containing foot-and-mouth virus amino acid sequence 144-159; abbreviations for viruses I~' 
are as indicated in the text; im '" intramuscular, in "" intranasal. sc::: subcutaneous. or::: oral, id '" intradermal, ip::: intraperitoneal, ivag "" intravaginal; G '" ISO. A", igA, M '" ISM; VN '" virus- III 
neutralizing antibodies, FI", fusion-inhibiting antibodies, HLI '" haemolysis-inhibiting antibodies; DTH '" delayed-type hypersensitivity; CTL::: cytotoxic T lymphocytes; LST '" lymphocyte 
stimulation test; lL2 '" in vitro antigen-specific interlcukin 2 production; NK::: natural killer cells; + + '" positive protection at the indicated doses. 
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Table II. A schematic outline representing the procedures leading to iscom production. 
I. Solubilization of (membrane) proteins by adding detergent e.g. TX-IOO, fl.1EGA-W, octylglucoside. 
2. Separation of solubilized and non-solubilized proteins. 
3. Addition of Quil-A, cholesterol and phospholipid. 
4a. Removal of detergent by dialysis. 
4b. Removal of detergent by centrifugation on a Quil-A-containing sucrose gradient. 
5. Removal of free Quil-A by centrifugation through a 10 (Jfo sucrose cushion. 
6. Analysis of is com formation and quality by: negative contrast electron microscopy, SDS-PAGE, immunob-
lotting and antigen-specific ELISA. 
phology of an iscom is independent of the protein 
incorporated. In fact, "empty" iscoms can be made 
which solely contain Qui! A and cholesterol. This 
cholesterol iscom or iscom matrix is a very rigid and 
uniform structure. The incorporation of amphipat-
ic oligo- or polypeptides requires the addition of 
phospholipids like phosphat idyl ethanolamine or 
phosphat idyl choline. 11 is speculated that the incor-
poration of phospholipids provides the flexibility 
necessary for the incorporation of proteins in the 
structure (Lovgren and Morein, 1988). 
Table II represents a schematic outline of the 
principles used for the formation ofiscoms. They are 
formed spontaneously when detergent is removed in 
a controlled fashion from a mixture of cholesterol, 
protein, phospholipid, detergent and Quil-A, Deter-
gents are generally needed to obtain and keep (mcm-
brane) proteins in a monomeric form, The best results 
with many viral membrane proteins were obtained 
when octylglucoside or MEGA-IO (decanoyl-N-
mcthylglucamide) were used as detergents. The de-
tergent can be removed in several ways, but dialysis 
and centrifugation on a Quil-A-containing sucrose 
gradient have been used most frequently, The cen-
trifugation method may be used when a non-
dialysable detergent like Triton-XlOO is used. Iscom 
formation is confirmed by negative contrast electron 
microscopy (fig. I), Furthermore, iscoms have a well 
defined sedimentation (19 S) constant in a sucrose 
gradient. 
One of the interesting features of iscom technol-
ogy is the fact that a wide range of proteins can be 
incorporated in the structure. fI.'lost viral membrane 
proteins are spontaneously incorporated upon for-
mation of the iscom structure. For the introduction 
of proteins which do not possess membrane inser· 
tion sequences several methods have been developed. 
Pretreatmcnt of hydrophilic proteins, e.g. BSA, by 
adjustment at low pH (2.5), reveals hydrophobic 
Fig. 1. Electron micrograph x 140,000 after negative con-
trast staining of iscoms which contain measles virus anti-
gens showing the typical cage-like strLlcture. 
regions normally hidden inside the protein structure 
and allows these regions to interact with the iscom 
matrix (Morein el aI" 1990). Palmitification of pro-
teins, the coupling by overnight incubation with 
palmitoyloxy-sllccinimide, prior to iscom formation, 
is also used to enable the incorporation of non-
membrane proteins. The immune response against 
ovalbumin iscoms prepared in this way proved to be 
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as expected for iscoms (Mowat et af., 1991a). The 
acid treatment may be harmful especially to certain 
conformation-dependent epitopes. The water-soluble 
nucleoprotein (NP) of influenza virus was chemical-
ly linked to bacterial lipopolysaccharide which ena-
bled its subsequent incorporation in the iscom 
structure (Weiss e( al., 1990). 
So far only limited data are available on the in-
corporation of peptides into iscom and the im-
munogenicity of such iscoms, although many studies 
are presently being carried out in this area (K. Lov-
gren, personal communication). It was shown that 
the response against a peptide based on the foot-and-
mouth disease virus amino acid sequence which was 
coupled to preformed influenza virus iscoms did not 
induce very high anti-peptide antibody tit res (Lov-
gren e( al., 1987). Using recombinant DNA tech-
niques, a Plasmodium jalcipaml1l antigen sequence 
was produced as a fusion protein in Escherichia coli. 
When coupled to influenza virus iscoms, this anti-
gen was shown to be immunogenic in rabbits 
(Sjolander et ul., 1991). 
Prolectiyc immune responses against \'lruses induced 
by iscoms 
HerpeSl'iridae 
Viruses which belong to the Herpesviridue fami-
ly are important pathogens which can establish acute 
and latent infections in many animal species includ-
ing man. Both humoral and cellular immunity are 
considered important for protection against infection 
with these viruses. Herpes simplex virus I (HSVI) and 
2 (HSV2) are members of the Afphaherpesv;rillae 
subfamily which infect man. Iscoms have been pre-
pared with membrane proteins of these viruses and 
tested for their immunogenicity and protective poten-
tial. ~\.'lice generated significant antibody tit res after 
immunization with HSVI iscoms and were protect-
ed against a lethal challenge with HSVI and HSV2 
after a single immunization with 5 Ilg HSV 1 iscom 
(Erturk et al., 1989). 
Pseudorabies virus (PrV), another member of the 
Afphaherpesvirilloe subfamily, causes disease and 
death in piglets. The selective incorporation of viral 
proteins in iscoms could be useful to discriminate be-
tween vaccinated and non-vaccinated animals with 
subclinical infection. Iscoms containing the gIl 
glycoprotein of PrY induced complement-dependent 
virus-neutralizing antibodies in mice (Tsuda et af., 
1991). A 1-llg dose provided partial protection in 
mice. Pigs immunized with 170!1g gil iscoms were 
completely protected against lethal challenge. 
Bovine herpes virus type I (BHVl), yet another 
member of this subfamily, is an important pathogen 
in cattle which causes infectious rhinotracheitis and 
30 
maybe responsible for other clinical manifestations. 
Differentiation between vaccinated and infected 
cattle on the basis of serology is possible when 
subunit vaccines are used that selecti\'ely incorpo-
rate certain proteins. Iscoms containing the enve-
lope glycoproteins of BHV I were shown to be 
immunogenic in rabbits (Trudel e( af., 1987) and 
calves (Trudel et al., 1988a; Merza et af., 199Ia). 
Both species developed virus-neutralizing and 
haem agglutination-inhibiting antibodies. Calves 
vaccinated with either 50 or 100 Ilg BHVI iscoms 
were protected against challenge with 5 x 106 
TCIDso BHVI. A control group of animals which 
had received a commercial inactivated vaccine proved 
to be unprotected against viraemia in the same 
experiment (Merza et al., 199Ib). 
Infection with cytomegaloviruses (CMV). which 
belong to the subfamily Be(aherpes~'irifloe, results in 
the establishment of latent infections in many spe-
cies that may eventually lead to serious complications 
in immunocompromized hosts. Monkeys which were 
iuuuunized with either CMV-infected monocytes or 
Cl\·IV iscoms developed anti-CMV antibody tit res 
(Wahren e( al., 1987). Cellular responses, measured 
in lymphocyte stimulation tests (LST), were of simi-
lar magnitude in both groups. Less antigen (15 Ilg) 
was needed when Cl\·IV iscoms were administered in-
tradermally. However. 150 Ilg of free unadjuvanted 
CMV nucleocapsid invoked poor cellular responses. 
No protection studies were carried out in this study. 
Epstein Barr virus (EBV), belonging to the sub-
family Gammalierpesvirillae, infects man and is the 
causative agent of infectious mononucleosis in indus-
trialized countries. In certain developing countries it 
is associated with the development of undifferentiat-
ed nasopharyngeal carcinoma and Burkitt's Iympho· 
mao Cottontop tamario monkeys (Sagllilllls oedipus) 
develop tumours after infection with a high dose of 
EBV. Iscoms containing the EBV glycoprotein gp340 
induced virus·neutralizing antibodies. A 5-!-tg dose of 
gp340 iscoms given 3 limes protected the monkeys 
completely from tumour development (t\·lorgan et af., 
1988). Human T cells from EBV-seropositive donors 
could be stimulated ill vitro with gp340 iscoms 
(Ulaeto et al., 1988). 
Hepatitis B yirus 
Hepatitis B virus (HBV), a member of the Hepad-
Iloviridoe family, causes a chronic infection in !lian 
which may eventually lead to the development of 
primary liver cancer. The first generation vaccines 
consisted of hepatitis B surface antigen (HBsAg) par-
ticles (20 nm) purified from plasma of infected 
donors. Recombinant DNA techniques have made it 
possible to produce HBsAg particles in yeast cells 
(McAleer e( al., 1984). Alum was required as an ad-
juvant to enhance immunogenicity of these particles. 
Immunization of mice with iscoms containing HBsAg 
derived from yeast generated high levels of HBV~ 
specific antibodies (Howard el al., 1987). 
Rubella virus 
Infection with rubella virus. a member of the fa-
mily Togaviridae, may cause a mild morbilliform 
rash, occasional fever, and a rather predictable lym-
phadenopathy in man. Since infection during preg-
nancy leads to neonatal malformations, vaccination 
during childhood is widely practiced. A live attenu-
ated rubella virus is used for vaccination worldwide. 
Iscoms containing the EI glycoprotein (haemagglu-
tinin) and the nucleoprotein of rubella virus have 
been prepared. Humoral immune responses in rabbits 
were as high as those observed with a commercial 
live-virus vaccine. The presence ofvirus-neutralizing 
and haemagglutination-inhibiting antibodies was 
demonstrated. Small amounts of the viral nucleo-
protein were present in these iscoms which may be 
beneficial for the development of cellular immunity 
(Trudel el al" 1989b). 
Bovine virus diarrhoea virus (BVDV) 
BVDV a member of the Flaviviridae family. 
usually causes subclinical infections in sheep and cat-
tle. Vertical transmission of the virus may lead to 
abortion and teratogenic defects. Lectin affinity~ 
purified BVDV proteins were incorporated in iscoms. 
Pregnant sheep were given two 50-f1.g doses of BVDV 
iscoms. All animals developed anti-BVDV antibod-
ies with neutralizing activity. Significant protection 
was observed against a challenge of the sheep with 
BVDV. Some 26 lambs out of 29 were born in the 
vaccinated group whereas only 5 lambs out of 
26 foetuses were born in the non~vaccinated animals 
(Carlsson el al., 1991). 
Paramyxovlridae 
The potential of iscoms for the development of 
subunit vaccines against members of the genus mor-
billivirus has been explored in our laboratory. Whole 
measles virus iscoms. which contain the fusion pro-
tein (F) and minor amounts of the haem agglutinin 
protein (H). induced virus-neutralizing, haemag-
glutination-inhibiting and fusion·inhibiting antibod~ 
ies. Iscoms containing immuno-affinity·purified F 
(F~iscom) induced antibodies with haemolysis inhi-
bition (HLI) activity but devoid of VN activity. Both 
F and H iscom preparations induced protection 
against intracerebral challenge with a rodent·adapted 
measles virus strain (De Vries et al., 1988a; Varsanyi 
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et 01., 1987). Immunization with F-iscom induced a 
measles·virus-specific cellular response, delayed type 
hypersensitivity (DTH) and measles-virus~specific 
T-cell clones could be generated from these mice (De 
Vries et al., 1988a). MV iscom also induced humoral 
(in monkey) and cellular (in mice) immune responses 
in the presence of passively transferred antibodies, 
a situation that mimics vaccination in the presence 
of maternal antibodies (De Vries el al., 1990). 
Canine distemper virus (CDV) is a morbillivirus 
closely related to measles virus that causes a disease 
in dogs with a pathogenesis similar to measles in man. 
CDV iscoms were shown to protect dogs against 
viraemia and clinical signs upon intranasal challenge 
with a virulent strain of the virus (De Vries el al., 
1988b). 
CDV iscoms were also used to vaccinate seals 
against phocoid distemper virus (PDV), a recently 
discovered morbiJlivirus that caused mass mortality 
among seals in the North Sea in 1988 (Osterhaus et 
al., 1989b; Visser el al., 1989). Vaccination was suc~ 
cessful since all animals developed PDV~neutralizing 
antibodies. Upon challenge with PDV, vaccinated 
animals were protected whereas two sham-vaccinated 
animals developed clinical signs and died. 
Respiratory syncytial virus (RSV) is another 
Paramyxovirus which causes severe lower respirato-
ry tract infections in man and cows_ Guinea pigs im~ 
munized with iscoms based on human or bovine RSV 
developed cross-neutralizing antibody titres. In mice, 
intramuscular immunization with RSV-iscoms in~ 
duced virus-neutralizing antibodies, CTL activity and 
protection against virus challenge (Trudel el al., 
1989; Trudel et al" 1992). 
Rabies virus 
Rabies virus belongs to the Rhabdoviridae fami-
ly and causes fatal disease in warmblooded animals. 
Most currently used vaccines against rabies virus are 
inactivated viruses which are used for pre- and post-
exposure treatment of rabies infection. Rabies virus 
iscoms prepared from whole purified virus were 
among the first iscoms described (Morein et al., 
1984). III vitro experiments showed that human 
CD4 + T·cell clones could be stimulated with these 
iscoms. Moreover, ill vitro stimulation of human 
peripheral blood lymphocytes with rabies virus is-
corns led to the production of virus-neutralizing an· 
tibodies. Immunization of mice with rabies virus 
iscoms induces a DTH response and neutralizing an-
tibody tit res (Hoglund et 01., 1989). In our labora-
tory, we have generated data which show that both 
MHC class-I· and class-Il·restricted T-cell responses 
can be generated after immunization of mice with ra-
bies virus (Claassen el al., submitted). Iscoms which 
contain lentil-lectin-purified rabies virus glycoprotein 
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were shown to be immunogenic in both mice and 
dogs. These iscoms could protect dogs against a lethal 
challenge with street rabies virus after pre-exposure 
immunization. l\'1oreover post-exposure protection 
against street rabies virus challenge could be induced 
with three 120-ng doses of rabies virus glycoprotein 
iscom in 90 070 of mice but not with three doses of 
a widely used human diploid cell vaccine (HDCV). 
When mice were given four doses of HDCV for post-
exposure treatment they died of anaphylactic shock. 
No such phenomenon was observed when the mice 
had been immunized with the iscom preparation 
(Fedaku et af., 1992). 
Influenza \'irus 
Influenza viruses (family Orthomyxoviridae) 
primarily infect the respiratory tract of many animal 
species. Therefore, local immune responses in the 
lung are considered important for protection. The 
two membrane proteins important for eliciting pro-
tective immune responses are haemagglutinin (HA) 
and neuraminidasc (NA). The HA molecule is sub-
ject to antigenic drift which interferes with the pro-
tection elicited by vaccines based on the relevant 
strains. Cross-reactive cellular immune responses 
rapidly reduce virus titres in thc lung and arc there-
fore considered important. 
Intranasal immunization of mice with two doses 
of S-ttg HANA iscoms elicited antibody titres (IgM, 
IgG and IgA) comparable to those elicited by virus 
infection (Jones et al., 1988 and Lovgren, 1988). Fur-
thermore, virus-specific antibody-secreting cells could 
be demonstrated in the lungs. In contrast, the same 
dose of HANA micelles induced lower responses of 
mainly IgM antibodies and no local B-cell memory. 
Serum antibody responses could also be demonstrat-
ed in guinea pigs and horses (Sundquist et al., 1988). 
Both iscoills and micelles induced CTL precursors in 
the lungs of mice but the levels were four-fold higher 
in iscom-immunized mice. Natural killer cells were 
found in similar quantities after immunization with 
either of the antigen preparations (Jones et al., 1988). 
Complete protection of mice against intranasal 
challenge with influenza virus could be induced by 
intranasal and subcutaneous immunizations with 
IIANA iscoms (Sundquist et al., 1988 and Lovgren 
et al., 1990). Iscoms containing the influenza 
nucleoprotein induced virus-specific antibody tit res 
but no specific CTL responses were observed. About 
50 070 of the immunized mice survived challenge with 
a virulent mouse-adapted strain (Weiss et ({I., 1990). 
RetrOl'iridae 
Iscoms containing the gp70/85 envelopc protein 
of feline leukaemia virus (FeLV), a type C virus of 
32 
the RetrOl'iri(/({e family, can induce protection in cats. 
Antibody responses as determined by ELISA, im-
munofluorescence, virus neutralization and Western 
blotting showed that over 80 070 of iscom-immunized 
cats responded compared to only 6 fJ/o of a,.group of 
cats vaccinated with a commercial vaccine (Akerblom 
et af., 1989; Osterhaus et 01., 1985 and 1989a). 
Iscoms containing gp51 of bovine leukaemia vi-
rus (BLV, HTLV IBLV group) induced good hu-
moral immune responses in mice and calves (Merza 
et 01., 199Ia). In calves, neutralizing antibodies could 
be measured after thc second inoculation. These 
results showed the potential of iscoms for retrovirus 
vaccine development. 
HUman immunodeficiency virus type 1 (HIVI) 
(subfamily LCJltivirinae) is the causative agent of 
AlDS in man. Until now, no safe and effective vac-
cines against this disease are available. The de\'clop-
ment of a suitable vaccine is hampered by the 
variability of the viral envelope protein gpl20 which 
induces neutralizing antibodies. Multiple injections 
in rhesus monkeys with iscoms containing gpl20 of 
HIVI induced ten-fold higher neutralizing titres than 
comparable amounts of gpl20 with an alum adju-
vant (Pyle et af., 1989). In mice, a 5-11g dose of these 
gpl20 iscoms induced two-fold higher titres when 
compared with a 50-ttg dose of gpl20 in complete 
Freunds' adjuvant. Sera from rheslls monkeys 
(Macaca l1Iulatta) cross-neutralized RF and MN iso-
lates of HIV. The induction of class-I-restricted 
precursor CTL in mice was demonstrated lIsing 
gp 160-iscom-immunized mice. Spleen cells obtained 
from these mice could kill target cells expressing HIV 
gpl60 or pulsed with a known immunodominant 
CTL peptide (Takahashi et al., 1990). 
Several animal models exist to study the inullu-
nity and pathogenesis of HIV-related viruses. Simian 
immunodcficiency virus (SIV) is a closely related len-
tivirus which can infect rhesus macaques and cause 
an AIDS-like syndrome. In a recent study from our 
laboratory. it was demonstrated that a SIV-iscom 
preparation as well as whole inactivated SIV ad-
juvanted with muramyl dipeptide (MDP) could pro-
tect animals against an intravenous homologous 
challenge with to 1",[1050 of cell-free SIV. All 
animals were protected from dcveloping SlY-specific 
viraemia for at least a twelve-week period after 
challenge. Fifty percent of the vaccinated animals in 
a similar expcriment were also protected for at least 
ninc weeks against an intravenous challenge with 
SIV-infected peripheral blood mononuclear lympho-
cytes (Osterhaus et al., 1992). In another study, 
cynomolgus monkeys (Alacaca /ascicularis) were in-
fected with HIV2 after immunization with 
HIV2-iscoms or inactivated HIV2 with complete 
Freund's adjuvant (CFA) (Putkonen et al., 1991) 
HIV2-iscom-immunized monkeys were not protect-
ed against infection with HIV2 which was probably 
due to the virtual absence of gpl2S in the iscom 
preparation used. These results demonstrate that vac-
cination against lentivirus infections should not be 
considered impossible. 
General considerations for (he use of iscoms 
as an anligcn-presenling moiety 
Mode of administration 
Iscom preparations have generally been ad-
ministered intramuscularly or subcutaneously. Only 
small amounts - I to iO Ilg ~ of incorporated an-
tigens are needed to elicit effecti\'c immune responses 
in mice. It was found that the time between first and 
second immunization is critical for the development 
of a booster response. An interval between 6 to 
8 weeks seems optimal to elicit a booster effect (Lov-
gren et al., 1990). Short immunization protocols like 
the NIH efficacy test for rabies vaccines, in which 
case the interval is only one week, give lower tit res 
and protection levels. One intraperitoneal immuni~ 
zation of mice with 360 ng of rabies virus 
glycoprotein iscom is sufficient to protect almost 
90 0J0 against intracerebral challenge with rabies vi-
rus (Fedaku et 01., 1992). 
Recently the use of iscoms for oral immunization 
was also investigated. Attempts to investigate the pos-
sibility of oral immunization were undertaken with 
influenza virus iscoms but these were largely unsuc-
cessful, probably because the administered antigen 
dose was too low, i.e. 5 (1g (Lovgren, 1988). No sys-
temic antibody response could be measured and it 
was speculated that iscoms could not resist degrada-
tion in the gastrointestinal tract. Intranasal immu-
nization with influenza virus iscoms, however, led to 
a specific antibody response of all classes and sub-
classes. including IgA. and also to cellular responses 
in the lung (Jones et 01., 1988). This showed that lo-
cal immunization with iscoms may lead to the induc-
tion of both local and systemic immune responses. 
Ovalbumin(OVA)-containing iscoms were shown to 
be immunogenic after systemic but also after oral im-
munization (Mowat et al., 1991). Oral immunization 
with OVA iscom induced specific serum antibodies. 
Cellular responses were measured by DTH response. 
The required dose for oral immunization was 
10 times higher {lOO (1g) than that needed for paren-
teral immunization. which is probably due to par-
tial degradation of the immunogen in the 
gastrointestinal tract before iscoms can reach im-
munocompetent cells or lymphoid organs in the gut. 
Repeated feeding with OVA-iscom induced ~'itHC 
class-I~restricted CTL specific for OVA (Mowat et 
al., 1991). When soluble OVA was given orally 
in comparable amounts no responses could be 
measured. 
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Secretory immune responses in the vagina of mice 
could be measured after intraperitoneal, subcutane-
ous or intravaginal immunization with iscom contain-
ing sheep red blood cell (SRBC) membrane antigens. 
Non~mucosal immunization in the pelvis induced 
higher systemic and local Htres than local applica-
tion. and local application required 10 times higher 
amounts of antigen (Thapar et al., 1991). 
The finding that iscom can be used for local im-
munization is important for the development of pro-
tection against pathogens which acquire access 
through mucosal membranes and therefore require 
musocal immunity. The importance of the mucosal 
immune system for vaccine development has recent-
ly been reviewed (McGhee et al., 1992). 
Toxicological aspects 
When iscoms are considered as vaccine candidates 
for humans, toxicological aspects of the incorporat~ 
ed adjuvant Quil-A should be considered. So far, one 
study has been published on the ill vivo effects of 
Quil-A-containing iscoms after intramuscular injec~ 
tion (Speijers et al., 1988). Only a moderate innam-
matary reaction was observed in lout of 6 rats which 
had received an iscom dose containing 60 (1g Quil-A. 
It should be noted that the haemol)1ic activity of 
Quil-A incorporated in iscom is ten times lower than 
observed with free Quil-A (Kersten, 1991). 
Attempts have been made to separate the in-
dividual components of Quil-A in order to segregate 
the haemolytic and adjuvant activity (Kensil et al., 
1991; Kersten, 1991). Kensil described the separation 
by reverse-phase HPLC of Quil~A into 4 fractions 
which all retained their adjuvant activity. One frac-
tion (QS-7) showed no direct lethal effect in mice at 
a dose of 500 tLg. Unfortunately this fraction was not 
tested for its ability to form iscoms. Kersten, using 
the same approach, reported the separation of Quil~A 
into 23 fractions. Six of these purified saponins could 
be used to form iscom-like particles of varying size, 
but these were consistently larger than iscoms pre-
pared from unpurified Quit-A. Immunogenicity 
studies were performed using iscom with the 
gonococcal PI protein incorporated. Iscoms made 
with the so·called fraction QA~3 were as immuno-
genic as total Quil-A iscoms. The haemolytic acti\'i~ 
ty of QA-3 was 15 times reduced as compared to total 
Quil-A. Since the mean size of QA-3-iscoms is 
between 110 and 145 nm, the influence of particle 
size on immunogenicity has to be evaluated. 
It should be noted that no negative side effects 
have been observed with the use of an iscom-based 
commercial equine influenza vaccines in horses 
(Sundquist et al., 1988), or with any other iscom 
preparation (Nagy et al., 1990). I\'loreover, Quil-A 
is accepted in veterinary vaccine preparations for pigs 
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and cows at 10 to 100 milligram doses, about 100-
to I,OOO-fold higher than that used in iscom prepa-
rations. Nevertheless, before iscom can be used in 
vaccines for human application, further toxicologi-
cal studies are needed. These studies should focus on 
iscoms and their individual components and should 
deal with acute and subacute toxicity as well as pos-
sible mutagenic effects and sensitization. This may 
be omitted for iscom administered orally since sapo-
nins are accepted food additives. 
How do iscoms work? 
The quantitative and qualitative effects on the im-
mune responses as found after iscom immunization 
raise the question as to what determines the im-
munogenicity of the iscom structure. The higher and, 
in some cases, longer persisting antibody titres can 
easily be explained if one assumes that incorporated 
Quil-A retains its normal adjuvant activity. It has 
been suggested that the retention time of the im-
munizing antigen at the injection site and the uptake 
amount in the lymphoid organs, as observed with in-
fluenza iscoms (Watson et af., 1989) and with Quil-A 
as adjuvant (Scott el al., 1985) may be Important for 
the observed effects. However, when Quil-A was 
used as adjuvant, the inflammatory reaction and an-
tigen retention could be completely inhibited by the 
<\dditlon of cholesterol without affecting adjuvant ac-
tivity (Scott et al.} 1985). A progressive redistribu-
tion of iscom-bound radioactive labelled antigen to 
the spleen was observed when compared to antigen 
in micelles (Watson et 01., 1989). Furthermore, we 
have recently observed that iscoms ;11 vivo are taken 
up in mice by a distinct subset of macro phages in the 
spleen which is not involved in the uptake of free in-
activated antigen (Claassen et 01., submitted). 
Furthermore, the multimeric presentation form 
of the incorporated proteins and the presence of 
Quil-A in the same unique structure proved to be es-
sential for the observed effects. Using different bio-
tin/protein ratios, it was shown that at least 3 biotin 
molecules have to be coupled to a preformed iscom 
to induce an antibody response 10 times higher than 
that achieved when only one biotin molecule is cou-
pled (Lovgren et of., 1987). This finding clearly il-
lustrates that the multimeric form is important for 
the observed adjuvant activity of the iscom structure. 
Although speculative, this might also be necessary 
for the induction of MHC class-I-restricted CTL, 
even when proteins like OVA, which are normally 
not immunogenic for these T cells are included. It 
is generally accepted that at least two distinct routes 
exist for the degradation of foreign antigen and the 
presentation different subsets of T cells (YewdeU and 
Bennink, 1990). First. the uptake of antigens into 
lysosomes. which leads to the degradation of foreign 
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proteins and to the formation of peptides which then 
associate with MHC class II molecules and are recog-
nized by T cells bearing the CD4 marker. Secondly, 
the cytosoJic processing pathway into which enter 
proteins which are synthesized in the cytosol. released 
into the cytosol by lysis of endosomes or by antigens 
penetrating through the plasma or endosomal mem-
branes. This pathway generates peptides that associ-
ate with MHC class I molecules which are recognized 
by CD8+ T cells. In general, non-replicating anti-
gens do not enter the cytosolic pathway, so that no 
priming for MHC class-I-restricted CTL occurs. The 
ability of iscoms to stimulate CD8+ CTL ill vivo has 
been demonstrated with different iscom preparations 
(Jones et al., 1988; Takahashi el al., 1990; Mowat 
et at., 1991; Trudel el 01., 1992), even after oral im-
munization (Mowat and Donachi, 1991). In our 
laboratory, data have been generated which show 
that iscoms can stimulate MHC class-I-specific CTL 
ill vitro (van Binnendijk el 01., submitted) and ;11 vivo 
(Claassen et al., submitted). The ill vitro stimulation 
of measles-virus-specific CTL is dependent on the 
presence of MHC class-i-matched antigen-presenting 
cells. It may thus be hypothesized that at least ill vitro 
iscoms are able to enter the cytosolic processing path-
way which leads to expression of peptides in the con-
text of MHC class I molecules. Iscoms could act as 
a carrier enabling proteins to penetrate the plasma 
and endosomal membranes partially or entirely, thus 
exposing iscom-bound protein to both proteolytic 
compartments. Perhaps iscoms are not only taken up 
by APC to enter the lysosomal compartment but they 
may also pass through or into the membrane of the 
cells, meanwhile protecting the protein for proteo-
lytic degradation, and thus exposing the protein to 
cytoplasmic proteases. Intact and partially degrad-
ed iscoms could be demonstrated attached to mac-
rophage cell membranes and within phagosomal 
membranes in close association with phagosomal 
membranes but not in the cytoplasm (Watson et al., 
1989), 
The proposed capability of iscom to pass into the 
membrane may be explained by their hydrophobic 
structure, and because they contain saponins which 
can intercalate into cholesterol membranes (Ozel et 
01 .• 1989). This in fact determines the haemolytic 
properties of Quil-A. Iscoms are extremely stable 
structures and thus may be able to pass through cell 
or lysosomal membranes and so enter the cytosolic 
processing pathway thereby stimulating COB + CTL. 
Conclusion 
In summary, we conclude that the iscom matrix 
is a promising moiety for the presentation of anti-
gen to the immune system. It lacks many of the dis-
advantages of traditional live vaccines as regards 
safety. The major points in favour of an iscom ap-
proach to developing new vaccines are the follow-
ing: they generate long-lasting biologically fUllctionai 
antibody responses; they generate immunological 
responses in the presence of maternal antibodies; 
they generate functional cell-mediated immune 
responses; they generate protection in several sys-
tems. However, before iscom technology can be ap-
plied to the production of vaccines for human use 
the toxicity of individual iscom preparations will have 
to be studied and documented in more detail. Since 
there is an urgent Ileed for new generations of vac-
cines, especially against viral infections like' HIVl, 
EBV and RSV, the further development of the iscom 
as an immune-enhancing moiety deserves more at-
tention. 
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Abstract 
Four types of adjuvants were evaluated as alternatives to the use of Freund's complete adjuvant in 
mice. The adjuvants evaluated included a water-in-oil emulsion (Specol), a mi~roorganism (Lacto-
bacillus), preformed immune-stimulating complexes (lSCOM) containing rabies virus glycoprotein 
and a saponin, Qui! A. The adjuvants and saline were combined with three weak immunogens (a 
synthetic peptide, a self antigen and a particulate antigen) and given by three different routes (intra-
peritoneal, subcutaneous and dorsal in the foot). The evaluation was based on clinical observations, 
behavioural studies, pathological lesions and capacity to support immunological responses to weak 
immunogens. Lesions were most severe after injection of antigen combined with Freund's adjuvant 
orQuil A, mild to moderate with Specol and minimal with Lactobacillus, iscom conjugates or saline. 
Despite pathological changes, no signs of prolonged pain or distress could be demonstrated based on 
clinical observations and behavioural studies. Minimal immunological responses were found after 
injection of antigen in combination with saline or Lactobacillus. T-cell activation and high antibody 
responses were [ound after injection of antigen-iscom conjugates or antigen in Freund's adjuvant 
emulsions. After Specol/antigen immunisations T-cell activation was demonstrated and high antibody 
titres were found except for Specollself antigen immunisations. Presented data suggest that Specol 
is a possible alternative to Freund's complete adjuvant for the induction of an immune response 
against weak immunogens except possibly self antigens, for which preformed iscoms seem very 
suitable. 
Keywords: Evaluation; Adjuvants; Pathology; Antibody; T·cell activation 
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1. Abbreviations 
FCA, Freund's complete adjuvant; FIA, Freund's incomplete adjuvant; I'A, Freund's 
adjuvant; iscom, immune-stimulating complex; PBS, phosphate-buffered saline; i.p., intra-
peritoneal(ly); s.c., subcutaneous(ly); d.f.p., dorsal foot pad; SP, synthetic peptide; MBP, 
myelin basic protein; PLN, popliteal lymph nodc; IL-2-PC, interleukin-2 producing cells; 
IFN-')'-PC, interferon-,), producing cells. 
2. Introduction 
To elicit effective B- and T-cell responses, Freund's complete adjuvant (FCA) has 
become the most widely used adjuvant in laboratory animals. However, besides the marked 
enhancement of the immune response, a broad spectrum of unwanted side effects can also 
be found (Toth et aI., 1989). Pathological changes seen after injection ofl'CA arc known 
to be very painful in humans (Chapel and August, 1976). Growing concern with respectto 
the severe side effects caused by FCA is leading to stricter regulations. In Canada (Canadian 
Council on Animal Care, 1991), the USA (National Institute of Health, 1988) and the 
Netherlands (Veterinary Public Hcalth Inspectorate, 1993) for cxample, guidelines have 
been publicised giving recommendations on the use of adjuvant products in laboratory 
animals. One of the reasons for continuation of the lise of FeA is a lack of information on 
possible alternatives to FCA, with regard to both side effects and immunological properties. 
Many products with adjuvant activity are available. Dependent on the type of immune 
response desired, an adjuvant may be applied. In an earlier study (Leenaars et ai., 1994) 
we evaluated adjuvants for the production of polyclonal antibodies and sidecffects in rabbits. 
For the induction of a specific immune response it is important to know the mode of 
action of the adjuvant. To elicit immune responses efficiently the production of cytokines 
is rcquired. Two major cytokines produced by activated helperT cells arc IL-2 (Kuziel and 
Greene, 1990) and lFN-')' (Gustafson and Rhodes, 1992). T-cell activation can also be 
studied by revealing the 39 kDa membrane protein (gp39) expressed on activated helper 
T cells, this molecule is essential for the activation of resting B cells into antibody producing 
cells (Noelle et aI., 1992; Van den Eertwegh et aI., 1993). 
Since mice are generally used in immunological research we conducted a study to compare 
side effects and immunomodulating effects of alternative adjuvants to FCA in mice. The 
adjuvants, selected on their mechanism, low toxicity and supposed immunological prop-
erties, included a water-in-oil emulsion, Lactobacillus strains~ immune-stimulating com-
plexes and saponin. To mimic normal laboratory problems in evoking immune responses 
and to ease discrimination between the adjuvants to be evaluated, the antigens used (a 
synthetic peptide, a self antigen and a particulate antigen) were weak immunogens. 
3. Animals, materials and methods 
3.1. AI/imals 
Male and female BALB/c mice were bred specific pathogen free (SPF) at the National 
Institute of Public Health and Environmental Protection (RIVM) breeding facilities, Bil-
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thoven, the Netherlands and were used at 10-14 weeks of age. At the RIVM, animals were 
housed in groups of five under SPF conditions in polycarbonate cages, environmental 
temperature of 20-22'C, relative humidity of 50-80% and with a 12 h day/night cycle. 
Mice were fed a commercial diet (Hope Farms, Woerden, the Netherlands) and provided 
. with boWed water ad libitum. 
3.2. Adjuvallts 
The following adjuvants were used: Freund's adjuvant (water-in-oil emulsion, Freund's 
incomplete adjuvant (FIA) containing mycobacteria (FCA); Difco Laboratories, Detroit, 
MI, USA), water-in-oil emulsion (Specol described by Bokhout et aI., 1981; Institute for 
Animal Science and Health (ID-DLO), Lelystad,the Netherlands), non-pathogenic micro-
organism, Lactobacillus (Lactobacillus plalltarum (A TCC 8014, 109 ml- I), Lactobacillus 
casci (A TCC 393, 109 ml- I); Claassen et aI., 1995), preformed iseoms containing rabies 
virus glycoprotein (RV-iscoms; preparation described below; Claassen and Osterhaus, 
1992) and purified saponin Qui! A ('Spikoside', Iscotec, Lulea, Sweden). 
Rabies virus (RV-Pasteur strain) was propagated in Vero-cell monolayer cultures (Van 
Weze1 et aI., 1978). Culture supernatant was cleared by filtration and concentrated by 
Amicon ultrafiltration (cut-off 106 Da). Virus was inactivated with f3-propiolactone (BPL) 
and stored at -70°C at a concentration of 900 /Lg ml- " This rabies virus antigen was lIsed 
for the preparation of RV-iscoms as described earlier (Fekadu et aI., 1992). 
3.3. Amigclls 
Synthetic peptide (SP215, an analogue of SP29) was synthesised as described by 
Boersma et al. (1989). SP215 is a sequence derived from the hinge region of human IgG2, 
comprising 21 amino acids. The self antigen was myelin basic protein from bovine brain 
(MBP, Van Noort et aI., 1993; Sigma, SI. Louis, MO, USA), consisting of 173 amino acids 
(18.5 kDa). The parliculate antigen Mycoplasma plleumolliac (MAC strain) was a kind 
gift of Dr. A. Angulo (RIVM, Bilthoven, the Netherlands) and was prepared by culture 
into Chanock broth, concentrated by centrifugation and washed with phosphate-buffered 
saline (PBS). Inactivation was done at 57°C during 30 min. Particles of kf. pneumolliae 
arc 0.1-0.8 /-tIll in diameter. 
3.4. Adjuvant/antigen preparation 
For the preparation of adjuvant/antigen mixtures, the antigens (amounts given in Table 
1) were diluted in sterile physiological saline and mixed with the adjuvant, except when 
antigens were injected in combination with preformed iscoms. SP215 (2 mg) was coupled 
covalently to 120 p.g RV-iscoms using l-ethyl-3-(dimethylaminopropyl) carbodiimide 
(EDC) as described previously (Deen et aI., 1990). MBP (2.1 mg) was coupled to 80 p.g 
RV-iscoms using EDe. After coupling for 30 min at room temperature (RT), iscoms were 
dialysed against PBS overnight to remove uncoupled antigens and EDC. Freund's adjuvant 
(PCA in primary and FIA in secondary immunisation, abbreviated as FA) and Specol 
emulsions, containing antigen, were prepared as recommended by the manufacturer of the 
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Table I 
Injected volume." per type of antigen and per route of administrationa and dose of antigcn applied in this study 
Antigcn 
SP215 
MBP 
M./melll1lolliae 
Dose 
(/Lg) 
50 
100 
15 
Volume (ml) 
Lp. 
0.1 
0.2 
0.2 
·'Lp., intraperitoneal; s.c., subcutaneous; d.f.p., at the dorsal site of the hind feel. 
s.c. dJ.p. 
0.1 2XO.040 
0.2 2XO.040 
0.1 2 X 0.040 
adjuvan!. Lactobacillus/antigen mixtures were prepared by adding antigen in slerile phys-
iological saline to Lactobacillus (I: I) and mixing well. Qui! A dissolved in water was 
added to Ihe antigen and mixed. lnlraperitoneally (Lp.) injecled animals received 10 /-tg 
Qui! A per injeclion while animals injected subculaneously (s.c.) or at the dorsal site of the 
hind fool (dJ.p.) received 20 /-tg Qui! A per injection. 
3.5. Experimental design 
Adjuvanls were evaluated in three experiments. In each experiment one type of antigen 
was combined with each of the adjuvants, with one exception: in combination with M. 
pneumolliae, preformed iscoms were substituted by Quit A. The size of this particulate 
antigen makes it unfeasible to couple to preformed iscoms. Per antigen and per injection 
route, a control group, injected with antigen in sterile physiological saline was included. 
Injected volume per route of administration and per type of antigen arc given in Table I. 
Five mice were used per group. Animals were given a primary injcction with the adjuvant/ 
antigen or saline/antigen preparations on Day O. Idcntical secondary injections were given 
on Day 42, except that ITA was replaced by FIA and the secondary injections of MBP-
iscorn conjugate were given on Day 91 owing to unavailability of the conjugated antigen. 
Blood samples were taken from the tail vein on Day ~ I to determine preimITIune titres, 
I wcck aftcr primary immunisation and at 7 day intervals thereafter. Scra were pooled pcr 
group except for sera collected at necropsy. These sera were collected and titrated individ-
ually. Scra werc stored at - 20°C. One week aftcr secondary immunisation mice were blcd 
after being anaesthetised by intramuscular inoculation of 0.1 Illi KRA (mixtureofKetaminc 
(50 Illg Illl-I), Rompun (20 Illg 011- 1) and Alropine (I mg ml- I) in a 7:3: I ratio). 
Animals were examined for gross lesions and relevant tissue samplcs were collected for 
histopathology. 
3.6. Clinical observation alld body weight 
Specific changes in common clinical signs to indicate pain. distress or discomfort in 
experimental animals were evaluated as described by Morton and Griffiths ( 1985). General 
condition was evaluated daily and mice were weighed twice a week. starting on Day - I. 
Injection sites were palpatcd for signs of pain and swelling at least once a week. 
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3.7. Behavioural and physiological state 
The behavioural changes and physiological state of the mice were studied in the primary 
observation test (POT), a systematic quantitative procedure described by Irwin (\968) and 
modified by Olivier (Solvay-Duphar, Weesp, the Netherlands). 
The POT procedure involved an initial phase of undisturbed observation and a later 
manipUlative phase during which the animal was subjected to different stimuli. Animal 
behaviour was studied before immunisation, 3 days after primary immunisation and weekly 
thereafter. 
The procedure started by placing a group of mice in a viewing jar followed by an 
adaptation period of I h. The observation study began by observing the animal's undisturbed 
behaviour within the viewing jar. i.e. dispersion in the cage, apathy, startle-reaction, rest-
lessness, watchfulness and respiration. Thereafter, the animals were individually transferred 
onto the viewing arena for testing: arousal response to transfer, spatial locomotion, gait, 
slip resistance, righting reftex, exophthalmos and pilo-ereetion. Throughout individual han-
dling, touch-reftex, provoked-freezing, provoked biting, skin colour, body tone, pupil size, 
urination-<lefecation and vocalisation were studied. After handling, mice were again placed 
in the viewing jar and wash activity was observed. Behavioural changes and physiological 
state of each mouse were scored. 
3.B. Pathology 
Necropsy consisted of complete dissection and examination of injection sites and major 
organs. Tissue of lesions and organs showing macroscopic abnormalities were preserved in 
4% buffered formaldehyde. A sample of the omentum was preserved of all i.p. injected 
animals. The size of the popliteal lymph node (PLN) of d.f.p. injected animals was scored. 
The left PLN was fixed in 4% buffered formaldehyde, while the right PLN was immediately 
frozen in liquid nitrogen for immunohistochemistry for demonstration of cytokine-produc-
ing cells and gp39 expression. Frozen tissues were stored at -70°C in air-tight aluminium 
containers containing a small amount of ice to prevent dehydration on prolonged storage. 
For histopathological evaluation, a selection of fixed tissue samples was embedded in 
paraffin, sectioned at 5 .um, and stained with haematoxylin and eosin. In the i.p. injected 
animals the extent of abdominal lesions was scored based on the relative amount of white 
plaques in the visceral and diaphragmatic peritoneum. The severity of peritonitis in these 
groups was scored based on gross detection of adhesions and omentum retrahens and on 
microscopic evaluation of (pcri)pancreatilis, fat necrosis and micro abscesses. In animals 
s.c. injected lesions were scored separately for primary and secondary injection site. The 
score was based on diameter of lesions and on microscopic evaluation of infiltrates and the 
presence of necrosis. In the d.f.p. injected animals swelling was scored grossly and severity 
of lesions was scored microscopically by involvement of deep layers and the presence of 
ulceration. Gross and histopathologic lesions were scored as follows: -. minimal; + . mild~ 
+ +, moderate; + + +, marked. 
3.9. lmnuilloassays 
Serum antibodies to MBP, SP215 and M. pllell11l0lliae were determined using a direct 
enzyme-linked immunosorbent assay (ELISA). For animals immunised with SP215 and 
43 
Immunogenic presentation of viral and bacterial antigens: iscom and OMY as a basis for new vaccines 
MBP, ELISA procedures wcre performed essentially as described by Zegers et al. ( 1991). 
Sera were diluted I: 100, I :300 and 1:900. 
For M. pnell11lolliae antibodies, ELISA was performed as described in detail by Lcenaars 
et al. (1994). The sera were diluted using three-fold dilutions from I :270 to 1:65610. 
3.10. Imlllunohistochemistry 
Detection of cytokine producing cells and gp39+ cells in PLN were performed essentially 
as described by Van den Eertwegh et al. (1993). Cryostat sections (-20°C, 8 /Lm) were 
fixed for 10 min in fresh acetone containing 0.02% H20 2. The murine monoclonal antibody 
(mAb) DB-I (specific for rat IFN-y and cross-reacting with murine IFN-y) and the rat 
mAb S4B6 (specific for murine IL-2) both conjugated to alkaline phosphatase (AP) were 
used as eytokine-speeific antibody conjugates. After washing the slides with PBS, AP 
activity (blue) was demonstrated by naphthol-substrate as described by Claassen et al. 
(1986). Immunohistochemical demonstration of gp39 was performed with MR-I (a ham-
ster mAb specific for murine gp39) horizontally overnight under high humidity at 4°C. 
Slides were washed three times with PBS followed by the murine mAb specific for ratl 
hamster-IgK (RG-7) chain conjugated to peroxidase (HRP) horizontally for I h under high 
humidity at RT. RG-7-HRP slides were washed three times with PBS and HRP activity 
(red) was demonstrated by AEC-substrate as described by Claassen et al. (1986). 
For both substrate types, the reaction was stopped by transferring slides to PBS. Sections 
were counterstained with haematoxylin, rinsed with tap water and embedded in glycerin-
gelatin. Cytokine-producing cells (IL-2 producing cells (IL-2-PC) and IFN-y producing 
cells (IFN-y-PC)) and gp39 + cells were counted per cryostat section. 
3. J I. Statistical evaluation 
For statistical evaluation change in body weight was calculated as body weight on test 
day minus body weight on last measured day before. Differences between adjuvant and no-
adjuvant groups were evaluated for significance using analysis of variance. Serum antibody 
responses at necropsy were analysed by the two-sample Student's I-test for comparison of 
two empirical means in a normally distributed population. A probability of 0.05 or less was 
considered significant. 
4. Results 
4.1. Clil1ical fil1dings 
After 7 days, the body weights of immunised animals were equal to or higher than body 
weights of control mice for the remainder of the post-immunisation period. Pilo-erection 
was observed two days after primary and secondary immunisation, mainly in FA groups 
and when M. pJ1euflloniae preparations were injected. Abnormalities (swelling, signs of 
pain etc.) after immunisation are described below per injection routc. 
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4,1.1. i,p. injection 
Body weights decreased significantly in groups of mice (11 ~ 5) i.p. immunised with 
FCA/anligen (3 oul of3 groups), Specol/antigen (2/3), Lactobacillus/anligen (113) or 
anligen-iscom conjugales (212). 
Afterprimary immunisation, i,p, injected animals showed no abnormalities at the injection 
site and palpation of the abdomen did not lead to any sign of pain such as vocalising or 
struggling. Wilhin I h after secondary immunisation (i.p.) wilh FIA/SP215 emulsion 
animals died. Within 2-3 days after secondary injection (Lp.) of iscom conjugates some 
animals died (combined with SP215, 2/5 and combined wilh MBP, 5/5). 
4,1.2, s.c. injection 
When mice were immunised subcutaneously, body weights significantly decreased after 
primary injeclion of FCA/ anligen (2 Olll of 3 groups), Specol/ anligen (2/3), Lactobacil-
lus/anligen (1/3) or antigen-iscom conjugales (112). AI Ihe s.c. injeclion sile of FA/ 
antigen emulsions, palpable nodules, varying in size between 1 and 5 flun, were found. One 
hour after secondary immunisalion (s.c.) with FIA/SP215 emulsion, one mouse died. In 
some animals s,c. injected with M. pneul1Iolliae combined with Specol or Lactobacillus a 
yellow spot was found at the site of injection. Secondary injection of Qui I AIM. plleullIoll;ae 
preparalions (s.c.) resulted in nodules of 2-5 mm. 
4.1.3. df.p. illjectioll 
In animals injected with FCA, body weighls were significantly decreased 2 days after 
immunisation, An ulcerative lesion was found at the injection site in two animals injected 
wilh Quil A/ M. plleumolliae. 
4,2, Behavioural changes and physiological state 
Pilo-erection was observed in the first days after primary immunisation (i.p,) with the 
FCA/SP215 or FCA/MBPemulsions. No significant changes in behaviour or physiological 
state of the mice were observed in other groups after primary immunisation, After secondary 
injections, pilo-erection was observed in all groups i,p. or s.c. injected with M, pllewllolliae 
preparations, Secondary injections resulted in mortality in some groups (specified above), 
4.3. Patlwlogical filldings at lIecrops), 
4.3.1. i.p. injection 
Table 2 shows gross and histopathologic lesions at necropsy, The most prevalent abdom-
inal abnormality was white smooth shiny thickening of the peritoneum covering liver, 
diaphragm and spleen. Microscopically these 'plaques' are granulomatous peritonitis, This 
was present in all FA and Speeol treated animals, In animals that dicd immediately after 
FIA/SP215 injection (i.p.) Ihe same plaques were found. Moreover, they showed cyanosis 
of extremities and congestion of intestinal serosa. Animals that died after secondary injection 
(i.p.) of antigen-iseom conjugate showed a red nose and congestion of intestinal serosa 
and liver while no abdominal granulomatous lesions were found. Histology of the kidneys 
of three animals showed acute degeneration of convoluted tubules, Omentum retrahens was 
45 
Immunogenic presentation of viral and bacterial antigens: iscom and OMV as a basis for new vaccines 
Table 2 
Score of gross and histopathologic lesions at necropsy (7 weeks after primary and I week after secondary 
injection), from mice injected with various adjuvant/antigen or saline/antigen mixtures via three injection routesa 
Adjuvant Antigen Pathological findingsto 
i.p. s.c. d.f.p. 
Extent" Severity" Primary" Secondary" Gross" 
PA SP215 " ++ 
MIlP ++ +++ +++ + 
M. pllell11l011iae +++ +++ + ++ 
Specol SP215 + + 
MIlP + 
M. pneulllolliae ++ + ++ + 
Lactob.f SP215 
MBP 
M. p"elllllOlliae + +++ ++ 
(scom.<; SP215 -, 
MBP" + 
QuilA M. pllelllllolliae + +++ ++ 
Saline SPl25 
MIlP 
M. plleulllolliae 
"ip., intraperitoneal; S.C., subcutaneous; d.r.p., at the dorsal site of the hind feet. 
toComparison of data is possible intraroute and not interroute because of anatomical differences. 
c_, minimal; +, mild; + +, moderate; + + + ,marked. 
tlNo data comparable since animals died within I h after secondary injection (see Section 4). 
"Primary and secondary injection on the same site. 
[Lactobacillus spp. 
fin one of three animals lesions were found (see Section 4.3.1.). 
h14 weeks after primary injection. 
INo data comparable since animals died within 48 h after secondary injection (see Section 4). 
++ 
++ 
++ 
+ 
++ 
++ 
+ 
+++ 
Hislo" 
+ 
+ 
++ 
+ 
+++ 
present in all groups treated with M. pllelmlOlI;ae-adjuvant preparations. Intestinal adhesions 
were only found in FA/MBP (3/5 animals) and in SP215-iscom conjugale (1/3) injecled 
animals. This last animal showed arteritis in the pancreas. 
4.3.2. s.c. illjeetioll 
FA injection sites most consistently showed lesions both I week after FIA and 7 weeks 
after peA application. rCA injection resulted in white subcutaneous nodules measuring 1-
9 mm, microscopically designated as fibrosing granulomas. PIA induced lesions grossly 
showed white nuid diffusely in the s.c. fat. Microscopy revealed oil spaces and fat necrosis 
surrounded by active fibrous tissue rich in granulocytes. At the primary injection site of 
SpecollM. plleumolliae, in 3/5 mice lhin-walled cysls (2-3 mm) wilh yellow fluid were 
present, microscopically diffuse pyogranulomatous panniculitis. Secondary injection of 
Specol! M. p"ellUloniae induced subcutaneous white lesions which microscopically arc 
granulomas around large oil spaces. A soft yellow mass was found after secondary injection 
of Lactobacillus/ M. plleumoll;ae and Qui! AIM. PlleU1JlOIll'ae, which microscopically 
appeared to be exudative panniculitis and diffuse nccrotising panniculitis, respectively. 
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Table 3 
Relation between T-cell activation. enlargement of pop lit cal lymph node~ (PLN) and humoral response of animals 
d.f.p. injected with various adjuvant-antigen preparations 
Antigen Adjuvant IL_2a tFN·y gp39 PLNf> Antibody responsec 
SP2t5 FA + + + ++ 1.68±0.4 
Speeol + + + ++ 1.78 ±0.2 
Lactob.d + 0.t9±0.2 
Iscoms + + + 1.97 ±O.05 
Saline O.04±O.S 
MBP FA + + + ++ 0.15 ±O.2 
Speeo! + + + ++ O.OHO.03 
Luclob. 
Iscoms + + + ++ 1.83±O.S 
Saline 
M. p"euJ1Iolliae FA + + + ++ ,,6 
Specol + + + ++ ,,6 
Luclob. + + + + 5 
QuilA + + + + ,,6 
Saline + + + 4 
3IL_2_PC. IFN-y-PC, gp39+ ceUs: -. no staining observed; +. staining observed. 
t>pLN: -. not enlarged', +, twice enlarged; + +, three limes or more enlarged. 
~Serum antibody responses I week after secondary injection; SP21S and MBP results are expressed a" absorbance 
a(405 nlll for diluted (I :300) sera. Values represent the mean ± SOof antibody rcsponsesoffivc mice. Mycoplasma 
plie//II/olliae results are shown as Jlog serial dilutions with a serum dilution from 1:270 (I) to 1:65610 (6). 
tlL(lCl(}bacill/(.~ spp. 
4.3.3. d.fp. injection 
Injeclion of FA/ anligen or Specol/ anligen preparations resulted in diffuse swelling of 
the metatarsal region and local swellings at the dorsal side just proximal to the metatarso-
phalangeal joints and of the tarsal region. Histologically granulomatous inflammation in the 
subcutis was presenLIn theFA treated animals lesions also involved muscles, tendon sheaths 
and periost. Lesions were most severe after d.f.p. injection of Qui I AIM. pneutllolliae. Feet 
were swollen and hyperaemic and two animals showed an ulcerative lesion. Microscopically 
these lesions were extremely exudative and also involved the deep layers. The relative 
enlargement of the PLN afler d.f.p. injection is shown in Table 3. 
4.4. AI/tibody response 
High serum anti-SP215 responses were found after injection of SP215 in combination 
wilh FA, Specol or preformed iscoms (Fig. I). The d.f.p. injection resulted in an Ii body 
responses comparable to s.c. injection. Primary injection of SP215 emulsified in FCA or 
Specol resulled in high antibody responses which reached a plateau al Week 5 while 
secondary injection had limited effect on antibody responses. The secondary injection of 
SP215-iscom conjugate had enhancing effect on the immune response. When SP215-isCOJ1l 
conjugates were injected d.f.p .• antibody responses were low until secondary immunisation. 
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Fig. I. Serum anti·SP21S antibody responses in a direct ELISA. Mice were primary immunised and boosted (i.p. 
or s.c.) with different adjuvant/SP21S preparations. The results are expressed as absorbance at 405 11m for diluted 
(I :300) sera, collected 4 weeks after primary immunisation. I day before secondary injection and I week after 
secondary injection. *, no datu available. Data from I week after secondary injection represent mean ± SD of 
antibody responses of five mice. 
A secondary injection (d.f.p.) of SP2l5-iscom conjugate enhanced the antibody response 
to a level comparable to FA/SP215 or Specol/SP2l5 emulsions. 
The i.p. injection ofFA/MBP emulsions resulted in high antibody titres (Fig. 2). After 
MBP-iscom conjugate injection (Lp.) serum antibody responses were still rising at the 
moment of secondary immunisation. When MBP was s.c. injected (Fig. 2) antibody titres 
were similar to those produced after d.f.p. injection. Low anti-MBP antibody responses 
were found after injection ofFA/MBP emulsions via s.c. or d.f.p. route also after a secondary 
injection. After primary injection of MBP-iscom conjugate (s.c. or d.Lp.) anti-MBP anti-
bodies increased till secondary immunisation (Week 13). Secondary injection (s.c. or 
d.f.p.) of MBP-iscom conjugate enhanced the immune response significantly. 
After primary injection of adjuvant! M. plleu11lolliae preparations minimal differences in 
antibody responses were observed between the adjuvants (data not shown). A secondary 
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Fig. 2. Serum anti-MEP antibody responses in a direct ELISA. Mice were immunised and boosted (i.p. or s.c.) 
with different adjuvant/MEP preparations. The results arc expressed as absorbance at 405 nm for diluted (I :300) 
sera, collected 4 weeks after primary immunisation, I day before secondary injection and I week after secondary 
injection. *. no data available. Data from I week after secondary injection represent mean ± SD of antibody 
responses of five mice. 
injection resulted in enhanced antibody responses in all groups. The effect of secondary 
injection of adjuvantlM. plleul1loniae preparations on antibody responses was higher than 
in the saline/ lvl. plleul1lolliae injected animals. 
4.5. T-cell activation 
Cytokinc production (IL-2, IFN-y) and gp39 expression were demonstrated by immu-
nohistochemistry (Table 3). IL-2-PC and IFN-y-PC cells were observed in PLN of animals 
injected with FA/SP215 (Fig. 3(a)) or Specol/SP215 emulsions or with SP215-iscom 
conjugate. Gp39+ cells were demonstrated in PLN of all animals injected with different 
adjuvant/SP215 preparations. No gp39 expression or cy(okine production were demon-
strated in PLN ofsaline/SP215 injected animals. 
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Fig. 3. Immunohistochemical visualisation of JL-2 producing cells and gp39+ cells in the PLN after secondary 
immunisation with antigen/adjuvant mixtures. Cryostat sections of murine lymphoid tissue were incubated with 
specific immuno-conjugates, followed by the appropriate substrates, as described in Section 3. IL-2-PC in a 
cryostat section of the PLN of a mouse, I week after secondary illllllunimiion with FIA combined with SP215 
(A). gp39 + cells in a cryostat sections of the PLN of a mouse, I week after secondary immunization with Speco!1 
"'t. pllelllllolliae (B), Lactobllcilfllxl M. pllelll1l(miae (C) or Qui! AIM. pneul1/ol/iae (D). 
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In PLN of animals injected with FA/MBP, Specol/MBP or MBP-iscom conjngate IL-
2-PC, IPN-y-PC and gp39 + cells were demonstrated. No cytokine-producing cells or gp39+ 
cells could be demonstrated in animals injected with Lactobacillus/MBP or saline/MBP 
mixtures. IL-2-PC, II'N-y-PC and gp39+ cells (Figs. 3(b )-3( d)) were observed in PLN 
of all animals injected with preparations containing M. pl1eulllolliae as antigen. 
5. Discussion 
In a comparative study in mice we here show that preformed iscoms can be used as an 
effective adjuvant for the production of specific antibodies to self antigen and small peptides 
while inducing minimal side effects when injected subcutaneously. In a previous study in 
rabbits (Leenaars et aI., 1994) we concluded that Specolmight be an acceptable alternative 
to PCA/F1A. Based on data of this study with three antigens, we suggest that this conclusion 
can be extended to the mouse. An exception was self antigen MEP, where only a very small 
amount of anti-MBP antibodies could be detected in serum ofSpecol/MBP injected animals. 
Cytokine-producing cells and gp39+ cells were demonstrated in PLN of animals d.f.p. 
injected with all three antigen/Specol emulsions whilePLN were enlarged and many plasma 
cells were present (data not shown). The enlargement of the PLN can be explained by the 
aspecific immune-stimulating effects of Specol as described by Boersma et al. (1992). The 
low level of antibodies might be explained by the minimal presence of specific B-cells for 
self antigen (MBP). Furthermore, we were unable to induce Experimental Allergic Enceph-
alomyelitis (EAE) in SILII mice with Specol/MBP as opposed to FCA/MBP (data not 
shown), indicating yet again that T-cells were not antigen specifically activated by Specol/ 
MBP. High antibody responses found after immunisation with Specol/SP215 confirm the 
data of Boersma et al. (1989) who found 25 j.tg of SP29 emulsified in Specol to be sufficient 
in mice to elicit an anti-peptide response. Specol can be a possible alternative to FCA; 
however, more research is needed to confirm that it is an alternative to FCA for a wide 
range of antigens. Pathological changes after i.p. injection ofSpecol emulsions were similar 
to those observed after injection of Freund's adjuvant emulsions, but the area affected was 
less extensive. 
Only the injection of MBP-iscom conjugate induced high antibody responses to MBP 
after s.c. and d.f.p. injection. The responses exceeded those induced by Freund's adjuvant. 
The secondary injection of MBP-iscom conjugate was given in \Veek 13 owing to the 
availability of the conjugated antigen. At Week 7, anti-MBP antibody levels in the MBP-
iscom group were already higher than those found in the FA/MBP group which received a 
secondary injection at \Veek 6. Moreover, levels still increased in the period until the 
secondary immunisation (at \Veek 13) and had not reached a plateau at that time. 
For the coupling of antigen to preformed iscoms, the amounts of antigen given in Table 
I were used per animal. However, possibly not all antigen was coupled to preformed iscoms 
and therefore the amount of antigen injected in combination with preformed iscoms may 
be lower than given in Table 1. It has been shown that when antigen is coupled to preformed 
iscoms immunisation can be performed at reduced antigen concentrations (Morein et aI., 
1987). Coupling of haptens and peptides to preformed iscoms is a laborious process and 
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not aillypes of antigen can be coupled. These are disadvantages if preformed iscoms are to 
be used as a ready-la-use product that serves as alternative to PCA. 
Besides the adjuvant. type of antigen and route of injection influenced the severity of the 
lesions found after immunisation with the adjuvant/antigen preparations. When different 
antigens were compared most severe lesions were found after injection of M. pllelllllolliae 
preparations. The nature of the antigen injected may be involved in the severity of induced 
lesions. When different injection routes were compared, i.p. injection resulted in relatively 
severe lesions (including intestinal adhesions, (peri) pancreatitis. abscesses) compared with 
s.c. injection and in some groups animals died after secondary i.p. immunisation. Within 1 
h after secondary i.p. injection ofrIA/SP2IS emulsions, animals most probably died as a 
result of anaphylactic shock as suggested by time course and observed circulatory distur-
bances (peripheral cyanosis and abdominal congestion). After the secondary i.p. injection 
of SP21S-iscom conjugate, two animals died after 2-3 days (not suitable for microscopy). 
In one survivor arteritis was observed which suggests the possibility of a type III hypersen-
sitivity reaction. Secondary i.p. injection ofMBP-iscom conjugate resulted in death of the 
whole group within 48 h. No evidence of acute immune complex disease was found (i.c. 
no endothelial proliferation or polymorphonuclear infiltration in vessels or glomeruli) in 
these five mice. The presence of free Qui! A in iscom preparations is not considered the 
cause of death. Quil A is known to have intrinsic haemolytic activity in vitro. When Quil 
A is ir,corporated in iscom the haemolytic activity is ten times lower than observed with 
free Quil A (Kersten, 1990). Macroscopically no signs of haemolysis were found and 
microscopically no haemoglobin was present in renal tubular epithelium. Marein et al. 
(1987) and Speijers et ai. (1988) observed minimal pathological effects after injection of 
iscoms. Speijers et ai. ( 1988) injected 0.2S ml measles virus iscoms containing 90 /Lg Quil 
A intramuscularly in rats and observed minimal local and no haematological effects. Other 
immunopathologic events may have caused the death of these animals since these animals 
died within 48 h after secondary injection while circulatory disturbances were found as may 
be observed in shock state. Besides these immunopathologic events after i.p. injection, 
minimal pathological lesions were observed after injection of preformed iscoms. 
At necropsy severe pathological changes were found after injection of FA. Despite the 
severe lesions we could not demonstrate signs of prolonged pain or distress based on clinical 
observations, weight gain or several behavioural studies. This is in cOITespondence with 
resuits of 1'oth et ai. (1989) who did not find prolonged signs of pain in mice after i.p. 
injection of O.S ml FA/saline ( I: I). Van den Brock et ai. (1994) however, suggest that 
i.p. injection of 0.1 ml FCA may lead to severe distress. The reasons for the fact that we 
could not demonstrate prolonged pain or distress while severe lesions were found could be 
that these lesions do not induce pain and distress in mice or the methods we used were not 
sufficient 10 detect prolonged animal distress. In order to control possible pain and distress, 
the induction of severe pathological changes need Lo be kept to a minimum. Amyx (1987) 
suggested that most of the undesirable side effects of the use of Freund's complete adjuvant 
can be eliminated by careful control of injection quantity and site selection. 
In conclusion, when alternative adjuvants are compared, the effect of the nature of antigen 
on immune responses and side effects. should be taken into account. We suggest that Specol 
is a possible alternative to FCA for the production of specific antibodies to small peptide 
and particulate antigen. \Ve demonstrated that s.c. injection of preformed iscoms can be 
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used for the production of specific antibodies to self antigen or small peptide and cause 
minimal side effects. 
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1.4 Aims of the present thesis 
The aim of this thesis is to generate data that could help in the rational design of novel 
generations of safe and effective subunit vaccines. Therefore, the studies described in 
this thesis address the evaluation of strategies that could be helpful in developing 
viral and bacterial candidate vaccines using the iscom and OMV antigen presentation 
systems. 
Rabies virus CRY) infection of mice was chosen as a viral model system in which the 
potential of the iscom presentation system could be evaluated. To this end a non 
adjuvated rabies vaccine was used as a basis to generate RV iscoms. The vaccine itself 
served as a control preparation. One basic question to be addressed with this system 
would be whether differences exist in the routing and persistence of the respective 
antigen preparations at the level of tissues and cell types involved in antigen 
presentation and immune responses. Since macrophages are known to playa major 
role in the presentation of particle antigens, it was considered important to specifically 
study the role of macrophages and other phagocytosing cells in this context. Methods, 
involving clodronate containing liposomes, were available to eliminate these cells ill 
vivo, which would allow studies concerning the differences in immune responses 
between depleted and control animals. 
It is known that in protection against certain viral diseases CTL play an important role. 
Given the published data which have shown that unlike most inactivated antigens 
inactivated rabies vaccines may induce CTL responses, we were also interested to see 
whether RV -iscom could induce a functional CTL response more efficiently. It was 
considered that the availability syngeneic target cells persistently infected with RV in a 
mouse model, would allow studies to compare the different antigen preparations in this 
respect. 
Since cytokines play an impOltant role in the induction of immune responses and at 
least some of the effector mechanisms of adjuvants are dependent on the release of 
certain cytokines, we designed experiments in which the response against RV could 
be modulated when rabies vaccine was directly adjuvated by the addition of different 
cytokines that are known to be involved in immuno-modulation. 
Neisseria meJlillgitidis infection of mice was chosen as a bacterial model system in 
which the potential of iscom and OMY, being two different antigen presentation 
systems with built- in adjuvant activity, could be evaluated and compared. To this end 
it was decided to test different candidate vaccine fOllllulations containing 
meningococcal class 1 OMP -purified OMP, OMV and iscom- with regard to their 
ability to generate an anamnestic and bactericidal antibody response. The responses 
were characterized with regard to IgG subclasses and involved epitopes. 
With the data generated in both systems the potential and limitations of the respective 
antigen presentation systems for the development of future candidate subunit vaccines 
against viral and bacterial infections, are discussed in the final chapter of this thesis. 
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Chapter II. I 
Antigen detection ill vivo after immunization with 
different presentation forms of rabies virus 
antigen: involvement of marginalmetallophilic 
macrophages in the uptake of immune-stimulating 
complexes 
Several mechanisms have been postulated to explain the relatively high 
immunogenicity of antigens presented in immune-stimulating complexes (is-
com). Their potency can in part be explained by the specific targeting of these 
structures to cells presenting antigens to the immune system. However, until now 
no method for the subcellular detection of iscom ill situ was available. In the 
present study, a novel, fast and simple method for the detectionofiscoms ill sitf(is 
demonstrated. By making use of the lipophiliC fluorescent carbocyanine dyes, 
1,I'-dioctadecyl-3,3,3' ,3'-tetramethylindocarbocyanine perchlorate (Oil) and 
3,3'-dioctadecyloxacarbocyanine perchlorate (DiO), rabies virus antigen and 
iscom prepared with this antigen were visualized with fluorescence microscopy. 
Thelabeled antigen and iscoms were observed in macrophagesofspleen and liver 
of mice within 1-2 h after intravenous administration. When administered 
intramuscularly or in the footpad, uptake in macrophages of draining lymph 
nodes could be demonstrated. In the spleen, labeled inactivated virus antigen 
localized preferentially in the marginal zone macrophages and toa lesser extent in 
the red pulp macrophages. In contrast. antigen presented in iscom was taken up 
mainly by the marginal metallophilie macrophages and to a much lesser extend by 
marginal zone macrophages or follicular-dendritic and -B cells. This method 
enables the detection of iscom and membrane viruses and allows the analysis of 
their relation to antigen-presenting cells ill silll. Here, \\'e demonstrate that iscom 
containing rabies virus antigen are taken up by a subset of macrophages in the 
spleen distinct from those that take up inactivated rabies virus antigen not 
presented in iscom, thereby possibly explaining the observed difference in 
immunogenicity of these antigen preparations. Furthermore, we show a lower 
efficiency on the induction of humoral and cellular responses after intravenous 
immunization for both types of antigen when compared with subcutaneous 
immunization. 
Since immune·stimulating complexes (iscom) were initially 
described by l\·lorein et at flJ, numerous studies have 
demonstrated their potential as a vaccine with built·in 
adjuvant properties. Bacterial, parasitic, viral and other 
proteins and peptides have been incorporated into iscom to 
enhance the immune response against these antigens C2J. 
Immunization with iscom generally induces both humoral 
and cell·mediated immune responses [3]. The antibody 
responses against antigens incorporated in iscom are gen-
erally higher and longer-lasting than those induced by the 
same amount of antigen not incorporated in this matrix. 
Furthermore, unlike most inactivated antigens, iscom can 
induce an MHC class-I-restricted cytotoxicT cell response 
specific for the immunizing antigen [4-6J. Little is known 
about the early events after immunization with iscom, e.g. 
which antigen-presenting cells are invo!ve'd or in which 
anatomical location (organ or compartment) the response 
is elicited. Watson et al. (7J described the inflammatory 
response and organ distribution of antigen after intraperi-
toneal immunization with influenza virus glycoprotein in 
iscom or micelles using radioactively labeled antigens, and 
showed that the spleen is important in the uptake and 
retention of iscom. However. no detailed information on 
the im'olvement of splenic antigen· presenting cells (e.g. 
macrophages, dendritic cells, B cells) in the uptake, pro· 
cessing and presentation of iscom or inactivated virus is 
available. Such knowledge would allow the study of distinct 
subsets of antigen·presenting cells in the differential im-
munogenicity of viral antigens presented in different ways. 
Here, we present a simple post-formation method for 
labeling virus and iscom by means of lipophilic fluorescent 
dyes. This method allows the study of virus and iscom 
distribution in the lymphoid organs at the cellular level. 
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2 Materials and methods 
2.1 Animals and chemicals 
Female BALB/e mice aged 12-16 weeks, were kept in 
Macrolon cages under an ll-h dark/13-h light regimen at 
20QC and were given acidified water (pH 3) and pelleted 
mouse food (Hope Farms, Woerden, The Netherlands) ad 
libitllm. Dil (1,1' -dioetadecyl-3,3,3' ,3' -tetramethylindo-
earbocyanine perchlorate; D-282), and DiO (3,3'-diocta-
decyloxacarbocyanine perchlorate; D-275) were obtained 
from Molecular Probes (Eugene, OR)_ Monoclonal anti-
bodies ERTR-9, specific for marginal zone macrophages, 
and MOMA-l, specific for marginal metallophitlie macro-
phages, were a kind gift of Prof. Dr. G. Kraal, Free 
University, Amsterdam, The Netherlands. 
2.2 Antigens 
Rabies virus (RV-Pasteur strain) was propagated in Vero 
cell monolayer cultures (8). Culture supernatant was 
cleared by filtration and concentrated by Amicon ultrafil-
tration (cut-off 1()6 Dalton). Virus was inactivated with 
~-proplolactone (BPL) and stored at -70QC at a concen-
tration of 900 J.lgfml. This rabies virus antigen was used for 
the preparation of RV-iscom as described (9). Briefly, RV 
proteins were solubilized with 10 % MEGA-1O (decanoyl-
N-methylglucamide) for 2 h at room temperature. The 
solubilized virus was layered on top of a 10 % sucrose 
cushion and centrifuged for 2 h at 200000 x g. Quil-A 
(Iscotee AB, Lulea, Sweden), cholesterol and phosphat i-
dylcholine (Sigma, St. Louis, MO) were added to the 
supernatant and the mixture dialyzed overnight against 
PBS. Free Quil-A and unincorporated proteins were 
removed by centrifugation over a 20 % sucrose cushion for 
48 h at 150000 x g. Incorporation of RV proteins was 
analyzed by SDS-PAGE and a glycoprotein-specific ELISA 
(10). 
2.3 Immunological responses and protection 
Immunological responses were measured 4 weeks after Lv. 
or s.c. immunization. RV-specific neutralizing antibody 
responses were measured by rapid fluorescence focus 
inhibition test (RFFIT) and T cell responses were meas-
uredasdescribed [II, 12}. Briefly, spleen cells were isolated 
and stimulated with different concentrations of RV-BPL. 
After 5 days, cells were pulsed with (JH} thymidine for 
18 h. Cells were harvested on glass filters and incorporated 
radioactivity was measured in a Betaplate scintillation 
counter (LKB, Uppsala, Sweden). For protection studies, 
BALB/c mice were challenged intracerebrallywith 30 LD50 
rabies challenge virus standard CVS-26 according to stan-
dard NIH potency testing of vaccines [13]. 
. 2.4 Fluorochrome labeling or RYanligen and RY-Iscom 
Stock solutions of DiI and DiO were made in pure ethanol 
or DMSO (2.5 mgfml). RV-BPL (100 ~{g), RV-iscom or 
empty iscom in 1 ml PBS were vigourously mixed with 8 !II 
(20llg) Oil stock solution and incubated for 1 h at 3rc. 
Any unincorporated DiI formed crystals during this incu-
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ballon period. After labeling, the samples were filtered 
using0,45-f.lm filters to separate crystalline Dil and labeled 
antigens (14). Labeled material was stored in the dark at 
4 QC for up to 4 weeks. 
Total amounts of carbocyanine label incorporated in virus 
and iscoms were determined with a Beckman DU-40 
UVNis spectrophotometer. Wavelength scans were made 
from 380 to 600 nm with peaks at 552 nm for Oil and 
492 nm for DiD. Association of carbocyanine dye with the 
iscom structure was demonstrated by purification of DiD-
labeled iscom by density centrifugation on a 10-60 % 
sucrose gradient fOr 18 h at 40000 x g [15}. 
2.5 Fluorescence microscopy 
Frozen 8-Ilm sections of organs were examined and photo-
graphed directly after cryo-sectioning with an Olympus 
(Tokyo) VANDX fluorescence microscope. Oil fluores-
cence was observed both as red with green light (excitation 
filter BP 545) and rhodaminefTRITC optics (emission: 
EO 570) and as golden-yeliow with blue light (BP 
490 + EY 455) and FlTC optics (EO 515). DiD fluores-
cence was observed only with FITC optics as green 
(excitation: BP 490 + EY 455, emission: EO 515). 
2.6 Enzyme- and immunocytochemistry 
Organ sections used for localization studies based on 
fluorescence microscopy were air-dried and fi.xed in 1 % 
paraformaldehyde at 37~C for 15 min for simultaneous 
fluorescence and immunochemical detection (acetone dis-
solves lipid membranes, causing a significant decrease in 
fluorescence of labeled iscom/virus). Sections for enzyme 
staining (nonspecific esterase; NSE) were fixed in acetone 
after fluorescence observation and photomicrography. 
r ... fonoclonal antibody staining on fixed sections for margi-
nal zone metallophilic macrophages (MOMA·1) was per-
formed as described (16). Endogenous acid phosphatase 
staining for the identification of all splenic and liver 
phagocytes and NSE staining for the detection of marginal 
metallophilic macrophages (M~Hvl) was performed as 
described [16]. Localization of the respective subsets of 
splenic macrophages has also been described (17). 
3 Results 
3.1 Incorporation of dyes in ,irus and Iscom 
The efficiency of the labeling of viral antigen and iscom is 
shown in Fig. 1. At the optimal dye concentration used 
(200 JIg dye/mg iscom), up to 80 % was integrated in the 
RV-iscom. Under the same conditions, RV-BPL took up 
approximately 50% of the dye. The carbocyanine dye 
associates specifically with the iscom structure, as shown by 
sucrose gradient density centrifugation of DiO-labeled 
iscom and in a recent report dealing exclusively with 
mucosal localization of iscom (15J. To determine whether 
the incorporation of these dyes influences the structure and 
immunological properties of iscom or viral antigens. 
labeled antigens were analyzed morphologically by electron 
microscopy as well as for their immunogenicity in mice. 
r------------------.,. 
_____ (or./rQ\ {100%1 
16 
___ .lfUS 
___ PBS 
" 
Figure 1. Incorporation of carbocyanine Oil in \'irus and iscom as 
determined by spectrophotometric measurements (wa\"e!ength 
scans from 390-600 om) after 2 h incubation (see Sect. 2.4). 
Control 100% contains the same amount of label as was added to 
the antigen pn::parations without filtration. Iscom, RV·BPL and 
PBS were all filtered 10 remove dye which was not take up in the 
lipid phase after incubation. 
Figure 2. Electron micrographs (x 106000) of unlabeled (left 
panel) and Oil-labeled (right panel) iscom matrix afler O.2-,~m 
filtration: note no differences in Iypical cage-like iscom struc-
ture. 
Fig. 2 shows representative electron micrographs of iscom 
matrix before (left panel) and after (right panel) Oil 
incorporation. No changes in the structure were observed 
after Dil uptake, and all samples were devoid of any 
particulate material other than the iscom. Results obtained 
with RV-BPL(data not shown) were essentially the same as 
for RV-iscom. Labeled virus and iscoms were shown to 
retain their nonnal immunogenic properties (data not 
shown) as the same results were obtained as presented in 
Fig. 7 for non-labeled material. 
3,2 Localization of antigen and iscom In the spleen after 
i.p. or j,v. Injeclion 
After i.p. and Lv, injection, both antigens could be 
demonstrated in the Kupffer cells of the liver within 15 min, 
shown, for iscom only, in Fig. 3a. No differences in liver 
localization pattern were observed between RV-BPL or 
RV-iscom. 
Chapter n.t 
When Oil-labeled antigens were injected Lp. or is., uptake 
in splenic macrophages could be observed as early as 20 min 
after administration. Labeled RV-BPL preferentially local-
ized in marginal zone macrophages(MZ/l.t) (Fig. 3b).When 
large amounts of RV-BPL were administered, antigen was 
also taken up by red pulp macrophages (RPM). Viral 
antigen was detected in roughly equal concentration ratios 
in /l.IZ/l.f and RPM after 1-7 days irrespective of the dosage 
given. 
Labeled iscom were taken up by MZM as shown for other 
antigens. However, iscoms preferentially localized within 
Mi\l1·1. As shown in Fig. 4, a section showing the uptake of 
Oil-labeled iscoms in the spleen was photographed 
(Fig.4a) and subsequently fixed in acetone. Following 
fixation, the section was incubated with a substrate for 
NSE, ~n l-,·IMM endogenous enzyme marker (Fig. 4b). It is 
clear from these pictures that similar patterns are obtained 
for Oil-labeled iscoms and NSE activity. Although iscoms 
were not found exclusively in MMM, but also in MZM. 
almost all NSE-containing macrophages can be seen to 
have ingested iscoms, whereas RV-BPL could not be 
observed in these cells. 
The involvement of MMM in the uptake of iscom was also 
demonstrated by a double-fluorescence study. First, Oil-
labeled iscom were injected in mice, and after2 h the spleen 
was removed, frozen. cryo-sectioned and paraformalde-
hyde-fixed. After fixation, sections were incubated with 
MOMA-l antibody and goat anti-rat conjugated to FITe. 
Using FlTC optics, Oil iscoms were observed as golden 
yellow and MOMA-I-staining cells as green. FITC did not 
fluoresce when using green light for excitation, showing 
iscom in red. Most MOMA-I- positive cells were positive 
for Oil fluorescence. albeit with differences in intensity, 
and hence for iscom uptake (data not shown). 
Follicular localization (either on follicular-dendritic or 
-B cells) of iscom was also observed {green dots in F 
(follicle) Fig.5J in a similar fashion as that shown for 
TNP-Ficoll [l8J and for Iiposomes [19J. 
3.3 Double·fluorescence labeling studies 
To confirm the differences in localization pattern of RV-
BPL and RV-iscom, the following experiment was per-
formed. RV-BPL was labeled with DiI and RV iscom with 
OiO. When observed using FITC optics. these labels 
fluoresce golden yellow for RV-BPL and green yellow for 
iscom, respectively. Mixtures of these antigens were 
injected intravenously. and after 2 h, the spleens were 
removed. Observation of sections revealed that RV-BPL 
and iscom co-localized in MZr..·I, but a small ring of cells on 
the border between marginal zone and periarteriolar 
lymphocyte sheath (PALS) contained only iscom (green 
yellow) and no labeled virus material (Fig. 5). 
3.4 Localizalion after intramuscul3f or subcutaneous 
injecllon 
When RV-BPLor RV-iscom were injected s.c. or i.m., both 
antigens were rapidly found in the draining lymph nodes, 
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Figure 3. (a) Fluorescence microscopic image of an S-flm livcr cryo·section showing Dil-iscom localization in Kuppfer cclls 2 h after 
intraperitoneal injection. S = sinus. (b) Fluorescence microscopic image of an 8-flm spleen cryo·section showing localization of RV in a 
typical ring of MZM, 2 II after i.v. injection. 
Figurt' 5. This shows the different localization of Oil-Iaheled 
rabies viru~ (golden yellow) in MZM and DiO-labeled iscoms 
(green yellow) after i.v. injcetion.1\m follicles (F) aT<: segregated 
by the marginal zone. Mr.-1M are 100'aled on the border. The dashed 
line indie.ltcs the border between I'.IMI'.I and I'.IZ1'>I. A[,o, follicular 
loca[ilation of the DiO·laheled iscoms (green spot~) in the follicle 
t;ln be seen. 
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Figwt? 6. Fluorescence microscopic image of an 8'flm cryo-section 
showing Oil-iscom localization in the popliteal lymph node 2 h 
after s.c. injcction in the fOlltpad. 
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Intramuscular injection in the hind leg resulted in the 
uptake of both antigens in popliteal and inguinal lymph 
nodes. Footpad·injected antigens were found in the popli· 
teal lymph node only. In lymph nodes, labeled antigens 
localized initially in the subcapsular macrophages, and 
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after a few hours in the medullary macrophages. Localiza· 
tion is shown for s.c.-injected iscom only in Fig. 6. No 
differences between RV-BPL or RV-iscom localization 
patterns or intensity were observed. 
Figure 4. (3) Fluorescence microscopic image of an 8·!~m 
spleen ccyo·section showing Djl-iscom loaclization 2 h aflcr 
i.v. injection. (b) Sho\\s the same scction after acetone 
fixation and incubation \\ith NSE substrate, specificafly 
enzymatically staining the MMM. 
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3.5 Immunological responses afler immunlzalioll \lith 
RV·BPL and RV·iscom 
In view of the observed differences in localization patterns 
of RV·BPL and RY·iscom after Lv. and i.p. injection, mice 
were immunized to study the induction of Band T cell 
responses and protection against challenge with virulent 
RV. The results. of which a representative experiment is 
shown in Fig. 7, showed that in mice, RV·iscom are about 
20-30·fold more potent than RV·BPL when injected 
subcutanousl),. RV·iscom and RV·BPL both induced good 
virus·neutralizing antibodies via both routes (Fig. 7A.B). 
Via the s.c. route. 0.08 ~Ig RY·iscom induced RV·neutra!· 
izing antibod)' titers as high as those found with 10 lAg 
RY·BPL. demonstrating the higher immunogeniclt)' of the 
RV·jscom. When administered Lv., c.omparable amounts of 
RV·iscom Induced significantl)' lower titers. T cell prolif· 
eration ill vitro after stimulation with RV·BPLwasused asa 
measure of T cell priming ill vh'o. Fig.7C,D show that 
RV-Iscom primeT cells more efficient I)' and at lower doses 
than RV·BPL, Immunization doses as low as 0.08 ~Ig 
RY·iscom still elicited T cell responses ;/1 vitro. and these 
data corresponded with the induction of neutralizing 
antibody titers. 
After intracerebral challenge with 30 LDso CVS-26, all 
sham-treated animals (II = 7) died (data not shown), Full 
protection was obtained with iscom with a dose as low as 
0.4 ~tg (11 = 6) when given via the subcutancous route 
(Fig. 7E). RY·BPL was full), protective at a dose of 10 ~Ig 
s.c. (Fig. 7F). When given intravenously, RV iscom were 
two- to fivefold less effective, but full protection could still 
be obtained with 2 lAg RV·iscom is. (1/ = 3). Taken togeth-
er, these data confirm the stronger immunogenicity of 
proteins incorporated into iscom, and also show a lower 
efficiency of the Lv. route of immunization over the s.c. 
route, especially for RV·iscom, 
4 Discussion 
RV-iscom, in contrast to inactivated RV antigen, are 
preferentially taken up by ~-fl\fl\.-f of the murine spleen after 
Lv. or Lp. administration. This is an interesting finding 
since. until now, no involvement of this particular subset of 
macrophages in antigen uptake has been demonstrated. 
RV·iscom were more immunogenic than RV·BPL in terms 
of induct.ion of virus·neutralizing antibodies, T cell res-
ponses, and protection against disease. The subcutaneous 
immunization route. which primarily acth'ates the draining 
lymph nodes, proved more efficient than immunization via 
the is. route. Furthermore, it was shown that carbocyanine 
dyes can be used effectively to label membrane viruses and 
iscom, permitting localization pattern studies of these 
antigens ill sitfl. 
Oil and OiO were taken up within a few seconds in viral 
membranes and iscom. The iscom matrix is highly hydro-
phobic and membrane proteins are easily incorporated 
during its formation. Due to this property and the lipophilic 
character of Oil and DiO, these dyes are easily incorpo-
rated in the iscom structure. II should be stressed that these 
carbocyanine dyes are taken up exclusivcly in lipophilic 
structures, i.e. membranes, and, therefore, do not bind to 
or interfere with function or immunogenicit)' of surface 
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proteins [14J. The use of antigens labeled in this way has 
enabled us to obtain data on the early processes of antigen 
handling iI/vivo. 
Recently, this method was used to stud)' the kinetics of 
Iiposome uptake in which MZM and RPM pia)' an impor-
tant role [14J. In this stud),. it was surprising to find that 
there are indeed differences in the cell populations which 
are invol\'ed in uptake of the antigens when they enter the 
spleen. MZM are known to pia)' an important role in the 
uptake of particulate antigens (e,g. Iiposomes. bacteria) 
since the), are among the first cells encountered upon entry 
in the spleen, 
Labeled RVand RV·iscom could be found in MZM within 
2 h after Lv. or Lp. injection. as would be expected. 
However, onl)' iscom were found in MMM. a cell popula-
tion which is located at the border of the marginal zone, 
characterized by slender processes protruding into the 
outer PALS, which is the main site of antibody production 
in the spleen. The role of these ceJls in the handling of 
antigens is unclear [20] but their involvement in the 
processing of antigens has been suggested by Kraal et al. 
(161· 
It should be noted that studies recentl)' showed that 
selective uptake and retention of antigens by the MZM 
ill viro functions as a wa)' of rapid antigen removal and 
elimination, thereb), obscuring it from the immune system 
and hampering a normal response [211. This may e.'<plain 
the relative inefficienc), of RV·BPL taken up by IvlZM to 
induce immune responses at low doses, in contrast to results 
found with iscom, which are taken up by MM1i. Similarly, 
the fact that significant amounts of both antigens given by 
the Lv. or i.p. route are taken up by the MZM could also 
explain the relath'e inefficiency of this route, 
The importance of the microenvironment for antigen 
processing and presentation ill ~'i~'o has often been stressed 
[20, 22J. From numerous studies, it is clear that extensive 
traffic and intimate contact of the cells in the spleen is 
necessary for the generation of the immune response. 
MZM degrade the entering antigens which are then 
transferred to secondary cells. It is not clear whether MMi\I 
behave differently from MZM in this respect. The strategic 
10calizationofMMM at the borderofthe marginal zone and 
close to the PALS (Fig. 4b) makes them ideal candidates 
for the transfer of antigens to antigen presenting B cells or 
perhaps interdigitating dendritic cells in the inner PALS. 
Howevcr, it is not clear which factor determines the specific 
uptake of iscam by MMr-.·{ while other antigens, i.e. 
proteins, erythrocytes, bacteria or RV·BPL, are not found 
in this cell population. RV·iscom and emptr iscom matrix 
localized in the same way. This finding demonstrates that 
the presence or absence of proteins in the iscom matrix does 
not influence localization behavior or the involvement of a 
particular subset of macrophages. Since low amounts of 
liposomes do not preferentially localize in MMM, a direct 
influence of cholesterol in this phenomenon can also be 
excluded, leaving Qui[·A or the uncommon structure of the 
iscom as possible factors. 
The labeled iscom we detected in the splenic follicles within 
hours after administration could be indicative for comple· 
ment-mediated uptake [18J and a possible role for follicu-
lar-dendritic cells in antigen presentation. As reviewed by 
Kosco 123] follicular dendritic cells have the capacity to pass 
antigen to B cells which in turn are capable of processing 
and presenting it to T cells, leading to germinal center 
formation [24]. On the other hand, macropbages can also 
efficiently present antigen to T cells, thereby functionally 
implicating subsets such as the MMM until proven other-
wise, as it the case for the suppressive MZM. Notwithstand-
ing the follicular localization of the iscoms. a role for 
follicular-dendritic or ·D cells in the presentation and 
processing of lscom, which Is also partly major histocom-
patibilitycomplexclass I·dependent, remains to be proven. 
Until now, only one study has described the early events in 
the immune response following I.p. injections of iscoms 
compared to micelles. In this study, it was shown that there 
was a significant increase in the inflammatory response and 
an increase in the uptake of radiolabeled antigen in the 
spleen following immunization with iscom [7]. Even more 
interesting was the obsel'Yation that a larger amount of 
antigen in iscom is retained in the spleen when compared to 
antigens In micelles. In the present stud)'. fluorescence in 
spleen and lymph nodes could still be demonstrated after 
1 week, but not differences were obsel'Yed between RV-
BPL or iscom. 
In conclusion, we have shown that macrophages from the 
marginal zone, and in particular the MMM, are inyoh'ed in 
uptake and, therefore, probably also in processing and 
presentation of iscom-associated antigens. No evidence 
was found for direct interactions between iscom and T cells 
(iscom were not found in the main T cell areas). However, 
the follicular localization of iscom indicates direct activa-
tion of B cells, a not-unlikely mechanism in view of the fact 
that no differential macrophage localization was observed 
in the lymph nodes after s.c. or i.m. immunizations. 
Further studies, involving splenic macrophage elimination 
[2SJ to establish the role of MMM and MZM in the immune 
response against iscoms and viral antigens, are now under-
way. 
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FLUORESCENT LABELLING OF vmus, BACTERIA AND ISCOMS: IN 
VIVO SYSTEMIC AND MUCOSAL LOCALISATION PATTERNS 
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and E. Claassen2 
ILaboratory of Immunobiology, RIVM, POB I, NL-3720 
BA, BiHhoven, and 2Deparlment of Immunology and 
Medical Microbiology, TNO-Medical Biological Laboratory, 
Rijswijk, The Netherlands 
INTRODUCTION 
For gut associated immune responses several ways of antigen uptake have been 
described: non-specific uptake between epithelial cells common non-specific uptake via 
epithelial cells: specific uptake via epithelial cells and specialised uptake via M cells, the 
latter of which seems to be most efficient. I Immunity against a variety of organisms which 
infect the body via mucosal surfaces is probably most effective when antibodies and 
immunocompetent cells are present at the site of infection. Mucosal antibody production, 
especially secretory IgA, is generally induced very poorly after intramuscular or 
subcutaneous immunization. Oral administration of antigens can be used to target the 
specialized lymphoid organs associated with the gut termed Peyer's patches, which are 
embedded in the small intcstine. This immunization route works well with live 
(recombinant) vaccines in both viral and bacterial systems. With non replicative vaccines, 
however, a major disadvantage is the degradation of the antigcns in the stomach and in the 
gut. 
Due to degradation, extremely large doses of the immunizing antigen are required to 
induce satisfactory immunity. The use of slow release particles (Challacombe e( al., these 
proceedings) or immune stimulating complexes (iscoms) for the presentation of antigens 
may circumvent this problem. Iscollls are cage-like antigen carriers (30-40 nm) with built-in 
adjuvant (Quil-A) activity (2, for review see 3). Iscoms containing antigens of different 
origin were shown to be immunogenic by parenteral and local immunization routes. 
Recently the use of iscoms for local mucosal immunization was also investigated. Intranasal 
immunization with influenza virus iscoms leads to a specific antibody response of all 
immunoglobulin classes and subclasses, including IgA, and also to cellular immune 
responses in the Jung.4 This showed that local mucosal immunization with iscoms may lead 
to the induction of both local and systemic immune responses. Ovalbumin (OY A) 
containing iscoms were shown to be immunogenic aner systemic but also after oral 
immunization.s Oral immunization with OVA iscoms induced specific serum antibodies. 
Cellular responses were measured by DTH. The required dose for oral immunization was 
ten times higher (100 ~lg) than that needed for parenteral immunization. This is probably 
due to partial degradation of the immunogen in the gastrointestinal tract before the iscoms 
can reach immunocompetent cells or lymphoid organs in the gut. This dose is 100 times 
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less than that needed to induce a response by OVA alone. (n addition to this repeated 
feeding with OVA, iscoms induced MHC Class I restricted CTL specific for OVA.6 In this 
study we describe the labelling of different types of antigens and an itl l'itro method to study 
the uptake and rOllting of diffcrent antigens in the gut. 
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MATERIALS AND METHODS 
Labelling of Antigens 
Iscoms, rabies virus antigen and Lactobacilli were labelled with DiD (3,3'-
diocladecyloxacarbocanine perchlorate; 0275) using standard procedures? for one hour at 
37°C. The efficiency of labelling of virus and bcoms was determined with a UVfVis 
spectrophotometer. Wavelength scans were made from 380 to 600 nm with a peak at 492 
nm for DiD. Association of DiO with the iscom structure was demonstrated by purification 
of DiO labelled iscoms by density centrifugmion. Latex microspheres were 0.5 I.un 
Covaspheres MX-FITC, Covalent Technology. Ann Arbor, Ml. 
III vitro Incubation of Isolated Gut Loops 
BALB/c mice were euthanized and the small intestine containing the Peyer's patches 
was rinsed with RPMI. Small segments of the ileum containing at least one Peyer's patch 
were filled with 200 ,.11 of an antigen dilution in RPMI and incubated in RPMI medium for 2 
hr at 37"C. After incubation gut loops were washed with PBS, frozen in liquid nitrogen, 
and 8 J.lm sections were cut and analyzed by fluorescence microscopy. 
RESULTS 
DiD labelling of p,uticlilatc antigens is vel)' efficient due 10 the lipophilic character of 
carbocyanines.8 Using our methodology with optimal doses, up to 80 % of the dye is 
incorporated in the lipid phase of the antigens.9 To demonstmte stable association of the 
dye with the iscoms structure. labelled iscoms matrix was purified on a 10-60 % sucrose 
gradient As shown in Fig. I B, a distinct band at approximately 30 % sucrose could be 
seen after centrifugation. This yellow band contained virtually all labelled material (lA). 
Furthermore, iscoms could only be visualized in fractions 7-10 by electron microscopy 
(data not shown). 
Attempts to demonstrate labelled antigens in lymphoid organs in the gut after oral 
administration were unsuccessfull. Subsequently, the method previously described by 
PappolO to study ill vitro uptake of antigens in isolated gut loops was adapted for use. 
Considerable autofluorescence in the Peyer's patch W<lS observed (2A) after sham 
incubation. Incubation of gut loops with labelled Lactobacilli showed that within 2 hr the 
bacteria were taken up specifically in the M cells in the Peyer's patches. Iscoms were taken 
up very rapidly and efficiently in the M cells. Free r<lhies virus did not localize in the 
Peyer's patch but was demonstrated bound to the surface of epithelial cells (not shown). 
Upt<lke of FITC-Iabelled latex microparticles could not be demonstrated in any mucosal cell 
type in the gut. 
DISCUSSION 
Recently we introduced a new method to study ill vivo localisation patterns of intact 
particulate antigens. I I In these studies particulate antigens were labeled with Dii. Tn this 
study we extended the lise of carbocyanin dyes for labelling and in situ detection of iscoms. 
Iscoms were labeled with DiO because of the significant golden yellow autofluorescence of 
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Figure lA shows the absorbance at 492 nm and the sucrose concentration of fractions obtained from a 
sucrose density gra9ient after centrifugation. Fractions 7~1O contain iscoms. IB shows one distinct band 
present after density centrifugation which contains all lmund DiG. 
macrophage-like cells in the Peyers patches. DiO has a bright green fluorescence (Dil :::: 
yellow) and can therefore easily be distinguished from the autofluorescent background. 
[n this paper we present novel data on the uptake of different types of intact 
particulate antigens in isolated gut loops. After labelling with DiO, antigens can be easily 
visualized using standard fluorescence microscopy. The present approach shows that 
iscoms can be labelled efficiently post formation, which is an advantageous characteristic of 
the method. 
After parenteral administration iscoms localize distinctly front rabies virus antigen. 
Following Lv. administration iscoms were taken up by a distinct subset of splenic 
nmcrophages, namely the marginal metallophilic macrophages. In contrast to this, rabies 
virus antigen was found mainly in marginal zone and rcd pulp macrophages.9 The finding 
that iscoms Cl1n be used for local mucosal, especially oral. immunization is important for the 
development of protection against pathogens which acquire access through mucosal 
membranes <lnd therefore requires mucosal immunity. The importl1l1cc of the mucosal 
immune system for vaccine development has recently been rcviewed. 12 Orally administered 
,lIltigcns are only immunogenic if they can reach lymphoid cells or organs in the gut. The 
observed differences in uptake and localisation of antigens after parenteral immunization 
Illay be responsible for observed differences in inununogenicity. In view of the differential 
localisation pattern observed after i.v. or i.p. administration, it was decided to investigate 
whether a similar difference in localisation pattern between virus and iscoills was also found 
in the GALT. 
Iscoms and Lactobacilli were taken up specifically by M cells in the Peyer's patch. 
Again rabies vims antigen localized distinctly and was mainly found in close association 
with epithelial cell surface and not with Peyer's patch M cells. This variation in localisation 
might explain the observed differences in efficacy (RV-iscoms vs RV free antigen). Using 
isolated gut loops we could not demonstrate any uptake of 0.5 f-llll latex particles in the 
Peyer's patches. This finding is an extension of the experiments of Eldridge l3 who showed 
uptake of polystyrene and polylactate particles, but not of cellulose-acetate or ethyl-cellulose 
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Fig~re 2. F1uorcscem:c micrographs Ill' l:!!-Im sections Ill' Peyer's patches after incuf)ation with RPMt-
medIUm (2A), RPM I containing lahdcd La("(olwnHli (2B) and RPMlconlaining labeled iscoms (2C). 
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microparticles, after oral administration. Elridge showed that particles of small size and 
high hydrophobicity were well absorbed in Peyer's patches. The high uptake of iscoms in 
Peyer's patch may well be explained by the similar hydrophobicity of the structure. 
However, relatively high doses of iscoms, when compared to parenteral immunization, are 
required for oral immunization to induce responses, probably due to degradation. 
Nevertheless, this study demonstrates the potential of iscoms as antigen carriers to target 
antigens to specialised antigen presenting cells in lymphoid organs of the gut. 
REFERENCES 
1. P. J. Van der Heijden. DOf.:toraf Thesis, Erasmus University of Rotterdam (1990). 
2. B. Morein, B. Sundquist, S. Hoglund, K. Dalsgaard, and A. Osterhaus, Nature 
308:457 (1984). 
3. I. Claassen and A. Osterhaus, Res. ImmwlOl. 43:531 (1992). 
4. P.O. Jones, R. Tha Hla, B. Morein, K. Lovgren, and G.L. Ada, Seand. J. 
Immunol. 27:645 (1988). 
5. A. M. Mowat, A.M. Donachie, G. Reid, and O. Jarrett,lmmunology 72:317 (1991). 
6. A. M. Mowat and A.M. Donachie, ImmwlOt. Today. 12:383 (1991). 
7. E. Claassen, J.lmlll/lllOl. Meth. 147:231 (I992a). 
8. Honig and Hume, Trends Neurose. 12:333 (1989). 
9. I. Claassen, A. Osterhaus. und E. Claassen submitted for publication 
10. J. Pappo, T.H. Ermak, and H.J. Steger, Immunology 73:277 (1991). 
11. E. Claassen, 41st Forum in Immunology, Res. Immllllof. 143:235 (l992b). 
12. J. R. McGhee, J. Mestecky, M.T.Dertzbaugh, J.H. Elridge, M. Hirasawa, and H. 
Kiyono, Vaccine 10:75 (1992). 
13. J. H. Eldridge, C.J. Hammond, J. Meulbroek, J.K. Staas, R.M. Gilley, and T.R. 
Tice, J. Cantrall. Release II :205 (1990). 
79 

Chapter II.3 
A new method for the removal of mononuclear phagocytes 
from heterogeneous cell populations in vitro, using the 
liposome mediated macrophage 'suicide' technique 
I.Claassen, N.van Rooijen and E.Claassen 
Journal of Immunological Methods, 1990,134:153-161 
81 

Chapter 11.3 
A new method for removal of mononuclear phagocytes 
from heterogeneous cell populations in vitro, 
using the liposome-mediated macrophage 'suicide' technique 
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(Received 23 January 1990, revised received 24 April 1990. accepted 171uly 1990) 
In tlus study we present a new method for the elimination of mononuclear phagocytic cells from cell 
suspensions. By making use of tiposome-encapsulated dichloromethylenc diphosphonate we were able to 
effectively remove macrophages from spleen cell suspensions. This effect was not observed when using the 
free drug or control (PBS) Iiposomes. The use of this procedure has no effect on other cell types, as 
measured by growth, protein production, antigen presentation and antigen specific T cell proliferation, 
though PBS liposomes in very high doses were able to inhibit antigen presentation. The finding that 
lymphocytes are not affected by the liposome encapsulated drug suggests that the observed loss of 
lymphocytes in vivo, after intravcnous dichloromethylene diphosphonate liposome treatment, may be due 
to damage inflicted by lysosomal enzymes released from dying macrophages. This method permits the 
removal of both macrophages and monocytes from heterogeneous cell populations (Lc., blood, lymphoid 
tissue suspension) in vitro with a very high ratc of reliability. With the concentrations and incubation time 
used, no negative effects on other cell types were observed. 
Key."wds: Mononuclear phagocyte; Uposome encapsulated dichloromethytene diphosphonate; Heterogeneous cell population: 
Removal of mononuclear phagoc)'tes 
Introduction 
In order to selectively remove monocytes and 
macrophages from heterogeneous cell populations 
(e.g., blood, spleen suspensions) several ap-
proaches have been proposed. Macrophages can 
be eliminated with silica, asbestos (d, Kagan and 
Hartmann, 1984) or I-carrageenan (d., Ishizaka et 
aI., 1989) or they may be removed by the use of 
carbonyl iron (cr., Wong and Varesio, 1984). Sep-
hadex G-IO has been proposed as a column matrix 
Correspondence (0: E. Claassen, Immunology, TNO MBL. 
p.o.n. 45, 2280 AA Rijswijk, The Netherlands. 
for the removal of macrophages from suspensions 
of immunologically reactive cells (cf" rvHshelI and 
Mishctl, 1984). 
Recently we developed a new method for the 
selective elimination of phagocytic cells in vivo, 
using liposome-encapsulated dichloromethylene 
disphosphonate (ClaMOP, reviewed in Van Rooi-
jen and Claassen, 1988; Van Rooijen, 1989), Un-
like free CI 2MOP, liposome-entrapped CI2~.fOP 
is taken up only by phagocytes that have easy 
access to the liposomes (e.g., in the liver, spleen 
and circulation) after intravenous administration. 
Once taken up, the liposomal membranes are di-
gested by phospholipases in the Iysosomes and the 
drug is released inside the cell. Macrophages can 
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be effectively killed in this way, as we demon-
strated at the light-mieroscopicalb'ei (Van Rooi-
jen and Van Nieuwmegen, 1984), by enzyme-
histochemical methods (Claassen et aI., 1987a), 
functional tests (Claassen et aI., 1986) and at the 
ultrastructurallevcl (Van Rooijen et aI., 1985). In 
order to study the role of macrophages in vitro 
under the same conditions as we used in our in 
vivo elimination studies, an in vitro equivalent of 
tltis macrophage elimination technique was re-
quired. Moreover the cause of the observed effects 
of CI 2 MDP-liposomes on lymphocytes in vivo 
(cr., Van Rooijen et ai., 1985; Claassen et aI., 
1986), due either to free CI 2 MDP, CI 2 MDP-lipo-
somes or enzymes released by dying macrophages 
was a subject requiring further investigation. 
In the present study we show that the approach 
used for the elimination of macropbages in vivo is 
also effective for heterogeneous cell populations in 
vitro. 
IHaterials and mcthods 
Experimental design 
Cells, from splcen suspensions (d., Claassen 
and Van Rooijen, 1985), or cell lines (UytdeHaag 
et aI., 1987), were washed and resuspended at a 
concentration of 105 cells/ml in DMEM (Gibeo) 
tissue culture medium. After incubation with lipo-
somes the suspension was mixed with an equal 
volume of Lymphoprep (density 1,077 g/ml, 
Nyegaard, Oslo Norway) and centrifuged for 15 
min at 1600 rpm (400 X g). The supernatant with 
free liposomes was removed and the pellet was 
resuspended and washed again in Iymphoprep/ 
Df"fE/\:f (I: 1). Cells were counted and used for 
various assays/culture systems. Data were 
analyzed with the t\\'o~sample Student's I test for 
comparison of two empirical means in a normally 
distributcd population (Sachs, 1984), P values are 
given in relation to untreated and PBS-liposome 
treated controls. 
Preparations of liposomes 
Multilamcllar liposomcs were prepared (sterile) 
as described earlicr (Van Rooijen and Van 
Nieuwmegen, 1984). To summarize the procedure 
briefly, 86 mg phosphatidylcholine and 8 mg 
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cholesterol were dissolved in chloroform in a 
roundbotlom flask. By vacuum rotary evaporation 
at 37 0 C a thin film formed on the wall of the 
flask. CI 2MDP (1.89 g diss91ved in 10 ml PBS) 
was enclosed by gently shaking for 10 min. The 
sllspension was kept for 2 h at room temperature 
and sonicated for 3 min at 20 0 C. After an ad-
ditional 2 h at room temperature free CI 2 MDP 
was removed by centrifugation (100,000 X g, 30 
min). Liposomes were resuspended in 4 ml PBS. 
The amount of liposome-encapsulated CI 2 MDP 
was dctermined according to Claassen and Van 
Rooijen (1986). 
ImmllllOcytochemistry 
Cytospin preparations of cell suspensions (and 
8,um cryostat sections) of spleen tissue were fixed 
for 10 min in acetone containing 0.02% 11 2°2 (to 
minimize endogenous peroxidase activity) freshly 
prepared. 
Endogenous acid phosphatase activity of splenic 
macrophages was demonstrated by incubation with 
naphthol AS-Dl phosphate and pararosaniline for 
30-45 min at 37 0 C (Claassen et aI., 1987a). 
Monoclonal antibody staining was performed es-
sentially as described previously (Claassen et aI., 
1988). Briefly, cryostat sections and cytospin pre-
parations were air-dried, fixed and incubated for 1 
h at 4 0 C with tbe appropriate dilution of the 
monoclonal antibody supernatant, rinsed thrice in 
PBS and incubated with rabbit anti-rat 19 coupled 
to horseradish peroxidase (Dako, Copenhagen) 
and 1 % normal mouse serum for 1 h at room 
temperature. After rinsing three times in PBS, 
HRP activity was demonstrated by incubation for 
10 min with 3,3-diaminobenzidine (0.5 mg/ml in 
0.05 M Tris-HCI, pH 7.6, containing 0.01 % H 20 2 )-
The reaction was stopped by transferring the slides 
to PBS. Thc monoclonal antibodies used included: 
r.,.'fOlvfA-2 for the detection of all splenic macro-
phages (Kraal et at, 1987), ERTR-9 for marginal 
zone macrophages (Van Vliet et ai., 1985), 
MOMA-l for marginal metallophilic macrophages 
(Kraal and Janse, 1986), Thy-1 for T lymphocytes 
(d., Claassen et aI., 1988), MT-4 for T-helper 
lymphocytes (Pierres et ai., 1984), Lyt-2 for T 
cytotoxic/suppressor lymphocytes (Ledbetter and 
Herzenberg, 1979), anti-Igr.,·{ for B lymphocytes 
(Braun and Unantlc, 1980), and were a kind gift 
from Dr. Georg Kraal (VUA, Amsterdam) and 
Dr. Willem Van Ewijk (EUR, Rotterdam). Slides 
(either coullterstained or not with haematoxylin 
for 15 s) were mounted in glycerinc gelatin or in 
malinol after dehydration. 
f/ybridoma growth and antibody production 
A mouse monoclonal hybridoma cell line 
(SH 4.k9 ), producing anti-TNP antibodies of IgGI 
isotype, was used to study growth and antibody 
production. The lise of these antibodies (as refer-
ence sera) and the anti-TNP ELISA has been 
described in detail before (Claassen et aI., 1988). 
Cells were incubated with different doses of lipo-
somes (Fig. 2) in DMEM medium (10s cells/ml). 
After incubation for 1 h at 37°C and 7% CO2 , 
cells were separated from liposomes and 1.7 x 104 
cells were seeded per well (24 well plate, Costar). 
After 3 and 5 days supernatants were removed for 
ELISA and the cells harvested and counted. 
Antigen preselltalioll and proliferation by Band T 
cells 
IL-2-dependent, ~\'fHC class-II-restricted, T cell 
clones and Epstein-Barr virus-transformed B cells 
(EBV-BC) were cultured as described earlier 
(UytdeHaag et aI., 1987). In lymphocyte transfor-
mation assays cloned T cells (10 4/weU) were cul-
tured in the presence of autologous irradiated 
(3000 rads) EBV-BC (10 4/well) as antigen pre-
senting cells and stimulating antigen (autologous 
immunoglobulin) in RPMI 1640 (Gibco) contain-
ing 10% (v/v) pooled human AB serum. After 4 
days the cells were pulsed for 18 h with 0.5 pCi 
[6-3HJthymidine (Amersham)/well. Cells were 
harvested and DNA-incorporated [3HJthymidine 
was measured with a LKB liquid scintillation 
counter (1205, Betaplate). 
To study the effect of CI 2 MDP, 105 T cells or 
10 5 EBV-BC were incubated in the presence of 
different doses (see results section) of free or 
Iiposome encapsulated CI 2MDP (in a final volume 
of 1 ml) for 2 h at 37 0 C. After incubation 0.5 ml 
Lymphoprep was added and the cells separated 
from the liposomes by centrifugation (15 min, 
400 X g). The cells were then washed thrice in 
RPMI1640 containing 2% (v/v) human AB serum 
and were tested as described above. 
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Results 
Sp/el'll sllspensiom from CI~MDP'freafed animal:> 
Spleen sections prepared from frozen spleens, 
of CI 2f\'IDP-liposome treated and control animals, 
were stained for the presence of endogenolls acid 
phosphatase and the macrophage markers 
MOMA-2, MOMA-I and ERTR-9 (sec materials 
and methods section ). Cl 2MDP-liposome treated 
animals (3 days after intravenous injection) con-
tained no macrophages. In cytospin preparations 
of cell suspensions made from these spleens (non-
frozen part) we could not find any macrophages 
(this study) or monocytes (Huitinga et aI., 
manuscript in preparation). Furthermore, these 
sllspensions contained normal numbers of T cells. 
However decreased amounts (from 42% ± 6% to 
33% ± 8%) of B cells were found. 
CI}MDP fiposome-treated spleen cell sllspensions 
Elimination of acid phosphatase positive cells 
could be achieved with doses from 50 to 200 
pI/ill! suspension in a dose and time related 
manner (Fig. la). Disappearance of all macro-
phages (as detected by endogenous acid phos-
phatase activity) correlated fully with disap-
pearance as determined by monoclonal antibody 
staining for: all macrophagcs (MOtviA-2); (Fig. 
Ib). marginal zone macrophages (ERTR-9, not 
shown) and marginal metallophils (~'10J\lA-l, not 
shown). Because, damage and eventually elimina-
tion could be detected 1-2 It earlier with the 
em.yme staining, the latter was used in subsequent 
experiments. 
Fig. la shows complete elimination of cells 
containing acid phosphatase after incubation of 
spleen cell-suspensions with 50-200 p.l/ml 
CI 2l\'IDP liposomes for 4 h at 37° C. 
No differences in the number of the following 
cells were observed after CI2~'fDP or CI 2 MDP 
liposome treatment as compared to the normal 
(untreated) or PBS liposome-treated mice: T 
lymphocytes (Thy-l)(Fig. Ib), T helper lympho-
cytes (MT-4), T cytotoxic/suppressor lympho-
cytes (Lyt-2), B IYlllphocytes (anti-mouse illl-
munoglobulin-~'I)(fig. Ib). 
Effects of CI]MDP 011 growth alld proliferation 
Fig. 2a shows no significant effect (P < 0.09) 
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Fig. 1. Elimination of macrophages, with different doses of CI 2 MDP·liposomes. from 1 ml spleen suspensions of BALIJ/c mice. a: 
data e):;pressed as a percentage of endogenous acid phosphatase positi\'C cells relative to controls (PBS.liposomes or untreated). b: 
decrease of macrophages and no effect on T and B cells as shown by immunostaining (see materials and methods section). 
of Cl 2 MDP-liposomes in concentrations ranging 
from 10 to 200 l.d/ml on the increase in number 
(19-33 fold) of hybridoma cells. The same was 
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found for CI 2 MDP tiposome-treated T or B cells. 
used in the antigen presentation assay. However. a 
decrease in proliferation was found upon incuba-
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Fig. 2. Effects of PBS and CllMDP liposomes on antibody producing hybridoma cells (treated for 1 h with Iipo50mes). measured 
after 5 da)'s incubation (at 37°C, 7% CO2 ), a: number of cel1s/mi obtained from seeding 0.17 X 1O~/weU at day O. h: anti-TNP 
antibody production measured in a TNP-ELISA using a I :256 dilution of the culture supernatant. 
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tion of hybridoma cells with PBS-liposomes at 200 
~ Vml (P < 0.05). 
Effecls of Cl}M DP Oil antibody production by hy-
bridoma cells 
As Fig. 2b shows, production of anti-TNP anti-
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bodies by SH4.1C9 hybridoma cells followed es-
sentially the same profile as the hybridoma growth 
curve. Using C1 2 MDP liposomes no significant 
(P < 0.09) effects were observed. Again, PBS-lipo-
somes exerted a significant effect at 200 J1i!rnl 
(P < 0.001). 
Effects of CI}MDP 011 allligell preselltation 
Pig. 3 shows T cell proliferation as a function 
of the dose of liposomes used for pre-treatment. 
The dOlled zone gives the absolute upper and 
lower response limit of untreated or CI 2 MDP-
treated cells. No significant effects of ClzMDP 
Iiposomes were found on the antigen presenting 
capacities of B cells (Fig. 3a). However, a marked 
inhibition was observed after treatment with 200 
ttl/ml PBS-liposomes (P < 0.005). Fig. 3b shows 
essentially the same for treated T cells. In addition 
200 ttl/ml CI 2 MDP liposoflles also inhibited pro-
liferation. Incubation with CI 2tviDP (either free or 
in Jiposomes) or PBS Iiposomes had no effect on 
the viability of the cells, as measured by 
eHlthymidine incorporation of un-irradiated cells 
(data not shown). 
DisclIssion 
In this study we have demonstrated the 
elimination of mononuclear phagocytes from het-
erogeneous cell suspensions by means of Iiposome 
entrapped Clzt>.·IDP. Free CI 2MDP, PBS or PBS 
Iiposomes in similar concentrations were unable to 
eliminate these phagocytes. 
Using doses as low as 50 J-tl/ml cell suspension, 
complete elimination of phagocytes could be ob-
tained. In the mouse a dose of 50-100 It I/Oll 
blood is necessary for complete elimination of all 
macrophages. After exposure of cells for 30 min to 
1 h all phagocytes were killed so that in vitro and 
in vivo dose effects were in agreement. Only the 
time interval that elapsed before acid phosphatase 
activity could no longer be observed was increased 
by decreasing doses of liposomes; thus short (e.g., 
30 min) incubation with the Iiposomal sllspension, 
and subsequent washings to remove the liposomes 
was sufficient to rcmove phagocytic cells The 
sensitivity of the cells was dependent on the am-
bient temperature and agitation of the suspension 
(pilot studies, not shown) and therefore the op-
tima should be determined for specific applica-
tions. Initially, this study was aimed at the genera-
tion of macrophage-free suspensions using spleens 
and lymph nodes of CI 2 MDP Iiposome-treated 
animals. Although in vivo elimination of phago-
cytes with CI 2 MDP liposomes proved very effec-
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tive. B cell numbers were reduced and hence these 
conditions would not be applicable where cells 
other than phagocytes must remain unaltered. 
[n vitro, in contrast, the present studies clearly 
showed that, within the dose range 50-100 J-tl/ml, 
no effects on B or T cell growth, protein synthesis 
or antigen presentation were observed. Thus, un-
like the use of silica or asbestos (cf .• Wirth et aI., 
1980; Elliot and Hartmann 1984), this treatment 
does not influence lymphoid cells in vitro. Fur-
thermore, this method appears to eliminate both 
macrophages and monocytes (Huitinga et a!., 
manuscript in preparation), independently of the 
adherence properties of these cells. Adherence 
properties arc frequently used to rcmove macro-
phages (Mishell and Mishell, 1984; Wong and 
Varesio, 1984). 
In the present study no toxic effects of free 
CI 2 MDP (cr., Labat et a!., 1984) were found on 
the cells investigated, indicating that within the 
dose range used (0.1·-10 mg/ml) the effects were 
due to Iiposome-mediated uptake. Purthermorc, 
leakage of CI 2 MDP from the Iiposomes or dying 
macrophages during incubation of the samplcs did 
not affect the lymphoid cells, since the maximum 
dose released (by complete disruption of all Ii po· 
somcs) was 2-4 mg for the 50-100 J-tI!ml solu-
tions used. This observation also has implications 
for in vivo studies in which we found a decrease of 
marginal zone B cells after treatment with 
CI 2 MDP liposomes, as studied by both im-
munocytochemistry (Claassen et ai., 1986) and 
eiectronmicroscopy (Van Rooijen et aI., 1985). In 
view of the present findings this loss of B cells 
could not be explained by the toxic effects of 
CI 2 l'-,·fDP Iiposomes or free CI 2 MDP, since the 
concentrations of these 5ubslances in vivo would 
be much too low for such an effect. Consequently 
we feel that the loss of marginal zone B cells was 
due to enzymes released by the dying macro-
phages, as previously suggested (Van Rooijen et 
aI., 1985). 
In earlier in vivo studies we demonstrated that 
charges in marginal zone macrophages, which 
specifically take up but do not process thymus 
independent type-2 (TJ-2) antigens such as TNP-
Ficoll are not responsible for either a decrease in 
the specific immune response against these anti-
gens after splenectomy (Claassen et ai., 1989) or 
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for macrophage elimination by CI 2 MDP+iipo+ 
somes (Claassen et al.. 1986a). To exclude the 
possibility that the D cells present in the marginal 
zone were in any way hampered by the liposome 
treatment, we performed a number of functional 
studies with D cell lines in this study. It is clear 
that these cells are not damaged in terms of growth, 
proliferation, antigen presentation or antibody 
production. From the data demonstrating antigen 
presentation by D cells and the fact that this 
process is not hampered by CI 2 MDP liposomes 
we can conclude that D cells may be involved in 
antigen presentation of TI-2 antigens after macro-
phage elimination (cf., Claassen et ai., 1989). 
PBS Iiposomes are supposedly nontoxic carriers 
(cr., Gregoriadis, 1985), and in our in vivo studies 
we have never been able to demonstrate toxic 
effects of phosphatidylcholine-cholesteroi Iipo· 
somes (cr., Claassen et ai., 1988), though a small 
number of studies have reported unwanted side 
effects of Iiposomes, with different compositions, 
in vitro (Chen and Keenan. 1977; Ng et al.. 1978; 
Nuzzo et aI., 1985; Grover and Sundharadas, 1986; 
Mayhew et aI., 1987). This study again shows 
effects of PBS Iiposomes on lymphoid cells. How+ 
ever these effects were only observed at very high 
doses and never in vivo (Claassen et aI., 1988). In 
view of the fact that the numbers of T or B cells 
were not affected but only their ability to pro-
liferate (cell division) we feel that this 'toxicity' 
can be ascribed to changes in the phospholipid 
membrane, e.g., by uptake from cholesterol by the 
cells from the tiposome (cf., also Mayhew et aI., 
1987). 
In conclusion we feel that this novel method for 
the elimination of mononuclear phagocytic cells 
from heterogeneous cell suspensions has definite 
advantages over existing methods for macrophage 
removal. In contrast to other methods, liposome 
encapsulation of the active drug selectively targets 
it to macrophages, thus preventing it from affect+ 
ing non-phagocytic cells such as lymphocytes. 
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SU,\I;\JARY 
In this paper we describe the effect of depletion of splenic macrophages on the uptake, and 
immune response against, different fonnulations of rabies \'irus antigen. Splenic macrophages 
were removed by intravenous injection with dodronate liposomes. p.propio]acton inactivated 
rabies viruS (RY-BPL) and immune·stimulating complexes (iscom) containing these antigens were 
given to macrophage-depleted and control mice. In the absence of phagocytic cells in th.: spleen, 
antigen is still trapped in the red pulp and to a lesser extent in the peri·arteriolar lymphocyte 
sheaths (PALS) for both antigen formulations. The localization pattern in the main area of 
immune response induction, namely the follicles, was unaltered after macrophage depletion. 
Functionally, the depletion of splenic and liver macrophages had no influence on the induction 
of specific antibody reSponses in both RY-BPL or RY-iscom immunized mice, even though the 
latter presentation foml was clearly associated with specific localization in the marginal metallophil-
lic macrophages. In RY·BPL immunized mice, macrophage depletion had no influence on 
proliferative T·cel! responses. However, macrophage·depleted mice that were immunized with RY· 
iscom showed a significant decrease in proliferative T·cell responses. These results confinn existing 
ideas on the spleen as a physical !liter rather than an induction site for humoral responses and 
shed new light on the efficient role of iscoms as antigen-presenting moieties in relation to their 
specific fn .';1'0 localization patterns and partial macrophage dependency. 
INTRODUCfION 
Several mechanisms have been postulated to explain the rela-
th'ely high immunogenicity of antigens presented in immune-
stimulating complexes (iscoms).1.2 Their potency can in part 
be explained by the specific targeting of these structures to 
antigen· presenting cells (APC) of the immune system. Recently 
• we de\'eloped a novel method for the in situ detection of 
iscoms.3 Employing this technique we demonstrated that 
iscoms containing rabies virus antigen were taken up by a 
, different subset of macrophages in the spleen than inactivated 
Receh'ed 28 December 1997; revised 1 April 1998; accepted 
1 April 1998. 
Abbreviations: Dj f, I, I' -dioctadecyJ-J,3,3 ',3'·tetramethylindo-
carboqanine perchlorate; hcom, immune stimulating complex; MZM, 
marginal zone macrophage,; MMM, marginal metallophilic macro-
phages; NSE, non·specific esterase; RPM, red pulp macrophages; RV 
rabies virus; RY·BPL, i3'propio!acton inactivated rabies \irus. 
Correspondence: Dr Ivo. J. T. M. Claassen, Laboratory for Quality 
Control, Institute fot Animal Science and Health, PO Box 65, 8200 
AB, Le!ystad, The Netherlands. 
rabies virus antigen, thereby possibly explaining the difference 
in immunogenicity. Furthennore, we found a surprising prefer-
ence for iscom, rather than intact virus, in the follicular 
trapping/uptake of these antigens. These results led to a 
biphasic presentation model for iscom with a specific localiz-
ation pattern in marginal metallophilic macrophages (MMM), 
away from antigen-degrading macrophages, in the first phase 
and direct presentation to follicular cells in the second phase. 
This model implies an entire or at !east partial dependency of 
the iscom·induced immune response on this particular macro-
phage subset. From several studies it has now become evident 
that the spleen processes antigen in two possible ways, 
depending on different types of non· lymphoid cells. Firstly, 
there seems to be a macrophage-dependent pathway for 
particulate-and thymus-independent type I (mitogenic poly-
saccharides) antigens.4 Second, there is an important role for 
the follicular (dendritic and B) ce!ls of the spleen in trapping 
and presenting soluble protein and TI-2 antigens to the immune 
system.} Because both virus (RY-BPL) and iscom can qualify 
as particulate antigens it remains to be established whether 
these antigens also require macrophage (pre)·processing before 
they can evoke an effective immune response. In view of our 
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earlier study on the difference in splenic localization of these 
two formulations of rabies antigen and based on the available 
literature suggesting a suppressi"e rather that immune-
,timulating role of splenic macrophages we decided to study 
he contribution of splenic macrophages in these responses. 
Ily making use of a well·established technique for splenic 
nacrophage elimination, employing clodronate liposomes, the 
>ole of maerophages, as opposed to the function of follicular 
cells (which are not affected), can be detennined.5 By making 
u~, of the discrete differences in repopulation kinetics of 
dith'rent splenic macrophage subsets6 their role in immune 
response induction could be studied. Furthermore, this elimin-
ation model can be combined ",ith the above mentioned 
labelling technique, thereby enabling the study of ill situ 
antigen localization under macrophage-free conditions. 
MATERIAlS AND METHODS 
Animals tImi chemicals 
Female BALD/c mice aged 12-16 weeks, were kept inmacrolon 
cages under an II hr dark/13 hr light regimen at 20' and were 
given acidified water (pH 3) and pelleted mouse food (Hope 
Farms, Woerden, The Netherlands) ad Itbitlllll. Oil (1,1'_ 
dioctadecyl-3,3,3 ',3'-tetramethylindocarbocyanine perchlorate; 
D-282) was obtained from Molecular Probes, Eugene, OR. 
Clodronate Iiposomes were prepared as described earlier. 7 
Antigens 
Rabies \irus (RY-Pasteur strain) was propagated in Yero-cell 
monolayer cultures.s Culture supernatant was cleared by fil· 
tration and concentrated by Amicon ultrafiltration (cutoff 
106 MW). Virus was inacti\'ated with P--propiolacton (BPL) 
and stored at - 70~ at a concentration of 900 jlg/ml. This 
rabies virus antigen was used for the preparation of RV-
iscoms, as described earlier.9 Briefly RY'proteins were solubil-
ized with 10''10 MEGA-tO (decanoyl-N-methylglucamide) for 
2 hr. at room temperature. The solubilized virus was layered 
on top of a 10% sucrose cushion and centrifuged for 2 hr at 
200000 g. Quil-A (Iscotec AD, Lulea, Sweden), cholesterol 
and phosphatidylcholine (Sigma-Aldrich, Zwijndrecht, the 
Netherlands) were added to the supernatant and the mixture 
was dialyscd overnight against phosphate· buffered saline 
(PBS). Free Quil-A and unincorporated proteins were removed 
by centrifugation over a 20% sucrose cushion for 48 hr at 
150000 g. Incorporation ofRV proteins was \'erified by sodium 
dodecyl sulphate-polyacrylamide gel eletrophoresis (SDS-
PAGE) analysis and a glycoprotein specific enzyme-linked 
immunosorbent assay {ELISA}. 10 
Immlllwlogico{ responses 
Clodronate liposomes were prepared as described in detail 
before/ briefly: 75 mg phosphatidylcholine and II mg choles-
terol were dissoh'ed in chloroform in a 500 ml round-bottomed 
flask. The thin film that fonned on the interior of the flask 
after low vacuum rotary e\'aporation al 37~ was dispersed by 
gentle rotation for 15 min ",ith 10 ml PBS (0'15).( NaClflO mM 
phosphate buffer pH 7·4) containing 1·89 g dichloromethylcne 
diphosphonate (a kind gift of Boehringer Mannheim, 
Gennany). The milky white suspension was kept for 2 hr at 
room temperature and sonicated for 3 min at 20' in a Sonicor 
waterbath sonicator (50 Hz, Farmingda!e, NY). After an 
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additional 2 hr at room temperature, the liposome suspension 
was diluted to looml in PBS and centrifuged (Ioo0oog, 
30 min) to remove free c!od~onate. Liposomes were resus-
pended in 4 ml PBS and microscopically checked for formation 
and size homogeneity. Three animals per group were injcctcd 
Lv. ",ith 200 ~ll Clodronate-liposomes or PBS intravenously. 
48 hr after treatment animals were immunized with I )lg RY-
iscom or with 10 jlg RV-DPL. At day 40 animals were again 
treated with either Clodronate liposomes or \\ith PBS and 
animals were booster immunized at day 42. At day 49 animals 
were killed and the spleen was removed for T-ceH proliferation 
studies. Immunological rcsponses were measured I week after 
the last i.v. immunization at day 42. Rabies virus specific 
antibody responses were measured by antigen binding ELISA 
as described earlier. and T-cell responses were mcasured as . 
described earlier. 1I Briefly, spleen cells were isolated and 
stimulated with varying concentrations of RV-BPL. After 5 
days cells were pulsed with [3H]thymidine for 18 hr. Cells were 
harvested on glass filters and incorporated radioactivity was 
measured in a Betaplate scintillation counter (LKB, Uppsala, 
Sweden). Sera were taken at weekly intervals and were analysed 
in a rabies-virus-specific ELISA for the induction of specific 
antibodies. 
Flllorochrome labe/fing of rabies rirusallligcfI and RV-iscolI/s 
Stock solution of Oil and was made in pure ethanol 
(2'5 mg/ml). 100 ~lg RV-BPL, RY-iscoms or empty iscoms 
were mixed with 20 mg Dil in PBS and incubated for one 
hour at 37'. After labelling the samples were filtered using 
0-45 mm filters to separate crystalline Oil and labelled anti-
gensP Labelled material was stored in the dark at 40 for up 
to 4 weeks. Administration was perfonned Lv. for several 
doses ranging from 0·' to 10 jlg per mouse. 
Fluoresce/Ice microscopy 
Frozen sections (811m) of organs under study were observed 
and photographed directly after cfyo-sectioning with an 
Olympus (Tokyo) Yanox fluorescent microscope. Oil fluores-
cence was observed both as red with green light (excitation 
filter BP 545) and 'rhodamine(fRITC' optics (emission: EO 
570). 
Ellzyme cytochemistry 
Organ sections used for localization studies based on fluores-
cence microscopy were air-dried and fixed in acetone for 
enzyme staining. Endogenous acid phosphatase staining for 
the identification of all splenic and liver phagocyte, was 
perfonned as described in detail earlier. 13 
RESULTS 
Localization of \irus and Iscom in the spleen after macrophage 
depletion, 
Already at 30 min after Lv. administration of Di11abeled RV-
BPL preferential uptake by marginal zone macrophages 
(MZM) could be observed in control mice (PBS at -48 hr) 
with some antigen also being taken up by red pulp macro-
phages. This image was identical to the localization patterns 
we described in a recent study for normal untreated mice.3 
The preferential uptake by MZM was maintained when 
observing sections at 60 or 120 min (Fig. la) and proved 
Chapter llA 
Hgure 1. In this figure the uptake of Dil·labelled antigens is sho\\n in the spleen 2 hr afier i.v. injection. (a) Uptake of RV·BPL 
in nonna! unlreated animals. (b) Uptake of RV-BPL in c!odronatc treated animals. (e) Uptake of RV·iscom in untreated animals. 
(d) Uptake of RV·iscom in clodronate Ir.:atcd animals, R, red pulp, M, marginal zone, P, ~ri·artcriolar J)rophoC} Ie sheath. 
completely in accordance with other localization studies on 
particulate thymus dependent anligens. 14•IS 
Splenic macrophages were depleted by i.v. administration 
of c!odronalc liposomes,16 depletion was complete as con· 
firmed with enzyme histochemistry for acid phosphatase of 
alternating sections from those shown in Fig. I (data not 
shown), Irrespective of this complctc absence of macrophagcs 
from the spleen, a massiw trapping and retention of Dil· 
labelled RV·BPL could be observed (irrespective of the dose 
given). Contrary to the discrete localilation pattern found in 
97 
Immunogenic presentation of viral and bacterial antigens: iscom and OMV as a model for new vaccines 
normal or PBS treated mice (in MZM and red pulp), RV-8PL 
seemed to be evenly distributed over al\ splenic compartments 
(Fig.lb). 
As described before,J iscom was taken up preferentially by 
M;\lM (bright yellow dots in Fig. Ie) and to a lesser extent 
by MZM and on cells in the follicles. In macrophage-depleted 
animals iscom was trapped and retained almost exclusively in 
the marginal zone and red pulp of the spl~n (irrespective of 
the dose given). Contrary to RV-BPL almost no iscom localiz-
ation could be observed in the PALS area of depleted animals 
(Fig.ld). 
Immunologkal responses after depletion of spleen maerophages 
Based on dose-response eUT\'es generated before l we chose for 
similarity of evcntual titre rather than dose of immunization 
(antigen). In this scenario Hlg of RV-iscom is equivalent to 
10 Jig of RV-BPL, both resulting in virus ncutralising anti-
bodies. spedfic T cells and 100% survival after challenge (i.e. 
ful! protcction).l 
Rabics.virus-spedfic antibody responses in serum were 
mea~ured weekly in antigen-specific ELISA. Serum samples 
w~rc analysed weekly after depletion of splenic macrophages 
and suhscquent immunization to obs~rn~ possible effects 
t'auscd by macrophage repopulation of thc spleen. It waS 
c,tablishcd that at day 7 no rcpopulation of the spleen with 
macrophage; has yet occured, marginal metallophils reappear 
betwecn 14 and 21 days and at day 28 the normal situation is 
almost completely restored (4.6.11 and data not shown). As is 
shown in Fig. 2(a) (represenative experiment from three per-
formed) no difference in the kinetics of the antibody rcsponse 
({luld br (lh~er\'ed when splenic macrophag.os were removed 
in RV-i,com immunized animals as compared with untreated 
animilk It ~hould bc noted that a trend towards higher titers 
in dcplcted RV-BPL animals could be observed (no! 
~ignincant). 
The c1odronate treatment was repeated at day 40 and 
animals were booster immunized with RV-iscom at day 42. 
80th trl',lted and untreated animals showed increased serum 
titrcs 'ilt 7 days after boost immunization as compared to 
primary re'iponses. Again, no effect orthe c1odronate liposome 
trcatmcnt was observ.od. Identicany, humoral responses after 
immunLwtion with RV-BPL were unaffected after c1odronate 
liposome treatment. 
Proliferative splenocyte responses in RV-BPL immunized 
animals were unaffected after treatment with c1odronate lipo-
somes (Fig. 2e). Howe\"er, when splenic macrophages were 
removed prior to imnlUnization .... ith RV-iscom a significant 
decrease in rabies-virus-specific spleen-eel! responses could be 
observed (Fig. 2d). III ritro restimulation ofT celts with either 
inactivated antigen or antig,;n as provided by paraformal-
dehyde (PFA)-fixed persistently ERA (Evelyn-Rokitnicky-
Abelseth)-infected PSI5 (H2d, haplotype) cells was also 
significantly decreased in c1odronate liposome-treated animals. 
DISCUSSIOX 
In this study we show that the T-cel! mediated immune 
response against rabies virus iscom is partly dependent on 
splenic macrophages. Depletion of macrophage; resulted in 
almost identical ill sill/ localization patterns for rabies virus 
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antigen presented as inactivated virus or in iscom. The elimin-
ation of splenic macrophages has no effect on the humoral 
response against rabies virus for both antigen formulations. 
When given in sufficiently high doses, 'empty' liposomes 
can efficiently block and suppress the macrophage system. 18,19 
Similarly, macro phages can be suppressed or depleted by using 
substances such as carrageenan, silica, carbonyl iron or anti-
bodies.20 We have developed and applied a liposomc-suicide 
technique for the actual elimination of macrophages. i ,16 The 
resulting modulation studies have firmly established the role 
of macrophages in innate (antigen removal) rather than in 
adaptive (antigen presentation) immunity.4.',15 Emphasizing 
the role of what is now called professional antigen presenting 
cells, such as dendritic and 8 cells, in the generation of 
antibodies and ceHular immunity.' Not very surprising it could 
be established in a similar fashion that the macrophage is thc 
principal antigen-presenting cell for liposome-encapsulated 
antigens21 as well as for other particulate antigensy·n 
Furthermore, CTL responses induced by membranous vesicles 
but not those induced by syngeneic antigen pulsed sp!enoc}'tes 
proved to be macrophage dependent21. Iscom and inactivated 
\irus can be regarded as h)'drophobic particulate antigens. In 
this study no differences in humoral response were observed 
in macrophage-depleted cells as compared with untreated 
animals, at the antigen dose and immunization regime studied. 
In view of the finding that trapping of both antigens occurs 
on follicular cells in depleted animals it can be concluded that 
follicular dendritic or follicular 8 cells are involved in antigen 
presentation of both RV-BPL and iscom. This observation. in 
combination with the observed decrease in T-cell responses 
against iscom in depleted animals. suggests a role for both 
follicular cells and MMM in the pre;;entation of iscom. And 
no or very limited role for MMM in the presentation of 
RV-BPL. 
To induce an efficient ~H-IC class I restricted immune 
response, invoh'ing the production of antigen specific cyto-
toxic T-cells (CTL), it seems necessary to target the antigen 
to the cytoplasm19 or induce processing by dedicated macro-
phagesH - H , It was shown that both anionic and cationicH 
pH-sensith"e liposomes could enter the class-I restricted 
(endoplasmatic reticulum/Golgi) pathway.22.24"25 The 
addition of Qui! A to liposomes has been shown to efficiently 
enhance their capacity to induce CD8+ CTL,16 Quil-A is an 
adjuvant and toxic by itself, and a crucial component of 
iscom which belong to the most potent adjuvants, for 
hydrophobic proteins, known. l - l 80th rabies virus iscom and 
RV-8PL can induce antigen-specific, class-J restricted CTL. 
Quil A containing liposomes proved 10 be an effective vehicle 
to shuttle hydrophillic proteins into the major histocompat-
ibility complex (MHC) class I pathway, resulting in induction 
of CDg+ Cytotoxic T lymphocytes (CTL). These and other4.21 
data point to a conflicting rolc for macrophages in direct 
stimulation of T cells in some systems and suppression of T 
cells in others. 
We ha\"e shown previously that the T-ceH responses are 
not directly influenced by treatment with c1odronate lipo-
somes. lS Consequently the observed decrease in T-ceH prolifer-
ation in RV-iscom immunized animals is likely a result from 
the absence of splenic macrophages. Because no decrease was 
observed in the CD-i T-ceJl dependent humoral response the 
observed decrease can be explained by in the class-I restricted 
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FIgure 2. In this figure the rabie. ,irus sp<'Cific immunological responses ar.:: shov.n 1xfof¢ and after treatment .... ith c1odronate 
liposomes. Rabies virus s~dfic ELISA serum litre> in RV·BPL (a) and RV-iscom (b) immuni~ed anima!\. immunization. 
Proliferati\-e spl~n cdl responses in RV·BPL (c) and RV·iscom (d) immunized animals. 
CTL responsc which is de~ndent on the presence of macro-
phages. Such a decrease has been described for the generation 
of primary ovalbumin (OVA)-specific CTL after splenic macro· 
phage elimination.19 Why this decrease does not occur in 
RV·BPL immunized animals, which nonnally generate CTL 
activity as well, remains unclear but, in combination with the 
localization data, it suggests a role for the MMM subset in 
the (pre)processing of antigen in iscom and not in other 
unactivated antigen forms. 
Removal of splenic and hepatic macrophages with dodron· 
ate liposomes is very efficient and actually eliminates phago-
cytic cells from the tissues altogether. 16 As de~ribed before in 
studies using radioactively labelled IiposomesJO this removal 
does not result in ~rsistently increased serum levels of the 
antigen nor in a decfease of splenic uptake or a change of 
antigen localization patterns. The present results show the 
localization patterns of this nonphagoC}'tic trapping by the 
spleen. As observed for a soluble thymus-independent antigenS 
it is evident that antigen is still trap~d by follicular (dendritic 
or B) cells of the spleen after macrophage depletion. In view 
of the crucial role of dendritic cells19 and follicular dendritic 
cells in the presentation of antigens to the immune system3•S 
this is an important observation. Furthennore, this is in 
accordancc with the primary function of the spleen, namely 
as a filter of the blood.4 .s In a large number of studies it has 
now been shown that removal of marginal zone macrophages 
leads to a relativc increase of humoral immune responses 
against particulate antigens17 or antigens in oil emulsions.J1 
This trend is also visible in this study (Fig. 2b). The preferential 
localization of iscom in MMM certainly leads to relative 
protection of the antigen for the degradable action of marginal 
zone macrophages and provides an explanation for the relativc 
effectiveness (1O-2S-fold efficiency gain in terms of dose3 ) of 
iscom in inducing immunc responses. Studies invol",ing devel· 
opment or optimization of iscom or other antigen presenting 
moieties should therefore include similar ill \'il'o localization 
and modulation studies to better predict eventual efficacy. This 
in turn will lead to vacdnes with higher efficacy at much lower 
antigen concentrations because much less antigen is lost by 
immunologically non-s~cific filtering. 
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Chapter II.S 
Incorporation of inactivated rabies antigen into iscom 
enhances its capacity to induce specific T-cell mediated 
immunity and protection in mice. 
I.Claassen, M.Poelen and A. Osterhaus 
submitted for publication 
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Chapter 11.5 
Sl/lIllllfllY 
It is well established that incOlporation of rabiesvirl/s (RV) antigen into iscom 
enhances its potency to indl/ce virus neutralizing antibodies and protection in mice. 
Here we show that intramuscular immunization of BALBIe mice with inactivated RV 
antigen, induces RV specific proliferative and cytotoxic T lymphocyte (CTL) responses 
more efficiently when the antigen is incOlporated into iscom. Analysis of tlte pltenotype 
of tlte RV specific CTL by depletion studies sltowed that Lyt-2 positive cells were 
involved in tlte RV specific CTL responses. These data add to our previous findings, 
iIllistrating tlte possibility to reduce the at/tigen concentration in rabies vaccine by 
presenting it in an iscolll stmctllre. 
Rabies continues to be the cause of more than 50.000 cases of fatal encephalitis in 
developing countries annually (WHO report). Although safe and effective cell culture 
vaccines for human use are available one of the limiting factors in their availability is 
the limited production capacity for RV antigen. Previously we and others have shown 
that incorporation of RV antigen into iscom not only enhanced its potency to evoke 
neutralizing antibodies but also to induce protection in a pre- and post- exposure 
setting in mice (Fekadu et ai., 1992; Claassen et ai., 1995). Vims neutralizing 
antibodies have been shown to be protective against infection with RV. There are 
however several indications that RV specific T lymphocytes may play an additional 
role in the protective immunity against rabies. These include, the demonstration of 
cellular inununity after infection or immunization (Wiktor et ai., 1977a and 1977b), 
the protective capacities of a rabies vims specific cytotoxic T lymphocyte (CTL) clone 
against challenge in mice (Kawano et ai., 1990), and the induction of protective 
immunity against RV infection after immunization with nucleoprotein (N), a protein 
that does not induce any neutralizing antibodies (Dietschold et ai., 1987; Tollis et ai., 
1991). Recently it was demonstrated that protection against RV can be induced by 
immunizing with a plasmid expressing the full length RV-GP (Xiang et ai., 1995). 
However the slow development of the immune response to genetic immunization 
makes these vaccines unsuitable for postexposure treatment of RV infection (Ert! and 
Xiang, 1996). 
Besides specific T helper cells, CTL may play an important role in the RV specific 
immunity: MHC class I restricted CDS' CTL have been shown to be important for the 
elimination of several vims infections. For the induction of this type of vims specific 
CTL, it is generally considered neceSSalY that de novo synthesis of viral antigen takes 
place. Therefore most inactivated vaccines fail to induce these responses. However, 
some antigenic presentation forms of inactivated vaccines, like the iscolll presentation 
fonn have been shown to induce these CTL (for review see Claassen and Osterhaus 
1992). Interestingly, in the past sollle reports have indicated that the current inactivated 
rabies vaccines do induce MHC class I restricted CDS' CTL responses (Sugumata et 
ai., 1990; Fujii et ai., 1994; Kawano et ai., 1990). Therefore, we have studied here the 
103 
Immullogenic presentation of viral and bacterial antigens: iscoll1 and OMV as a model for new vaccines 
potential of beta propiolacton inactivated rabies vaccine, produced in cell culture, to 
induce RV specific CTL in its non-adjuvated form and after incorporation into iscom. 
Rabies vims is a negative stranded RNA vims and its genome encodes five proteins: 
the large protein (L) , the glycoprotein (0), the nUcleoprotein (N), the phosphoprotein 
(NS) and the matrix protein (M). Resistance to RV infection is mediated by both 
humoral and cellular responses. Protection against rabies is mainly dependent on vims 
neutralizing antibodies (VNA) directed against the O-protein of the vims. Cell 
mediated inununity (CMl) especially cytotoxic T lymphocytes (CTL) with the 0-
protein as target have been described but their role in protection is not clear. The N-
protein camlOt induce VNA but the N-protein and synthetic peptides mimicking parts 
of the N -protein can induce protection in mice in the absence of VNA at the time of 
challenge. Although the mechanism of this protection is still unclear it clearly 
demonstrates a role in protection of either N-protein specific T-helper cells or CTL. 
It is generally assumed that CTL recognising infected target cells in the context of the 
correct MHC class I haplotype play an important role in the elimination of viral 
infections. For the induction of MHC class I restricted CTL de 1l0VO synthesis of 
proteins is regarded essential. However exceptions have been described. Interestingly 
Wiktor et ai. initially showed that inactivated RV can induce CTL responses (Wiktor et 
aI., 1977a). 
Most data on RV specific CTL have been obtained after immunization with inactivated 
or attenuated vaccines. CTL responses have been desclibed after innnunization with 
live attenuated vims (Sugamata et aI., 1990; Wiktor et aI., 1977b) and with inactivated 
RV (Wiktor et aI., 1977a and 1977b; Morgeaux et aI., 1989). CD4 T- cell responses 
against RV have been described in both mouse and man (Bunschoten et aI.,1989,1990; 
Celis et aI., 1988a, 1988b). Alternatively, iscom containing antigen have been shown 
to induce class I restricted CTL responses (Takahashi et aI., 1990; Mowat et aI., 1991). 
Iscoms are small (40-80mn ) cage like stmclures that contain multiple antigen 
molecules and the adjuvant Quil-A (Morein et aI., 1984). The iscom structure is a 
matrix with high adjuvant activity for the induction of anti viral immune responses in 
general ( for review see Claassen and Osterhaus, 1992). We have described that RV-
iscom require a lower antigen dose to induce high VNA titers, proliferative T-cell 
responses and protection as compared with RV-BPL. Here we have analyzed whether a 
qualitative difference exists between RV-BPL with RV-iscom for their priming 
capacity of CTL ill vivo. 
To this end we have constmcted RV-iscom, using BPL inactivated rabies vi1llS as 
described earlier (Claassen et aI., 1995). We extended our observations in previous 
experiments with regard to the induction of rabies vims specific T-cell proliferation 
and protection with a wider range of antigen concentrations (figure 1). Indeed RV-
iscom proved to be more efficient in the induction of protection and proliferative T-cell 
responses confinning superior inununogenicity of the RV-iscom over RV-BPL. 
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Similarly CTL responses induced by either of both antigen preparations were 
measured. 
In figure I the induction of protection against intracerebral challenge is also shown. 
Groups of 5 BALB/c mice were innnunized intramuscularly with either RV-iscoms 
(0.001 - I mg), BPL inactivated rabies virus (0.01 - 30 mg) intramuscularly (i.m.), or 
live FlUty Low Egg Passage virus (Flury-LEP) intraperitoneally (i.p). As a control 
mice were immunized with iscom matrix, a cage like structure similar to the iscom 
structure but not containing any antigen. I.m. immunized mice were booster 
immunized at day 14 and all mice were intracerebrally (i.c.) challenged with 30LD50 
CVS-26 at day 28. Mice immunized with I fIg RV-iscom were completely protected 
against i.c. challenge with RV. Groups inullunized with IOflg and 30flg RV-BPL (not 
shown) were also completely protected. Iflg RV-BPL is not sufficient to completely 
protect against challenge (figure IA). This confinns data presented earlier by our 
group that even at doses as low as OAflg RV-iscom after subcutaneous immunization 
all animals were protected (Claassen et al., 1995). Mice immunized with iscom matrix 
were not protected at all (figure ID). 
To study priming of T-cells for their capacity to respond to rabies vitus antigens ill 
vitro, spleens of immunized mice were removed at day 21 and mono cell suspensions 
were prepared. Cells were cultured in Iscoves Modified Dulbeccos Medium (IMDM) 
supplemented with 10% nonnal BALB/c serum and conditioned supel11atant from rat 
spleen cells. ParafOlTI1aldehyde (PFA) fixed P815 (H2d haplotype) cells and P815 
cells persistently infected with Evelyn-Rokitnicky-Abelseth (ERA) rabies virus (P815-
ERA-P) (a kind gift from dr. Lodmell) were added to the spleen cells to specifically 
stimulate ill vivo primed CTL. Infection of P815 cells was assayed by 
itllmunofluorescence. RV-BPL was added to the wells at concentrations of 0.03, 0.1 
and 0.3flg per well to specifically stimulate L3T4 T-cells. 3H thymidine was added 
after 5 days and incorporation of radioactive label was measured after 18 hours. 
Stimulation indexes were calculated using the following fOl11lUia 
incorporated CPM antigen 
S.l. ~ ----------------------------
incorporated CPM medium 
Results of the mean of two independent experiments (3 mice per group) are given in 
figure I, left panels. From this figure it can be concluded that RV-iscom more 
efficiently induce specific T-cell proliferation (S.I.>4) in a range of O.OI-lflg. 
Immunization with 10 or 30flg RV-BPL induces T-cell responses equally high as 
those observed after inununization with lflg RV-iscom (data not shown). 
To demonstrate RV specific CTL responses, one week after isolation and stimulation 
of immune spleen cells with PFA fixed P815-ERA-P cells, the blast cell population 
was isolated using a percoll gradient centrifugation and the cells were tested in a 
chromium release assay for their ability to kill infected target cells at different 
effector/target ratios. Uninfected P815 cells were used as control. P815 and P815-
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figure I:Pallelsji-om left to right show survival after i.c. challellge ill groups of 5 mice, CTL responses 
and S.f of proliferative responses of spleen cells. IA shows responses after immunization with I pg RV-
iscom 0 or RV-BPL .. , IB: immunization with D.lpg. IC: Imllllmization with O.O/pg. ID shows 
responses after immullization with iscom matrix 0,0 , or FIIII),-HEP II, .A. 
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ERA-P cells were labelled with 51Cr for one hour and washed with IMDM. Effector 
cells were added in different ratios to a constant amount of labelled target cells (5 x 
103 /well). After one hour supemates were collected and counted in a Packard gamma 
counter. The percent specific cytotoxicity was detennined using the following fonnula: 
CPM( experimental)-CPM( spontaneous) 
--------------- ------------- ---------- --------- x 100 
CPM( maximum)-CPM( spontaneous) 
In figure I (middle panel) CTL responses one week after ill vitro stimulation are 
shown. Again RV-iscom (figure 3A) require about ten-fold lower dose (I!lg) to induce 
specific CTL activity (app.30%) comparable to that after inlllUnization with 10!lg RV-
BPL (app 40%) (data not shown). In contrast, inlllUnization with l!lg RV-BPL 
induced only background activity (app 10%). Innnunization with iscom matrix did not 
induce detectable CTL activity (figure 1D). 
To demonstrate that in all cases MHC Class I restricted T-cells are involved in the 
killing of P815-ERA-P target cells L3T4 and Lyt-2 positive T-cells were depleted 
from the in vitro stimulated T-cell population. T-cell subsets were removed by 
incubation of the cell populations with monoclonal antibodies specific for the L3T4 or 
Lyt-2 subset coupled to magnetic Dynabeads®. This treatment resulted in almost 
complete depletion of one subset as is shown after double labelling with anti L3T4-PE 
and anti Lyt-2-FITC (Beckton and Dickinson, Mountain View, Califomia) in FACS 
analysis. Figure 2 shows typical results of FACS analysis after depletion of T-cell 
subsets. 7 days after ill vitro stimulation the spleen cells contain both L3T4 cells (upper 
left quadrant) and Lyt-2 positive T-cells (lower right quadrant) and a population of 
double negative cells (figure 2A). After depletion with Lyt-2 coated magnetic 
Dynabeads the lower right quadrant is empty (figure 2B). The upper left quadrant of 
the panel 2C no longer contains cells after treatment with L3T4 coated Dynabeads. 
When the remaining T-cells were tested in a CTL assay only T-cells bearing the Lyt-2 
phenotype were able to kill ERA infected P8I5 cells (figure 2C) as efficient as the 
unsorted population (figure 2A) . L3T4 T-cells were unable to lyse infected target 
cells (figure 2B). These data demonstrate that the CTL responses measured after 
immunisation with either RV-BPL or RV-iscom or live Flury-LEP all restricted by 
class I MHC molecules. In addition to the above described experiment it should be 
noted that P8I5 lacks expression of H-2 molecules belonging to the class II MHC 
complex. 
In the present paper we have described that RV-iscom can prime ill vivo for CTL 
activity in vitro. The dose necessaty for the induction ofCTL was only I!lg protein in 
the RV -iscom preparation as compared with at least lO11g with RV-BPL. 
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figure 2: shows that CD8+ T-cel/s are responsible for CTL activity 2A: CTL responses after 
immunization with Flwy, lpg RV-iscom, empty iscom or 30pg RV-BPL of unsorted spleen cell 
population, 2B: CTL responses after depletion of L3T4 cells and 2C: CTL responses after depletion of 
Lyt-2 cells. FACS analysis o/ullsorted alld Lyt-2 depleted or L3T4 depleted spleen cell populations 
(from top to bottom). 
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Apparently both iscom and inactivated virus can enter the class I antigen processing -
pathway to elicit CTL. For iscom this was demonstrated ill vitro were measles virus 
iscom could specifically stimulate measles virus specific C08+ CTL (van Binnendijk 
et a!., 1992; Morgeaux et a!., 1989) demonstrated that purified GP or NP could no 
longer prime for class I restricted CTL in hybrid H2kd mice. This suggests that at least 
the way in which the antigen is presented to the immune system is of importance for 
the induction of the light immune response. Morgeaux described also high killing of 
target cells due to the induction of natural killer (NK) cells after immunisation with 
inactivated RV, but not in control immunized mice. Our T-cell depletion studies 
demonstrate that NK cells cannot be held responsible for the killing we observed in our 
experiments. 
Another possible advantage of iscom for inmulIlization against RV has been published. 
Iscom which contain lentil-lectin pUlified RV glycoprotein were shown to be 
inmmnogenic in both mice and dogs. These iscoms could protect dogs against a lethal 
challenge with street RV after pre-exposure itmuunization. Moreover post-exposure 
protection against street RV challenge could be induced with tlu'ee 120 ng doses ofRV 
glycoprotein iscom in 90 % of mice but not with three doses of a presently widely used 
human diploid cell vaccine (HOCV). When mice were given four doses of HOC V for 
post-exposure treatment they died of anaphylactic shock. No such phenomenon was 
observed when the mice had been immunized with the iscom preparation (Fekadu et 
a!., 1992). 
The contribution of MHC class I restricted CTL in protection against RV is not clear. 
The induction of CTL after vaccination with inactivated virus antigen correlated with 
resistance to intracerebral challenge with RV in one study (Wiktor et a!., 1977b) but in 
vivo depletion of the C08 subset did not influence resistance to intraperitoneal SRV 
challenge (Perry et a!., 1991). In the same study the depletion ofC04 T-cells resulted 
in the loss of resistance SRV challenge. In contrast with this finding it has been shown 
that transfer of GP specific CTL clones induced protection of mice against lethal 
challenge with RV (Kawano et a!., 1990). 
Recently it was published that inununisation with inactivated vaccines leads to the 
generation of GP specific CTL activity only, whereas after itmnunisation with live 
virus CTL responses against other structural proteins of the virus (N, NS and M) could 
also be demonstrated (Fujii et a!., 1994). The role of CTL specific for other proteitls in 
protection against RV is unclear. 
Collectively our data show that incorporation of RV antigen in iscom, enhances its 
capacity to induce T-cell mediated immunity and protection in mice. 
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Modulation of antiviral immune responses by exogenous cytokines: effects 
of tumour necrosis factor-a, interleukin-la, interleukin-2 and interferon-y 
on the illlmunogenicity of an inactivated rabies vaccine 
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(Iud ~Dl'partmelll oj Virology, Medical FacilIty, EraslI/us VI/irersi'}, Rotterdam, Pos/blls 1738, 3000 DR Rolierdam, 
The Netherlands 
/11 \'iI'O administration of exogenous c}'tokines may 
influence elicited immune responses, and hence may 
change the efficacy of a vaccine. We im'cstigated the 
efiecls oftullloUr necrosis factor-x (TNF-x). interleukin-
Ix (IL-Ix), interleukin-2 (lL-2) and interferon-i' (IFN-i') 
on the immune response elicited by inactivated rabies 
virus vaccine in a mouse model. Each of the cytokines 
increased \'irus-specific IgG responses after primary and 
after secondary immunization. A single dose of 1·3 ng 
TNF-x or lL-I1:. when injected shortly before vac-
cination, only marginally stimulated resistance to chal-
lenge infection (four- and se\'en-fold. respectively) 
without enhancing virus neutralizing antibody (VNAb) 
responses. In contrast, a single injection of lOJ units of 
IFN-j' or five daily injections of 1·6 ~Ig IL-2 increased 
vaccine dilutions protecting 50% of mice (PD~o values) 
Introduction 
Antiviral protection by immunization is established after 
a cascade of cellular interactions in which soluble 
mediators collectively temled cytokines are involved. 
Certain macrophage-derived cytokines such as 
interleukin-I (IL-I), interleukin-6(1L-6), tumour necrosis 
factor (TNF) and interferon (IFN) playa critical role in 
the early activation of accessory cells and in the 
subsequent co-stimulation of helper and effector lymph· 
oid cells (Unanue & Allen, 1987; Weaver & Unanue, 
1990). The secreted cytokine profile of antigen-stimulated 
T helper cells largely determines the nature of the 
immune response (Janeway et al., 1988; l\losmann & 
Coffman, 1989). The factors influencing the distinct 
Iymphokine gene expression in antigen-specific T helper 
cells are less well understood but appear to depend upon 
the type and dose of antigen (Parish, 1972; Carding et 
77- to 50-fold. respectively, with a concomitant en-
hancement of VNAb. At a 1: 10000 dilution of a 
standard inacti\'ated rabies vaccine preparation both 
IFN-i' and lL-2 increased protecth'e immunity without 
enhancing VNAb responses: in non-vaccinated animals 
this treatment had no effect on resistance to challenge. 
Combined administration of IFN-i' and IL-2 syner-
gistically enhanced VNAb responses. In contrast to the 
other C)'lokines tested. IFN-? prefcrentially stimulated 
"irus-specific IgG2a production. It also augmented the 
mccine-induced priming of rabies virus-specific spleno-
C)1e proliferation. These results document that certain 
c}1okines alone or in combination are potent immuno-
logical adjuvants which may direct and modulate 
immunization-induced antil'iral immune responses. 
al., 1989), the lymphoid microenvironment where helper 
cell activation occurs (Daynes et al., 1990) and the local 
cytokine profile at the onset of antigen recognition 
(Seder el al .• 1992; Locks!ey et al" 1991). The latter may 
follow initial non-specific immune responses including 
IFN production. activation of natural killer cells or 
triggering of mast cells and basophils (Romagnani. 
1992). Administration of exogenous cytokines may 
therefore represent a means of improving the magnitude 
and Ilature of immune responses elicited by vaccines. 
Improvement of the immunogenicity of a vaccine or 
model antigen has been demonstrated in several systems 
when exogenous cytokines were administered during the 
immunizatioll period, for example IL-I (Staruch & 
Wood, 1983), TNF (Ghiara el al., 1987), IL·2 (Nunberg 
et al., 1989). IFN-i' (Playfair & De Souza, 1987; 
Finkelman el al., 1988; Heath el al., 1991) and IL-6 
(Takatsuki el af.. 1988). Moreover. the aclion of 
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traditional adjuvants like bacterial lipopolysaccharide, 
Freund's complete adjuvant, AI(OHh (~.fannhalter et 
al., 1985) and muramyl dipeptides (Bahr et 01., 1987; 
Oppenheim et of., 1980) is at least partly based on the 
induction of cytokine secretion (Tornai & Johnson, 1982; 
Odean et of., 1990). Thus, particular cytokines either 
administered or induced, may selectively stimulate or 
inhibit immune reactions. These phenomena may have 
direct implications for immunization strategies, because 
pathogens may be eliminated by one effector mechanism 
but may escape or cause exacerbated reactions during 
others (Mosmann & Coffman, 1989). Furthermore, 
studies in this field may contribute to the understanding 
of the ill rim immunoregulatory activities of cytokines. 
In this study we investigated the effects of putative 
stimulatory cytokines, including TNF·~, IL4}a, IL·2 and 
IFN·y and of a combination of IL·2 and IFN-y on the 
immunogenicity of an inactivated rabies vaccine. For 
potency assessment we used an ill l'il'O protection test, 
recommended by the WHO for the asses-sment of human 
rabies vaccines. Induction of protective immunity by 
rabies vaccines has largely been attributed to virus 
neutralizing antibody (VNAb) (Kaplan et of., 1975; 
Turner, 1976; Wunderli el 0/., 1991). However. Dietz· 
schold and coworkers (1992) ha\·e suggested that it is not 
solely correlated with neutralizing activit)' of antibodies 
but also with their ability to prevent virus spread 
between cells and to inhibit transcription of viral RNA. 
Other investigators have demonstrated the induction of 
rabies viruNpecific cytotoxic T lymphocytes (CTLs) by 
this type of vaccine (Wiktor et af., 1977; Morgeaux t'l af., 
1989; Sugamata t'l af., 1990), which arc not usually 
primed by non· replicating vaccines. Here wedemonstrate 
that each of the cytokines tested enhance the antiviral 
immunity induced by an inactivated rabies vaccine to 
various degrees. IFN-y, which was shown to enhance the 
production of antiviral IgG2a, proved to be the most 
potent and suitable for practical use. 
.iVlethods 
.\ficc. Outbred NIH (RIVM: NIII) mice and inbr~d C57BL/6 (H-2') 
mice l\ere obtained from the Nationat Institute of H~ahh and 
Environmental Prot~tion and used at -I to 5 weeks of age. The mice 
Ilere kept in bJ.rrier-contained animal facilities and both sue;; \lere 
used. The nperimental protocols \lere approved by the Animal> 
WelfMe Officer of the National Institute of Public Health and 
Enyironmentat Prot.x:tion. 
1'1"''''5. The Pitm~n-Moore (PM) strain ofrabie;; lirm tpM/wt-3S· 
1503·3m) lIas propagated in dog kidney cells (PM-DKCV). The 
challenge lirus standJfd (C"S) strain of rabk, I[rus \I~S propagated in 
IHIK·21 dt, and purified by gradient centrifugation. 
1'(I«iI/,'. The in~ctil·ated rabies I·accine (balch R4t-A) had Ixen 
prep.H«1 from a concentrated. purified PM lirus lusp<nsion by 
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inacth"ation lIith ,B-propiolactone according 10 standard methods (van 
Wezelet of .• 1987). It contained about 200 Ilg protein p<r I mldole. of 
\lhich aboul SO )Ig pro,·ed to be gly..:oprotein as determined by ELISA 
(O>terhaus e/ af .• [990). 
C)lokin.·5. R(combinant (r) human IL·II\': (3x 101 units (U)/mg 
protein} and murine rTNF·1\': (7 x 10' U/mg protein) \lef( diluted in 
PBS directly before use and injected inlrap<fiton(atly (i.p.) IS min 
b.:fore vacdnalion on days 0 and 7, at a conc~nlration of 1·3 ng/mouse 
(i.e. 4 x 101 U IL-I/mouse and 101 lytic U TNF/mome). Human rlL· 
2 (Prokukin, EuroCetus. 3 x 10' Cetus V/mg. equh·aknt to J·8 x 10' 
International V/mg protdn) lias reconstituted in sterile \I,lter. diluted 
in PBS and inj.x:ted i.p. daily on days 0 to 4 and 7 10 II at a 
concentration of 1·6 )lg/mouse (i.(. 3 x 101 V/mouse). The rat rIFN·j' 
(4 x 10' V/mg protein). \lhich displays biologic-al acti,ity in both Tats 
and mice, had been produc(d in Chinese hamster QI-ary cells and was 
purified by monoclonal antibody affinity chromatography as pre,iously 
described (\·3n der Mdde (/ (II .• 1986). PrepJrations \lere assayed in a 
I·esicular stomatitis lirus cytopathic effe;::t inhibition a,say on ral 
embryo fibroblasts. and their aclilit)' is npres>ed in U staadardized 
against a laboratory referenc(. In most exp<'riments IO J V IFN-
i"/mouse (i.e. 0-25 )lg/moule) was inje;::ted i.p . .lIthe indicaled times. 
/nJJlllO!i;aliom. Groups of (ightto 20 mice Ilere immuniud \lith t\lO 
injections of an R-I I-A vaccine dilution (0·25 mt) lia Ihe i.p. route on 
days 0 and 7. On day 14 the animals "er( challenge-d by intracerebral 
(1.0:.) inje..:tion \lith 30)11 of C"S·26 rabies lirUS containing appro,i-
mately 30 LD,~. In the subsequent period the animals were obsened 
for Ihe development of rabies·relaled s}mptoms including paralysis. 
Mortalily in the non·vaccinated control animal, generally occurred 
bell\een 7 and 14 days after infection. Other groups of mice receiwd 
the yaceine in conjunction lIith C}tokine treatment. Titration of the 
CVSchalleng( lirus was incJudeJ in (achnp<riment; this is mandatory 
since reproducibility of LD" I·alues is poor. a problem generally 
rt'l:ogniud in vaceine potency testing. Therefore only data from the 
sam( nperiment were compared. 
A1IIibo'~r U5l'omes. On da}"s 6 and 13. mke 'I ere anaesthetized and 
bled from the retro·orbital pinus. In indilidual s~rum samples rabie;; 
vjrus-sp..'(ilk Ig titres lIere determined by ELISA and VNAb titr~s 
lIere measured by a rupid fiuorescence f(Xus inhibition test (Zabn (/ 
al .• t979). The ELISA lilr( is defined as th( re.:iprocal of the hig.hest 
serum dilution at \lhkh Ih( ab,orban,( I\as equal to thre( lime, the 
bad.:ground value. 
Prolfjcr<lll'" splenocyte f.'51'0/1jt'S. CS1BL/6 mou,e splenoqt(, 
i,olated 2 I\(eks after the tast immunization Ilae (ultured in 96-\lelJ 
round·bollom plales at a demity of 3 x 10' cells P"<'r \\ell in Iscole·s 
modifie-d Dulbe-.::.::o·5 medium containing 1% C57BL/6 mouse serum. 
Inactil·ale-d rabies ,irus was added at Ih( concentrations indicated in 
Fig. 3. After 4 days of inculnlion .II 37 ec in a humiditkd atmosphere 
containing 5% CO,. cultures \Iere pulse-ialxlkd \lilh o-Sj.lCi 
['HJthymidine (Amersham) for 16 h. Cells Ilere h~ne,ted on glJSS 
filter, and the incOlporateJ radioactil·ily \las measured in a Betaplate 
fidt bed scintillation counter (LKB-Wallac). 
SI<1IiSII("<1f <11111(\"515. To (ompare group means of "NAb litre;;. data 
lIere e,·alu . .I\ed using the Wikoxon·Mann-\\'hitney te.lt. In order to 
take inlO account the greater probability of a t}P"<' [ error due to 
multiple comparisons. the lewt of significance \las pre·;et according to 
BonfeHoni·s adaptation at P < [0 OS/number of (omparisonsJ inSlead 
of a (,,00 P < OOS. Group me.lns of splcnoc}te prolifer.lt[le response, 
and Ig isot}p<' rJtios ofPBS·lre.ltoo laccinecontrols and IFN-i·-treJled 
mice lIere (ompar(d by using the tllo·tJiled Student's 1·1(,1. The 50% 
protecth·e laceine doses (PO!,) lIer( (akuiJtcd 3((ording 10 Reed & 
Mueneh (19.18). 
Results 
Exogenolls cytokinl's augment immulli::atioll-indllced 
protecrire amiJ'iral immllllity 
Two immunizations of mice with PM-DKCV (dilutions 
I: 100, I: 1000 or I: 10000) resulted in a dose-dependent 
resistance to challenge. At the highest vaccine con-
centration (dilution I: 100) TNF-~ and IL-I~ improved 
survival upon challenge, resulting in high (90'%) or 
(a) 
t: 
·1 75 
~ 
~ 
li 50 
e 
" 
Vaccine dilution 
Fig. I. Effoct of TNF-l. IL-b, IL-2 and IFN-;.- on th~ protecthe 
a,thil)" (a) and YNAb r<';;pnnse;; (h) induced by inaCli\'aled r~bies 
lirus. NIH mice(IO p.:r group) Ilere immunized i.p. \\ith Ih<' indkated 
dilutions of inactivated rabies ,iru;; "Jcdne (R41-A) at da)"s 0 and 7; 
15 min 'xfore each immunizalion Ih~ animals lIere injocud Lp. Ililh 
murine rTNF-x (~) (I.J ngjmouse). human rIL-b (0) (1'3 ng/ 
mouse). rat rIFN-,(B) (10' U = 0'25,'g/mouse) or PBS (0). Anolh~r 
group of mie.: roceh'ed human rlL-2 (0) (3 x 10' U = 1·6 Jig/mouse) 
administered daily on days 0 to 4 and da}s 7 to I L The animals \\<'re 
bled on day 13 and challenged Le. Ililh CVS-26 (3~ LD,,1 on day 14. 
YNAb tilr<';; (mean value.\ ±S.f.~I.) \\ere determined for Jhe indilidual 
mice p.:r group. 
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Table I. f."'Dect of cytokil/es 01/ induction of rabies I"irus-
specijh' serum IgG* 
Virus-spedlk serum IgGt 
----,,--
Vaccine dilution \'occine dilution 
1:100 I: 100() 
Treatment Day 6 Day 13 DJ.y6 Dol)" 13 
PBS 45±~8 73HISO < ]0 167±9] 
TNF-l 192±62 3560± 1149 18±7 270± 140 
IL-b 208±6S 8060±30S9 28±11 1332±S18 
IL-2 560±93 86S0± 1819 9HH 33S0HSS 
IFN-;: 39S+ 166 30S0+ 773 86+ 30 I3M+5S0 
• NIH mice (the pu group) llere Lp. immuniud Ilith a I: 100 or a 
I: 1000 \"acdne dilution a\ day 0 and boosted "ilh the Mme l,lCcine 
dose .II day 7. The animal;; I'~re injocted \,ith PBS or different C) lokines 
as indi(.lled in the kgend of Fig. L 
t The anima!s \lere bled on da)s 6 and D. Geometric me.ms 
(±S.E.~I.) of anti·rabie, liru;; IgG titres lIer<' determined as preliomiy 
describ.:d (Zalan "/111., !979). 
complete survival, respectively, compared to 40% sur-
vival of mock-vaccinated mice (Fig. I a). At a vaccine 
dilution of I; 1000. TNF-x treatment had 110 effect on 
survival, whereas IL-i'X treatment caused a prolongation 
of sUfvival times, with a mean time to death of 9·6 days 
as compared to S'3 days in the control group (data not 
shown). No increase in numbers of long-term survivors 
was observed (Fig. I a). At the I: 10000 vaccine dilution 
TNF-~ and IL-i'X did not influence resistance (0 
challenge. 
In contrast. IFN-i' and IL-2 dramatically increased 
survival upon challenge at all the vaccine concentrations 
tested (Fig. I a). This efrect was still observed in groups 
of mice injected with a non·protecti"e vaccine dilution of 
I: 10000. Co-administration of IFN-I' or IL-2 induced 45 
and 60% survival. respectively. IFN-i' Of lL-2 treatment 
in non·immunized animals had no eOcct (data not 
shown). When compared to the PBS-treated vaccine 
control group, PDoo values were increased 4·2-fold by 
TNF (PDSG = 1016), 6'S-fold by IL-I (POoo = 101S), 50-
fold by IL-2 (POso = 101 ;) and 30-fold by IFN-i' (PO:;G 
= IOJJ); PD,o of PBS = iO!. 
Exog<'nolls (I"wkines calise all iI/crease in (llIfirirallgG 
responses after primary alld secol/dary i/lll/llllli::(ltioll 
The levels of the humoral immune response were 
determined by measuring antibody titres in sera collected 
from immunized mice at days 6 and 13, 6 days after 
primary and secondary immunization, respectively. All 
cytokines tested augmented rabies virus-specific IgG 
levels four- to 12-fold within 6 days after primary 
immunization. At day 13 a five- to IO-fold increase in 
specific serum IgG response was noted in all cytokine-
treated mice (Table I). 
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1:15625 
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IL-2 alld IFN-, ell/lallce I'irlls-nelltrali=illg allfibody 
respol/ses 
VNAb tilres were determined in day 13 sera of vaccinated 
mice. In \'accine conlrol mice the VNAb titres decreased 
with a lowering of the vaccine dose. which correlated well 
with survival upon challenge. Neither TNF-:( nor IL-I:( 
influenced the VNAb response at any vaccine con-
centration tested, although both enhanced protective 
immunity at the I: 100 vaccine dilution (Fig. I a), 
At the I: 100 and I: 1000 vaccine dilutions IL-2 and 
IPN-, significantly (P < 0·0125) enhanced VNAb re-
sponses (Fig. 1 b). Remarkably. at the lowest vaccine 
dilution (I : 10000) both mediators failed to do so despite 
increasing survival upon challenge. These results suggest 
that enhanced prote<:tion by TNF-:( and IL-Io: at high 
vaccine doses and by IL-2 and IFN-, at low vaccine 
doses is not solely mediated by VNAb but may also 
result from antibody that does not neutralize ill \'i!ro or 
from enhancement of other, probably cell-mediated. 
immune mechanisms. 
INF-;' callses (III iI/crease ill (ll/til'irallgG2a production 
Since IFN-I' emerged as the most practical immunity-
enhancing cytokine, requiring only a single injection 
shortly before vaccination, we examined its activity in a 
broader range of fivefold vaccine dilutions (1 :25 to 
I: 15625). Again. it increased PD.lO values 25- to 77-fold. 
At all vaccine concentrations tested IFN-)! co-
administration increased protective immunity (Fig. 2a). 
Enhancement of protection correlated with increased 
VNAb levels at each vaccine concentration (Fig. 2b). At 
the lowest vaccine concentration. however, once again 
low VNAb titres were noted despite good protection. 
Given the documented role of cytokines in Ig class 
switching, we found that IFN-i' caused an increase in the 
levels of both virus-specific serum IgGI and IgG2a (Fig. 
2c). Remarkably, the individual isotype distribution in 
these mice proved to favour specific Ig02a (Fig. 2d) 
Fig. :!. Eff~~t of IFN-i' on prote.;til-e immunity j'l). dere!opment of 
r,lbie. VNAb (l>J and antilir,11 IgGI and IgG:!a Ie and J). NIH mice (10 
pu group) \\ere immunizoo i.p. Ilith the indic,md dilutions of 
in.lctilated rabk5 liru5 v,Icdne IR41-A) at days 0 and 7: tllO hour. 
~fore e,lch immunil,ltion the ;lnimals II ere inje.:ted Lp. \Iith r~t rIFN-
i' (a) (to' U '" D-25IJg/mouse) or mod:-injeckd (0)· The animals 
lIef': bled on d,lY 13 and ~h:J!lenged i.c. on d,lY 14 Ilith CYS·:!6 (10 
LD,.,). (<1) Percentage of long-term chJ!knge SUrlj\'O(5. (l>J VNAb titres 
(me,ln \;J!ue>±s,l.~I.) determined for eight indilidual mk.: per group. 
k) Antilir,l! IgGl and IgG~,1 ,crum antibody (me.m±s.E.}!) de-
termined for four to eight mice po;'( group. (d) IndiliduallgG].!/igGI 
(,1ti05 of antilif.!l antibody offour to eight mice p"'r group. No IFN-
i'(O): IFN·;·(AI. 
10 (") 
"' ~ 
"-
~ 
<J 10 (b) 
, 
Fig. 3. E['-:;1 of ill lAo IFN-,' administration on {JJ Iii/'0 proliferatiw 
rc,ponses of rabies lirus-spcdfic splenoC}tes. CS1BL/6 mice (two pu 
group) were giren 10' U rat rIFN-7(.) and immuniud 2 h later with 
a I: 100 (a) or I: 1000 (h) dilution uflhe ina,tl\'3Ied rabi¢. \-jrul \'alXine 
R .. II-A. on days 0 and 7: aU inoculations lIef.:' \'ia the i.p. route: PBS 
was used as a control (0). SpIe.;n cells isolated on da~' 21 Ilere 
stimulated with different concentrations of inaclil'aled rabie. virus 
antigen. Prolifera!il'e response I\as measured by the incorpon,tion of 
['Hjlh)midine. Results are shown as the net mean±S_Of. [re;pons,," 
~badgfOund (medium)] of quadrup!kate v(llues obtained from two 
mice per group. 
whereas the other cytokines did not alter specific 
IgG2ajigG I subclass ratios (not shown). 
IFN-, ellhances lhe priming of rabies rirlls-spl!cijic 
SpfeIlO(I'/e prolijermil'e respollses 
To determine the effect of ill rim administration of IFN-
,on cell-mediated immune reactivity, ill ritro lymphocyte 
stimulation tests were performed. To this end, spleen 
cells isolated 2 weeks after the last immunization were 
stimulated with PM-DKCV. Fig. 3 shows th',lt ill \'il'O 
IFN-i' administration induced a significant enhancement 
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-2 -24 -6-0-250 +2 +4 +24 
Time in relation [0 vaccination (h) 
Fig. 4. Effe.:t of toe time of IFN-;' administration on inactivated rabies 
\irus vaccine (R41·AHnduced challenge prole.:tion (<I) ~nd Vl'\Ab 
respons(s (b). NIH mice (10 per groUp) were immuniud i.p. Ililh a 
I: 1000 \'acdne dilution on days 0 and 7 and Lp. inje.:tcd Ilith w rIFN· 
j' tal (101 u = 0·25 }lg/mouse) at different time; before or after 
immunization as indicated: PBS I\~S used as a control (0). The 
animals lIere bled on day 13 and chJllenged I.e. \\ith 128 tD), CVS-~6 
on day 14. (a) Perantage of long-Ienn challenge suni\'ors. (b) VNAb 
litre;; (mean \'alues±s_U!.) detwnined for [h-e indilidunl mice per 
group_ 
of the proliferative responses ranging between Iwo- and 
3·7·fold (P < 0·04), depending upon the concentration of 
P~·I-DKCV. These findings demonstrate an IFN-j'-
mediated enhaIlcement of the ill rho priming of 
splenocyte responses, which may have contributed to the 
observed augmentation of protective immunity. 
IFN-j' at/III;lIisfralioll pOSf-;IIIJl/U/li'=ttlioll muses (/ 
deacase ill pro/ecli!'(, illJIIlllnit,l" lIlId VNAh respol/ses 
The time of IFN-i' injection proved to playa critical role, 
Under conditions where the vaccine alone induced 
complete resistance against a low challenge dose (I28 
LD;,,). IFN-j' injection in the 6 h interval before 
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Table 2. Eflect of combined treatmenl willi IFN-y and 
IL-2 on raccine-indllced "NAb responses· 
C)lokine trealment 
PBS control 
IFN-, 
Il-2 
IfN-,+IL-2 
M.:an "NAb lilre (range)t 
Vacdne dilution 
I: 10000 
7 (4 to 16) 
21 (4 to 64) 
9(410 16) 
417 (4 to ION) 
• Group; of mice, Lp. immunized on dars 0 and hlith 0 25 ml of the 
indicated R41-A \-accine dilution, \\ere Ir';-<lted \\ilh .:lther IfN-;' 
(10' U. al ~2 h on days 0 and 7). Il-2 (3 x IO! U on da),; 0 to 4 and 
days 7 to 1 I), or both IFN-, and Il-2, and bkd on day 13. 
t VNAb titres \-Iere determined in a rapid fluorescenc.: focus 
inhibition Ie,!. Re,ults. are sho\ln as geometric me<ln (range) of 
indh-iduaililres for groups ofliw mice. 
vaccination did not influence the levels of protection but 
stimulated VNAb responses (Fig. 4). In contrast, when 
IFN-i' was injected 24 h before or 2 to 48 h after 
vaccination a marked suppression of both parameters 
was noted. In a similar experiment in which 20% of the 
control mice survived a high challenge dose (617 LD,q), 
IFN-, administration before vaccination (0 to 2 h) 
stimulated challenge resistance. In mice receiving IFN-/, 
24 h before immunization or between 2 and 24 h after 
vaccination, again both the protection and VNAb titres 
had decreased (data not shown). These findings show 
that depending on the timing of Iymphokine administra-
tion, either a stimulation or an inhibition of immune 
responsiveness could be observed. 
Combillcd Irca/llu'l/{ Irilh fL-2 alld IFN-/, fllrilln 
increases I'NAb responses . 
Since both IL-2 and IFN-, enhanced vaccine efficacy it 
was of interest to examine whether they would act 
additively or synergistical1y. Combined IFN-y and lL-2 
treatment did not further enhance resistance to chal1enge 
as compared with immunization in conjunction with IL· 
2 only. Dnly a 3-day increase in survival limes was noted 
under the conditions tested (data not shown). At a low 
vaccine concentration (dilution I: 10000) neither IFN-y 
nor IL-2 alone affected antibody responses. The com-
bined cytokine treatment, however, synergistically en-
hanced the development of VNAb (Table 2). 
Djsclission 
In this study, we demonstrate that co-injection of each of 
the cytokines TNF-:x, IL-IIX, IL-2 and IFN-}' with 
inactivated rabies vaccine increases the induced pro-
tecth'e antiviral immunity. The mechanisms underlying 
120 
protection against Lc. rabies virus challenge are not fully 
understood. Inactivated rabies virus induces circulating 
VNAbs which are directed against the viral surface 
glycoprotein (G) (MacFarlan cl af., 1986). Neither 
injection of non-neutralizing anti-G and anti-rabies \'irus 
nucleoprotein antibody nor inoculation of spleen cells 
from mice immunized with the inactivated vaccine 
preparation induced protection against i.c. challenge 
(Wundedi el at., 1991). Although antigens from inacti-
vated virus preparations are probably processed by the 
endocytic pathway and presented byc1ass II molecules to 
CD4+ helper T cells, we could detect CDS+ CTL activity 
in vaccinated mice, as have other authors (Wiktor el al., 
1977; Morgeaux ('I af., 19S9; Sugamata el al., 1990; 
MacFarlan cl al., 1986). Immunoprotection against 
rabies encephalomyelitis has also been suggested to 
result from antibody-mediated disruption of viral cell-to-
cell spread and inhibition of viral RNA transcription 
(Dietzschold el al., 1992). Destruction of the blood-brain 
barrier fol!owing i.c. challenge allows the inoculum to be 
distributed to the periphery (Cairns, 1950). Part of the 
i.c. inoculated virus may activate vaccine-sensitized 
peripheral T cells before being neutralized by circulating 
antibodies. Therefore, the contribution of cell-mediated 
immune lllC{;hanisms in the elimination of virus-infected 
cells in the central nervous system should also be 
considered in our system. 
The establishment ofimmunizatioll·induced immunity 
is under the control of distinct cytokine cascades. In 
mice, physiological cytokine production reflects the 
expansion of functionally distinci T helper cell subsets: 
Th-I cells produce TNF, IL-2 and IFN-i' and give rise to 
cellular reactions, whereas Th·2 cells producl! IL-4, IL-5, 
IL-6 and IL-IO and lead to antibody production. The 
subset-specific cytokines stimulate expansion of their 
own subset while inhibiting the other (Fiorentino el af., 
1989); activation of Th-I or Th-2 subsets is often 
mutually exclusive. Thus, administration of particular 
cytokines during or shortly before the immunization 
period may be expC{;ted to influence the physiological 
cytokine balance and may inhibit or stimulate antigen-
specific immune reactions. 
In immunized control mice (no cytokine added) we 
found a corrclation between protection and induction of 
VNAb, as reported before by Wunderli and co-workers 
(1991). In mice immunized in conjunction with a 
cytokine however, discrepancies between VNAb titres 
and protection were noted. Both TNF-x and IL-lx, 
when given shortly before the vaccination, stimulated 
protection at the highest vaccine concentration (I: 100 
dilution) without increasing VNAb titres. In contrast, 
both IL-2 and IFN-J.' stimulated protective immunity 
which correlated well with increased VNAb responses. 
Notably, at the lowest vaccine concentrations tested 
(I: 10000 and I: 15625 dilution), which g,'lVe minimal or 
no protection, both cytokines prolonged survival in the 
absence of increased VNAb titres (Fig. 1 and 2). These 
data suggest that other protective immune mechanisms 
arc stimulated. These are antigen-dependent and specific, 
since injection of the cytokines alone did not confer 
protection. Indeed, virus-specific IgG responses were 
augmented four- to 12-fold as early as 6 days after 
primary immunization and fiye- to IO-fold after sec-
ondary immunization in cytokine-treated mice. These 
non·neutralizing antibodies may be expected to con-
tribute to protective immunity. 
The mechanism of the ill 1";1'0 cytokine actions is 
difficult to define because of their numerous and complex 
activities. The elTects resulting from early cytokine 
administration demonstrate a modulatory activity at the 
beginning of the immune response. Indeed, the com-
mitment to a Th-I or Th-2 response appears to occur 
Yery soon after antigen exposure (Scott, 1991). Although 
inactivated rabies virus by itself can stimulate secretion 
ofIFN-i' (Celis et af., 1986) and IL-2 (Ertl et al., 1989) by 
T helper cells ill ritro, it is unknown whether ill l'il'O 
Th-2-characteristic Iymphokine secretion is stimulated 
as well and eventually to a larger extent. Since the PM-
DKCV induces both VNAb responses and cell-mediated 
immunity, including CTL priming and delayed type 
hypersensitivity (not shown), it is difficult to speculate 
about induction of either T helper subset. 
In contrast to the moderate effects of TNF-?: and IL-
l?:, the Th-I-derived Iymphokines IFN-i' and fl-} 
vigorously stimulated \'accine potency and VNAb re-
sponses at high vaccine doses. IL-2, given daily over a 5-
day period, probably acts by stimulating the proliferation 
of antigen-reactive T cells. fl-2 is the principallympho-
kine produced by naive helper T cells (Swain et al., 
1991); it acts as a growth factor for both Th-I and Th-
2 cells (Williams et al., 1991), and has a direct role in the 
induction of B cells (Ztlbler et al., 1984). Our Il-2 data 
are consistent with the findings of Nunberg and co-
workers (1989) who suggested that IL-2 acts by in-
creasing the cellular immune response to the rabies 
vaccine. However, because of the requirement for 
repeated injections the use of IL-2 as an immunological 
adjuvant is not practical for routine pre-exposure 
vaccination protocols. 
In contrast, IFN-,' is a practical and potent modulator. 
It is the key regulatory Th-I Iymphokine which favours 
Th-I-type respOnses and antagonizes Th-2 reactions. 
Recent studies in murine Leishmallia infection models 
have demonstrated that a single injection ofIFN-,', when 
included in the parasite inoculum, enhanced Th-I and 
decreased Th-2 responses in BAlB/c mice (Scott, 1991). 
Early inje<:tion in our system provided enhanced chal-
lenge protection, increased VNAb responses and aug-
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men ted the priming of rabies virus-reactive splenocyte 
proliferation. In the mouse, the Iymphokine is known to 
promote IgG2a secretion from IgG2a-collnnilled B cells 
ill ritro (Snapper & Paul, 1987; ~losmann & Coffman, 
1989; Bossie & Vitelta, 1991). Our data show that ill \'il'O 
IFN-i' administration facilitates antiviral IgG2a syn-
thesis. This Ig isotype mediates complement·dependent 
virus destruction and antibody-dependent cell-mediated 
cytotoxicity. The augmented antibody responses and 
elimination of infected cells may have contributed to the 
increased protective immunity observed. If we assume 
that physiological IFN-i' production requires a few hours 
to become established, our finding that post-vaccination 
IFN-? injection decreases immune responsiveness is 
surprising. A similar time-dependent inhibitory effect has 
been noted with an experimental malaria vaccine (Heath 
& Playfair, 1991). In this model IFN-i' adjuvanticity 
correlated with increased expression of MHC class II 
molecules but was inversely related to lymphocyte influx 
(Heath et af., 1991). The stimulatory elTect ofIFN-? may 
therefore also result from improved antigen presentation 
or uptake. 
Th-l-Iike responses are belieyed to playa major role in 
the control of most acute virus infections (Mosmann & 
ColTman, 1989). However, immunization-induced Th-2 
reactions resulting in high antibody titres may protect by 
immediate neutralization of the viral inoculum. Since 
combined treatment with IFN-i' and repeated daily 
injections of Il-2 further stimulated VNAb production 
this regimen may be especially valuable to increase the 
efficacy of vaccination by preventing systemic spread in 
those infections which depend upon viraemia during 
pathogenesis, which is not the case for rabies virus 
infections. 
Previous studies have demonstrated the beneficial 
effects of type f fFN injection in mice and monkeys 
previously infected with rabies virus at the same site 
(Harmon t't af., 1975; Baer t'f af., 1977). Further studies 
to evaluate whether the observed cytokine modulation 
also improves systemic post-eoXposure immunization in 
rabies infection are in progress. If so, this application 
would be of major impOrlance for the protection of 
humans after accidental exposure. 
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Chapter III. I 
Production, characterization and 
control of a Neisseria mellillgitidis 
hexavalent class 1 outer membrane 
protein containing vesicle vaccine 
Ivo Claassen"', Jolanda Meylis*, Peter van der Leyt, Carla Peeterst, 
Hans Bronst, Jolanda Robert·, Dominique Borsboom*, Arno van der Ark*. 
Illeke van Straaten*, Paul Roholl§, Betsy Kuiperst and Jan Poolmant 
An experimental serogrollp B menillgococca! mccille was prepared from (11'0 genetically 
engineered strains,' each expressing three different class lower membrane proteins 
(OMPs) (PorA). The tll'O strains expressed fhe sUbtypes PI.7,16;PI.5,2;PI.19,15 and 
P 1.5",10; P 1.12, 13;P I. 7h,4, respectire/y. Ollter membrane vesicles (OM V) were prepared 
from these strains by deoxycholate extractioll, mixed with a!umillillmphosphate as 
adjllmm and formulated (0 final mccilles. The class I OMPs represellf ea 9(f'/a of the 
protein ill the vaccine. The mccine was found safe for human lise alld induced a 
bactericidal immune response ill mice agaillst fil'e of the six wild type slraills, which serl'ed 
as donors for the mriOlls porA gelles. Copyright © 1996 Elsevier Science Ltd 
Neisseria mCllfngitidis serogroup B strains are respon-
sible for a large number of clinical cases of bacterial 
meningitis in the Netherlands and worldwide1•2• General 
immunization of the population appears to be the only 
means to reduce the mortality and morbidity due to 
meningococcal disease, beyond antibiotic therapy. 
The B capsular polysaccharide, being the first choice 
as a vaccine component, was found to be nonimmuno-
genic3• After chemical modification and conjugation to 
a carrier protein the polYsaccharide was found to be 
immunogenic in animals. Results with volunteers are 
not yet described. The issue of safety, however, need~ to 
be addressed. The B polysaccharide is structurally iden-
tical to saccharide containing components such as 
N·CAM in man and manunals. Currently more experi-
ence has been obtained with vaccines which are based on 
meningococcal outer membrane proteins (OMPs). A 
number of large scale efficacy trials have been carried 
out with meningococcal OMPs either purified5 or in an 
outer membrane vesicle (OMY) formulation 6• In each 
tlaboratory for the Control of Blologlcat Products, Nationat 
Inslilute for Public Health and Environmental ProtecUon, 
POB 1,3720 8A 8itthoven, The Netherlands. tlaboratory for 
VaccIne Development and Immune Mechanisms, National 
Institute for Public Health and Environmental Protectlon, 
POB " 3720 8A Bilthoven, The Netherlands. flaboratory for 
the Production of Bacterial Vaccines, National Institute for 
Public HeaUh and Environmental Protection, POB 1,3720 
SA BilthOven, The Netherlands. §laboratory of Pathology, 
NalJonat Institute for Publlo Health and Environmental Pro-
tection, POB " 3720 BA Billhoven, The Netherlands. 
(ReceIved 17 August 1995; revised 23 December 1995; 
accepted 4 January 1998) 
instance, the O~'fPs were derived from wild type strains 
and the vaccines were designed to combat occurring 
epidemics. These vaccines, contain multiple OMPs de-
rived from one meningococcus. These OMPs are mainly 
the class 1,2 or 3, 4 and 5 proteins. Such first generation 
OMP vaccines demonstrated efficacies around 50-80% 
except in infants were their efficacy is negligible? 
III vitro bactericidal antibody assays were found to be 
partly strain specific, reYealing a particular imporlance 
of the class I OMps. These findings are in line with 
immunogenicity and protection data in mice and in 
rats9• The extent of heterogeneity of the class I OMP is 
limited 10 which motivated us to develop multivalent 
class I OMP containing meningococcal OMY vaccines, 
We constructed a number of vaccine strains which are 
able to express three class I OMPSll.12. The expression 
of Class 3 OMP was eliminated because this protein 
contributes little to the induction of bactericidal anti-
bodies in mice and manS•9• The B-polysaccharide and 
Jacto-N-telraose structures are deleted since those are 
shared with host structures and immune responses 
against them are poor and may even be deleterious. The 
expression of Opc is left untouched. since this protein 
may induce cross reactive bactericidal antibodies8, al-
though the expression is poor by many case isolates 13• 
The heterogeneity and variability of Opa proteins ap-
pears very highl4 so we did not attempt to realise a high 
expression. although some Opa is left in our vaccine. 
The six PorA proteins chosen, which constitute about 
90% of the vaccine protein, were chosen on the basis of 
epidemiological dala from the Netherlands l but also 
cover the majority of a global strain collection lO• A 
major issue to be resolved remains the occurrence 
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of microheterogeneity, Le. point mutations/deletions, 
within PorA and the cross reactivity of human poly-
clonal antibodies to such heterogeneityt5. This issue will 
be addressed by clinical studies with the vaccine 
described. In addition to PorA, other major OMP exist 
that bind/induce bactericidal antibodies such as Tbp-2 
and F~B. These proteins reveal strong hetero-
geneityl 17 which currently is not understood in enough 
detail. Meningococcal vaccine development in essence is 
still a matter of debate. We have made a first choice for 
a set of proteins on the basis of combined epidemiologi-
cal, genetical, structural and immunological data. 
In this paper we describe the production and control 
of an experimental hexavalent class 1 OMP contain-
ing (P1.7,16;Pl.S,2;Pl.19, IS; PIS,IO;PI.l2,13;PI.7b ,4) 
OMV vaccine using two vaccine strains. Bacteria are 
treated with deoxycholate (DOC) to extract OMVs. The 
OMVs were isolated and mixed with aluminumphos-
phate as adjuv.1llt. The vaccines made thereof were 
found to be safe and immunogenic and suitable for 
human use. A safety study with adult \'olunteers has 
been carried out and \\;11 be presented in a follow up 
paperlS. 
MATERIALS AND METHODS 
Bacterial strains 
Two N. II/m;lIgitidis strains PLl621S (CPS-, 
PI.7,16,5,2,19,15) and PLl0124 (CPS-, 
PlS,IO,12,13,7\4)t2 were used for the production of 
the OMV-vaccine. 
Vesicle production 
Hexavalent meningococci-B vaccine was produced 
using two different N. mcnillgiticiis trivalent strains 
PLI6215 and PL10124, each producing three different 
class I proteins. 
The cultivation medium was meningococci medium 
according to Frantz, with main components: L-glutamic 
acid, L-cysteine, glucose and yeast extract 19. Cells were 
cultivated at 36'C for 18 h, in a 135 I volume. 
The cell harvest was concentrated by centrifugation 
by continuous flow centrifugation (Westfalia separator) 
and the cells were resuspended in NaCI buffer. The cell 
suspension was homogenized for 30 min and the total 
wet weight of the suspension was detennined The cell 
suspension was centrifuged for 60 min at 2900 g. The cell 
pellet was resuspended in 0.1 M Tos-IO mM EDTA-
buffer, 7.5 times wet weight. Extraction of the vesicles 
was perfonned by the addition of lf20th volume of 
0.1 M Tris, 10 ruM EDTA, DOC (100 g I-I) buffer. 
Vesicles were separated from cell debris at 20000 g at 
4'C for 1 h (Centrikon T-I170). The supernatant 
containing the vesicles was concentrated by ultra-
centrifugation at 125000 gat 4'C for 2 h. The OMV 
pellet was resuspended in 0.1 r ... 1 Tris, 10 mM EDTA, 
DOC (5 g I-I) buffer and the suspension was centrifuged 
again at 125000 g at 4'C for 2 h. The concentrated OMV 
were resuspended in 3% sucrose 50lution2o• The two 
trivalent bulk products were mixed in equimolar 
amounts based on class I OMP protein content with 
AIPO..\ as adjuvant. Throughout the process thiomersal 
(l00 mg I-I) was added as preservative. 
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Electron microscopy and immunogold labelling 
OMVs were ultrasonically treated to disperse the 
vesicles and were attached to Formvar/carbon-coated 
nickel grids. Grids were ,vashed with a 0.01 M PBS 
supplement with 0.5% BSA and 0.1% gel{ltine (PBG) 
and the vesicles on the grids were fixed briefly with 1% 
glutaraldehyde in PBS and negatively stained with 1% 
potassium phosphotungstate pH 6.0. The grids were 
examined in a Philips EM400T electron microscope at 
80 kY. 
For immunogold labelling grids were washed with S% 
BSA+I% nonnal goat serum in 0.01 M PBS followed 
with PBO to avoid aspecific background labelling. The 
grids were incubated at 4'C for 16-18 h with anti·OMP 
monoclonal antibodies diluted in PBO. After washing 
with PBO the vesicles were labelled with goat-anti-
mouse IgG conjugated to 6 11m colloidal gold (GAMG6) 
(Amion, Wageningen, The Netherlands), diluted 1:20 in 
PBG, for 4 h at 20'C. Control incubations were carried 
out with irrelevant monoclonal antibodies also diluted in 
PBG. 
The grids were washed again with PBG and the 
vesicles 011 the grids were fixed briefly with 1% glutaral-
dehyde in PBS, washed in PRO, and negatively stained 
as described. 
Protein determination 
Protein concentration was measured according to 
Peterson21. Briefly vesicles were solubilized in the pres-
ence of O.1S% (w/v) DOC for 10 min. Proteins were 
precipitated by the addition of 72% (w/v) trichloroacetic 
acid (TCA) and centrifuged at 3000g for 15 min at 4'C. 
The pellet was dissolved in distilled water. The protein 
content was detennined using copper-tartrate-
carbonate and Folin Ciocalteu's phenol reagent. The 
absorption at 750 nm was detennined after 30 min 
incubation at RT and compared to a bovine serum 
albumin standard (Pierce, USA). 
1\1onoclonal antibodies 
MonoclonEli antibodies (MoAbs) against individual 
subtype specific epitopestO, difterent OMPs and mutant 
lipopolysElccharide (LPS) were used in ELISA, immuno-
blotting and immunogold EM. A list of the MoAbs used 
and the antigens which they recognise is given in Table 1. 
SDS-PAGE, quantitation or protein bands and 
Inununobloltlng 
Vaccine samples were analysed on 10% poly-
acrylamide gels in the presence of2% (w/v) SDS22. After 
electrophoresis proteins were stained by si1"er stainingH 
or by 0.1 % (w/v) Coomassie Brilliant Blue staining. The 
relative amount of class 1 OMP in the vaccine was 
determined by staining the gel using Coomassie Brilliant 
Blue. The intensity of Coomassie Brilliant Blue stained 
protein bands was determined by gelscanning and the 
relative amount of class I OMP is calculated using 
Imagemaster (Phannacia, Sweden) software and given 
as percentage of the total protein content. 
Unstained proteins were transferred to nitrocellulose 
sheets by electroblotting. Proteins were visualized using 
Table 1 The MoAhs and the meningococcal antigens that they 
recognize 
MoAb 
MNI4Cl1.6 
MN5CttG 
MN22C2.55 
MN16CI3F4 
MN3CSC 
MN20F4.17 
MN20B9.34 
MN2.0A7.10 
MN24Hl0.7S 
MN15A14H6 
MN3B9F 
15·1PS.5 
S3141 
4ASB2 
MN31D8.51 
Protein specificity 
Pl.7 
PI.t6 
Pt.5 
P1.2 
PI.1S 
P1.IO 
PIA 
P1.12 
PI.13 
Class 30MP 
Class 4 aMP 
Class 5 aMP, specirlCity 5.5 
0", 
l3lPS 
galE lPS 
These MoAhs havs been used for ELISA, lmmunoblo\ting analysis 
and Immunogold EM 
type specific MoAb (Table J) or sera derived from mice 
and Protein-A-HRP conjugate (Amersham, UK). 
Identity (est by ELISA 
The identity of the vaccine was detennined by identi-
fication of characteristic epitopes using ELISA. Slarting 
at a concentration of 0.3 Jig class I OMP per well 210g 
dilution's of the vesicles were coated in PBS 0.01 M pH 
7.2 on PYC 96-wetl plates (Greiner) overnight at room 
temperature. The coated plates were incubated at 37'C 
for 1 h with subtype-specific monoclonal antibodies in 
PBS om M pH 7.2+0.05% (v/v) TweenSO+0.5% (wI\» 
BSA (Table J). The binding of MoAbs was demon-
strated using biotinylated goat-anti·mouse-IgG 
(Amersham, UK) in PBS om M pH 7.2+0.05% (vlv) 
TweenSO+0.5% (wN) BSA at 37'C for I hand strepta-
vidin horseradish peroxidase (Amersham, UK) in PBS 
0.01 MpH 7.2+0.05% (v/v) TweenSO+0.5% (w/\') BSA 
at 37'C for 30 min. Binding of the conjugate was 
visualized using TMB/ethanol substrate. Binding of 
specific monoclonal antibody should be demonstrated, 
whereas binding of non-specific antibody (directed 
against subtypes of the other strain) should be absent. 
LPS determination 
The LPS content was determined by SOS_PAGE24• 
Vesicles were dissolved in a buffer containing 2% (v/v) 
ft-mercaplo-ethanol and 2% (w/v) SOS and boiled 
for 5 min followed by proteinase-K (2.5 mg ml- 1, 
Boehringer) treatment for I h at 60'C. The treated 
samples were separated by SOS-PAGE with a 14% 
polyacrylamide gel. LPS was oxidized with 0.4% (w/v) 
periodic acid and visualized by silver staining. Unknown 
LPS samples were compared with an LPS standard in 
the same gel. LPS concentration was also determined by 
gaschromatographl5• 
Endotoxin determination 
The biological activity of the endotoxin was deter-
mined in the limulus amebocyte lysate (LAL) assay. The 
Iipid-A part of the endotoxin molecule can activate the 
gelation of the limulus lysate. The OMV vaccine was 
incubated in a fivefold dilution with a fixed concen-
tration of limulus lysate (Heamachem Inc., S1. Louis, 
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USA) at 37'C for 4S min. The endotoxin activity was 
visualized using Bromlhymol Blue. Unknown activity of 
the endotoxin was compared with Escherichia coli 
standard endotoxin (FDA, Bethesda, USA). 
Inacth·ation and sterility control 
Trivalent bulk products were tested for absence of1ive 
organisms by incubation of the product on gonococcal 
agar and Trypton Soy Broth (TSB) medium for 3 days 
at 37'C in a 5% CO2 atmosphere. 
To test sterility on final lot 5 ml was added to ISO ml 
Clausen and Ihioglycolate and incubated for a minimum 
of 13 days at 20--25'C for Clausen and 30-32'C for 
thioglycolate. No growth should be observed. 
Immunological responses 
Immunogenicity testing was perfonned in NIH mice. 
Eight week old female NIH mice were immunized 
subcutaneously with 10 Jig total protein (l:lOth human 
dose) of OMY vaccine with 2 mg ml- 1 AlP04• After 2S 
days mice were euthanized and blood samples were 
collected. 
Sera were tested for the presence of subtype specific 
antibodies using an OMY based ELISA, by immuno-
blotting and with a subtype specific bactericidal assay. 
Reference sera for all experiments were obtained from 
mice which were hyperimmunized with killed wild type 
bacteria. 
For OMV based ELISA, plates were coated with a 
fixed concentration (0.025--0.i/lg total protein per well) 
of OMV derived from a single subtype [H44176 
(P1.7,16), 2996 (PI.S,2), Me51 (PI.I9,IS), 870227 
(PIS,IO), 870446 (PI.I2,13), 892257 (PI.7",4» in PBS 
0.01 M pH 7.2 overnight at room temQerature. After 
washing serum samples were titrated in a 210g dilution in 
PBS 0.01 ~-1 pH 7.2+0.05% (v/v) TweenSO+0.5% (w/v) 
BSA and incubated at 37"C for 1 h. The binding of 
antibodies was demonstrated using biotinylated goat-
anti-mouse-IgG (Amersham, UK) in PBS 0.01 M pH 
7.2+0.05% (vlv) TweenSO+O.5% (w/v) BSA at 37'C for I 
hand streptavidin-horseradish peroxidase (Amersham, 
UK) in PBS 0.01 MpH 7.2+0.05% (v/v) TweenSO+0.5% 
(w/v) BSA at 37'C for 30 min. Binding of the conjugate 
was visualized using TMB/ethanol substrate. 
Bactericidal antibodies were deteollined in subtype 
specific bactericidal assays. Bacterial strains as men-
tioned above were used to deternline subtype specific 
antibodies except for P1.7h,4 in which case SS0049 was 
used as target for bactericidal antibodies. Brielly 25)11 of 
bacterial suspension (lOs ml- I ) were incubated with 
baby rabbit complement (Pel-Freez Clinical Systems, 
Brown Deer, Wisconsin, USA) and 210g dilutions of 
immune serum at 37'C for I h in a volume of 100)11. 
Seven microlitres of this mixture was pipetted onto 
gonococral agar plates in triplicate and incubated over-
night at 37'C in a 5% CO2 atmosphere. The serum 
bactericidal titre was reported as the highest reciprocal 
serum dilution yielding 50"10 killing of bacteria. 
RESULTS 
Production 
Over a period of 2 years six independent Ol\-fV 
production runs were carried oUI, three productions 
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runs were performed of each experimental vaccine strain 
on a 135 I scale as described, After extraction and 
purification vesicles could be demonstrated in all prep-
arations by negative contrast EM, an example of which 
is shown in F/'gure J. 
Total protein yield of the OMY production was 
determined after extraction and purification. Total pro-
tein yield ranged from ca 250 to 1000 mg in the final 
product. The differences in yield did not influence the 
composition or immunogenicity of the of the OMY 
(data not shown). 
Yacclne characterization and Identity tests 
The composition of the OMY vaccine was character-
ized using different immunochemical and biochemical 
techniques, 
As shown in Figure J vesicles can be visualized using 
negative contrast staining and electron microscopy. 
OMY size ranged from 50 to 150 nm in different 
preparations. Intactness of the vesicles in these prepar-
ations ranged from 25 to 60% of the \'esicles. The 
remaining vesicles were partly broken ("half moon 
structures"). Only very lillie amorphous granular 
material was found. Aggregates of \'esicles were also 
obsef\'ed frequently especially after the addition of 
sucrose. 
Protein content was estimated by the method de-
scribed by Peterson21 • To demonstrate the presence of 
all relevant class I OMP epitopes an ELISA method was 
used, Yesicles or bacteria were coated on PYC plates 
and the presence of the relevant epitopes are character-
ized using subtype specific MoAbs (Table 1). The results 
of a typical assay are shown in Figure 2. All relevant 
epitopes can be demonstrated in both trivalent strains 
and in the OMVs which were made from these strains. 
In strain PLlOl24 OMV a reaction is observed of the 
Pl.?" epitope with the PI.7 specific monoclonal, this 
reaction is normally absent in bacteria of the same strain 
(Figure 2b). It is known that this epitope is present inlhe 
original strain, but as a hidden epitope which cannot 
normally be detected26• It is clear from this figure that it 
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is possible to discriminate between vesicles obtained 
from different strains. Immunogold electron microscopy 
using subtype specific monoclonal antibodies re\'ealed 
that the relevant epitopes were present on the outside of 
the vesicles (Figure 3) and that vesicles derived from the 
two trivalent strains can be identified on basis of the 
class I protein (Figure 4). 
When analysed on SDS-PAGE (Figure 5) the three 
class I OMPs which were expressed by PLl6215 call 
be separated and their MW can be calculated. Using 
immunoblot analysis we have been able to demonstrate 
the origin of the three class I OMPs (data not shown), 
The MW of these proteins differ from that in the original 
strains due to the cloning procedure which is carried 
out l2• Class I OMPs in PLlOl24 OMY can only be 
separated in two bands, The band with the lowest MW 
in PLlOl24 contains two different class I OMPs as was 
demonstrated by immunoblotting (data not shown). 
Class 4 and class 5 OMP are also present in the vesicles. 
A protein of 82 kD is also present in small amounts 
«1%) in all OMY preparations. 
The relative amount of class I OMP in the OMYs can 
be calculated using densitometry. Coomassie Brilliant 
Blue stained SDS-polyacrylamide gels were scanned 
using ImageMaster software. The relative amounts of 
the different OMPs in the OMY vaccine is given in 
Table 2. These results demonstrate that a relatively high 
portion of total protein in the \'esicles is class I OMP 
which are responsible for the induction of bactericidal 
antibodies. The bactericidal antibodies follow the 
typical serosubtype characteristics. For clinical research 
two vaccine lots were prepared that contain 50 and 100 
pg total protein per dose (0.5 ml). In Table 2 the 
composition of the OMV vaccine of the 100 Jig dose is 
given. 
Taken together these results demonstrate that the 
vesicles are of the desired structure and composition j.e, 
contain intact proteins with the relevant epitopes in a 
high concentration, 
Sarety tests 
Regarding the safety of the OMY the following 
parameters were considered. 
• Inactivation of the bacteria which are used to 
prepare the OMY. 
• Sterility of the intermediate and the end products. 
• Determination of the toxicity related with the 
presence of bacterial endotoxin by LAL assay, LPS 
determination and pyrogenicity testing in rabbits. 
• Abnormal toxicity of the hexavalent vaccine. 
All safety tests were perfomled according to inter. 
national guidelines or requirements [European Pharma-
copeia (EP) and WHO]. For OMY based vaccines no 
specific requirements have been formulated by the EP or 
WHO. The only comparable vaccine is the Norwegian 
Folkehelsa vaccine based on H44176 OMylO. This 
vaccine has been pro\'en to be safe and effective, 
Endotoxin determination 
The bacterial LPS is a component of the bacterial 
outer membrane. Moreover, LPS is a structural compo-
nent of the OMY and, although it is a toxic molecule, it 
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Figure 2 Presence 01 subtype specific epitopes In the two vaoclne stralns PL 16215 and PL 10124 and vesicles derived thereof as measured 
In ELISA. (Al Results obtained with PL16215 bacteria and OMV, (8) the results obtained with Pll0124 bacteria and OMV 
Figure 3 An eleclronmlcrOQraph of an Immunolabelled vesIcle 
preparation of PU6215 (Al. The P1.2 apilopa is visualized on the 
sulface of the vesicles by lmmunogold labelling using the mono-
clonal antibody MN16C13F4 (anU P1.2). Numerous 6 nm gold 
particles surround the vesicles (B). Control incubation with the 
monoclonal MN24Hl0.75 (anU PUS) showed no gold particles. 
Sars Indicate 100 nm 
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• 
• ~ 
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Figure 4 Vesicles of tha PLI6215 and PL10124 strains were 
labelled for P1.2 and P1.13 with the Immunogo!d method. The 
percentage of OMY positive lor the two class 1 epitopes Is given. 
Approximately 300 vesicles were analysed per sample. 0, Control 
Incubation without subtype SpecirlC MoAb;D, a·Pt.2 Incubation; and 
., a·PI.13 Incubation. Almost 100% of the vesIcles 01 each straIn 
were positive lor the correct class 1 epitope 
is at the same time being studied as a possible vaccine 
adjuvant. Therefore we have carefully monitored the 
LPS content and the biological activity of the LPS in 
the vesicles. LPS free vesicles cannot be prepared since 
the presence of LPS in the OMY is necessary for the 
stability of the OMY vaccine. The LPS/protein ratio is 
lowered during the production process by partly replac-
ing LPS by DOC. The LPS content was detennined on 
the intennediate products by SDS-PAGE and silver-
'kDa 
97.4 
66.2 
55.0 
42.7 
40.0 
31.0 
21.5 -
1 2 3 4 5 
FIgure 5 10% SOS-PAGE pattern 01 differenl vaccine bulk prod· 
ucts. Class I OMP are ca 40 kOa. Lane 1, low molecular weIght 
markers; lana 2, OMV PL16215 2}Jg to1al proteIn; lane 3, OMY 
PL16215 4}Jg tolal prolein; lane 4, OMV PLI0124 2}Jg lolal prolern; 
lane 5, OMY PL10124 4}Jg lotal protein 
Table 2 The compositkln of the he~avalenl vaccine 101 contaIning 
lOOllg of to1al proteIn; one human dose contains 0.5 ml 
Substance 
Protaln 
Class 1 (6 subtypes) 
Class 4 
Class 5 (5e and 5.5) 
82 kDa 
pH 
DOC 
S·PS 
LPS (GalE) 
AIP04 
Sucrose 
Thlomersal 
Concenlratkln 
200llg ml-1 
89% 
7% 
3% 
d% 
6,' 
22}Jg ml-1 
Absent 
20}Jg ml-1 
2mgml-1 
30 mg ml-1 
0.7 mg ml-1 
staining24• Results ranged from 2.S to 10% LPS relative 
to the protein content. Both European Phannacopoeia 
and WHO failed to provide requirements. 
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Figure 6 Immunogenlcity of a hexavalent vaccine lot. The antibody 
response was measured In an OMV based ELISA againsl different 
subtype strains and Is given as a reciprocal log titre of two fold serum 
dilutions. 0, Pre·vaccination Htres; II, posl-vaccinalion titres alter 
28 days 
The biological activity of the endotoxin was deter-
mined in the Iimulus amoebocyte lysate (LAL) assay. 
Hexavalent final lot samples were tested in a fivefold 
dilution and contain 977 and 195 EU ml- 1, respectively, 
when compared with E. CQIi standard endotoxin. The 
endotoxin activity is within the range of DPT/polio 
vaccines and is therefore regarded as safe. Moreover, the 
endotoxin activity of LPS in vesicles is much lower than 
that of free purified LPS10 (own obsen'ations). 
To determine the pyrogenicity of the OMY vaccine a 
study in rabbits was performed. Samples of a hexavalent 
vaccine final lot (which contains the highest amount of 
LPS) were injected Lv. in rabbits (1 ml kg- I) at 1:100, 
1:300 and 1:1000 dilution and temperature rise was 
monitored. Furthermore a placebo which contains only 
aluminumphosphate and thiomersal, was injected at 
1:100 dilution. For the 1:100 vaccine dilution a repeal of 
the test was necessary. The other dilutions passed the 
test. Temperature rises of 1:300 and 1:1000 dilutions 
were comparable with those obtained with the placebo 
(data not shown). 1:1000 dilution of the vaccine corre-
sponds with the requirements for 23-valent pneumo-
coccal polysaccharide vaccine and mOllO-, bi- and 
tetravalent meningococcal polysaccharide vaccines. 
Immunological responses 
IllllllUnological responses were studied in NIH mice. 
Sera obtained from these mice at day 28 after immuniz-
ation were analysed for the presence of anti meningo-
coccal antibodies by ELISA, immunoblotting and 
bactericidal assays. Serial dilutions of sera from mice 
immunized with OMY vaccine revealed subtype specific 
responses in ELISA and bactericidal assays (Figure 6 
and Figure 7). Antibody responses against all individual 
subtypes which are included by the vaccine can be 
demonstrated on plates coated with vesicles derived 
from the original strains. Some epitopes seem to be more 
immunogenic than others. The P1.I9,15 and P1.7h,4 
subtypes induced very low responses. Since an EUSA 
only demonstrates the elicitation of antigen binding 
antibodies but not of functional bactericidal antibodies 
the sera were also tested in a bactericidal assay. The 
results of these experiments are given in Figure 7. In this 
assay no anti-PI.19,15 (test strain) antibodies with bac-
tericidal activity could be demonstrated, but all other 
strains were killed in the presence of complement. 
In immunoblol experiments antibodies were demon-
strated mainly directed at class I mvlP but also against 
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FIgure 1 Baclericldal activity 01 sera 01 m1ce Immunized with 
hexavalent vaccine lot. Results are given as reciprOC<lt log titre 01 
two fold serum dilutions. 0, Pre·vaccination liters; ., post-
vaccination titres alter 28 days 
other OMP that were present in the vesicle (data not 
shown). The 82 kDa protein which was present only in 
small amounts « 1%) induced high antibody titres in 
mice as detennined in immunoblotting. This reaction 
has also been observed in post-vaccination sera from 
humans after vaccination with H44176 vesicles27 
DISCUSSION 
In the bacterial vaccine world, whole cells (inactivated or 
attenuated), toxoids and capsular polysaccharides (pref-
erentially conjugated to proteins) are established vaccine 
principles. In addition to this there is a need for OMP 
based vaccines. Most research and clinical work is 
dedicated to meningococcal OMP vaccines. The OMY 
principle combines easy production procedures with 
pOlent delivery adjuvant characteristics. The OMP con-
tent of OMY vaccines can be manipulated by recom-
binant DNA technology and LPS in its various forms 
can be used as an adjuvant. Therefore, the meningococ-
cal OMV vaccine deserves further attention as a menin-
gococcal vaccine development and as a general principle. 
We describe the preparation of an experimental hex-
avalent class I OMP containing OMY vaccine. Bacterial 
OMPs need to be presented in a membrane like structure 
to remain in or regain proper confonnation. We have 
chosen an O~·IV formulation for vaccine purposes since 
this is a production friendly way of preparing immuno-
genic O~1P containing vacdnes. In our hands when 
Oi\·IY had disintegrated into AGM (amorphous 
granular material) the OMP were still immunogenic 
but the antibodies induced had very low bactericidal 
activity28. The likely explanation for this phenomenon is 
epitope competition at the B lymphocyte level, leading 
to a response against surface exposed epilopes (Le. 
bactericidal antibodies) in case of an OMY vaccine and 
to a response against non-exposed epilopes in case of an 
AGM type vaccine. Alternative approaches for the 
Oi\lV vaccine principles are artificial membrane like 
structures such as liposomes or ISCOMs (immune 
stimulating complexes). In that case the OMPs need to 
be purified and reintegrated into membrane like 
structures. Such procedures are more complicated in 
production terms as compared to the OMV principle. 
We have used modified meningococci for our vaccine 
purposes. The vaccine strains did not express class 3 
OMP, B polysaccharide and the lacto-N-neotetraose 
structure. In addition to class I Ol\-IP which represent ca 
90% of the protein, class 4 and class S OMPs and some 
82 kDa OMP are present in the vaccine. Each strain 
expressed three different class I OMPs. The advantages 
of combining three diflerent class 1 OMP in one strain as 
compared to mixing OMY derived from three individual 
strains are obvious. The relative amount of class I 
protein is enhanced and thus it is possible to make a 
vaccine with a relatively low protein content (100 Itg per 
dose) that contains a high amount of target protein. 
Moreover the LPS content in a vaccine that is a combi-
nation of six OMY preparations would be much higher 
than in the vaccine described. 
The OMVs derived from these strains, were found to 
be stable over time (18 months) and after thermo-
degradation experiments (data not shown). In each 
strain class I o~,tps are synthesized in equimolar 
amounts and OMVs of the two individual strains are 
mixed to contain equal amounts of all class I OMPs, 
The choice for the class 1 OMP was driven by findings in 
man and animals which demonstrate this ~rotein to be a 
major target for bactericidal antibodies2 • The hetero-
geneity of the class 1 OMP appears to be limitedlO. The 
Pl.l9,IS SUbtype in the trivalent Or-.'IV was non· 
immunogenic in the animal model tested for bactericidal 
antibody induction, Immunization of NIH mice with 
OMV containing only the Pl.19,IS subtype and no other 
class 1 OMP did induce bactericidal antibodies (data not 
shown). The decreased immunogenicity of the PU9,IS 
epitope in the trivalent vaccine in mice is now studied in 
our laboratory, however. an anli-PU9.IS response 
could be demonstrated in some human adult volunteers 
i.e. fourfold rise in bactericidal antibody titre IS. Whet;,er 
it is immunogenic in children after a first immunization 
remains to be investigated. 
The vaccines were also found to be safe for human use 
although LPS is present in a ](Y% wlw ratio as compared 
to OMP. It is known that the Or."IV structure has a 
shielding effect on the endotoxin properties of LPS20. 
Taken together the results with regard to safety of the 
vaccine do not deviate much from the data obtained 
with the Folkehelsa vaccine2o. Since this vaccine proved 
to be safe in adolescents we do not expect adverse 
reactions Oil the basis of these observations. 
A phase I study in adults with this v'lCcine has been 
carried out lS and phase II studies in children and infants 
have started. 
ACKNOWLEDGEMENTS 
The authors would like to acknowledge Dr 1. H. 
Frederiksen (Folkehelsa. Oslo, Norway) for LPS deter· 
mination using gas chromatography and fruitful discus-
sions and Dr K. Teppema and M. Burger (RIVM, PAT) 
for their valuable ultrastructural research. The develop· 
ment of the experimental vaccine described in this 
manuscript was supported by the Dutch Prevention 
Fund, Grant 28-2249, 
REFERENCES 
Scholten, RJ.P,M., Bijlmer, HA, Pootman, J.T. et al. Meningo-
coccal disease in The Nelhariallds, 1958--1990. Steady In· 
crease of the Incidence rate since 1982 partially caused by new 
serolypes and subtypes of Neisseria meningitidis. J. Clin. 
Infect. 1993, 18, 237-246 
Chapter Ill. I 
2 Peltola, H. Meningococcal disease: 51111 v,.ith us. Rev. Infect. Dis. 
1984,5,71-91 
3 Wyle, F.E., Artensteln, M,S., Brandt, B.l. al al. Immunological 
response in man to group B meningococcal polysaccharide 
vaccines. J. Infect. Dis. 1972, 126,514-522 
4 Jennings, H,J., Roy, R. and Gamian, A. Induction of meningo, 
coccal QIOUP B polysaccharide·specific IgG antibodies In miCe 
using an N-proprionyiated B polysaccharide tetanus toxoid 
conjugated vaccine. J. Immunol. 1986,37, 1708-1713 
5 Zollinger, W.O., Bos!ego, J., Moran, E. et at. Meningococcal 
serogroup B vaccine protection trial and follow·up studies in 
Chile, NIPH Ann. 1991, 14.211-213 
6 Bjune, G., H"jby, E.A., Gronnesby, J.K. et al. Effect 01 outar 
membrane vesicle vaccine againsl group B meningococcal 
d;seasa in Norway. Lance/1991, 338,1093-1096 
de Moraes, J.C., Perk.ins, B.A., Camargo, M.C. el al. Protective 
efficacy of a serogroup B meningococcal vaccine in Sao Paulo, 
Brazi\' Lance/1992, 340, 1074-1078 
8 HOlby, E.A., Rosenqvisl. E.A., Froholm, l.O. at 81. Bactericidal 
"lnlibodies after Vaccination with the Norweg1an meningococcal 
serogroup B outer membrane veskle vaccine: a brief sUNey, 
NIPHAnn.1991, 14, 147-156 
9 Saukkonnen, K, leinonen, 1.1., Abd,llahl, H. and Poolman, J.T. 
Comparative evaluation of polential components lor group B 
meningococcal vaccine by passive proteclion in Ihe infant ral 
and In vitro bactericidal assay. Vaccine 1989. 7, 325-328 
10 Abdillahl. H. and Poolman. J.T. Neisseria meningilidis group B 
serosubtyping usIng monoclonal antibodies whole-cell ELISA. 
Microbiol. Pathogen. 1988, 4, 27-32 
11 Van der ley, PA and Poo!man, J.T. Construction of a multi. 
valent meningococcal vaccine strain based On the class 1 outer 
membrana protein. Infect. fmmun. 1992, 60, 3156-3161 
12 Van der ley, P.A" Van der Biezen, J. and Poolman, J.T. 
Construction of Neisseria Meningi/idis straIns carrying multiple 
chromosomal coples of the porA gene lor use In the pro<luclion 
of a multlvalent outer membrane protein vaccine. VaCCine 1995, 
13,401-407 
13 Rosenqvisl, E., Hoiby, E.A., Wedega, E .• Kuseck, B. and 
Achtman, M. The 5C protein of Neisseria meningi/idis is highly 
immunogenic in humans and induces bactericidal antibodies. 
J. !nfecl. Dis. 1993, 187, 1065--1073 
14 AM, E.l., Oempsey, J.A., Hobbs, M.M., Klapper, D.G. and 
Cannon, O.G. Characterization of the opA (class 5) gene family 
of Neisseria menlngilidis. Mol. Microbia!. 1991,5, 142fH437 
15 Rosenqvist, E., Hoiby, E.A., Wedege, E. el al. A new variant of 
selOsublype PI.16 in Neisseria meningitidis from NOIway, 
assoclaled with increased resIstance to bactericldal antibodies 
Induced by a serogroup B outer membrane proteIn vaccine. 
Microb. Pathogen. 1993, 15, 197-205 
16 legrain, M., Mazarin, V., Ir\'iin, S.W, et al. Cloning and charac-
terization of Neisseria meningi~"dis genes encoding the trans· 
lerrin bind;ng proteins !bpi and Tbp2. Gene 1993, 130,73-80 
17 Pellerson, A., Kuipers, A.J., Pelzer, M. et al. Monoclonal 
antibodies against the 70·lcilo<lalton llOn·regulated protein 01 
Neisseria meningitidis are bactericidal and strain specific. 
Infeci. Immun. 1990, 58, 3036 
18 Peeters, C.C.A.M., Rumke, H.C., Sundermann, L.C. et al. 
Phase I dinlcal lrial with a hexavalent PorA containing menin· 
gococcal outer memblane vesIcle vaccine. Vaccine 1996. in 
press 
19 Frantz, J.D. Growth fequirements of the meningococcus. J. 
Bac/. 1942, 43, 757~761 
20 Frederiksen, J.H., Rosenqv1s1, E., Wedege. E. et al. PfOduclion, 
characterization and control of MenB,vaccine 'Folkehelsa': an 
outer membrane Vesicle vaccine against group B meningo-
coccal disease. NIPHAnn. 1991, 14, 67--80 
21 Petelson. G.L. A simplifJCation of the plotein assay 01 loWry 
el al. which is more gene/ally applicable. Anal. Biochem. 1977, 
83,346-356 
22 laemmii, U.K. Cleavage of structural proteIns during the 
assembly of the head 01 bacteriophage T4. Nature 1970, 277, 
680-685 
23 Wray, W., Boulikas, T., Wray, V.P. and Hancock., R. Silver 
slaining of proteins In polyacrylamide gels. Anal. Biochem. 
1981,118,197-203 
24 Tsai, C., Boykins, R. and Frasch, C.E. Asensitive sliver stain for 
detecting npopolysaccharides in polyacrylamide gets. Anal. 
Biochem. 1982, 119, 115--119 
25 Bryn, K. and Jantzen, E. Analysls 01 lipopolysaccharides by 
methanotysis, trifluoroacelylatlon and gas chromatography on 
133 
Immunogenic presentation of viral and bacterial antigens: iscom and OMV as a model for new vaccines 
a fused·silica capillary oolumn. J. Chromafogr. 1982, 240, 
405-413 
26 Wedegs, E., DaJseg, R., Caugant, DA, Poolman, J.T. and 
Froholm, L.C, Expression of an inaC¢)sslb\e PI ,7 subtype on 
menlngOC«CaI class 1 prolelns, J. Mod, Microbfol. 1993, 38, 
23-28 
27 Wedege, E., Bjuns, G., Fraholm, LO., Hoiby, E.A. and 
Rosenv\sl, E. Immunoblotting studies of vacclnee and patlent 
sera from a NOM'eglan serogroup B meningococcal vacclnation 
Irlal. NIPH Ann. 1991, 14, 183-186 
134 
28 Poolman, J.T., Van der ley, P.A., Wlertz, E.J.H.J. and 
Hoogerhout, P. Second generation meningococcal OMp·lPS 
vacclnes, N/PH Ann. 1991, 14, 233-241 
29 Poolman, J.T., llmmermans, JAM., Hopman, C.T.P, 81 a/. 
Comparison of meningococcal ouler membrane proleln 
vaccines, solubilized with detergent or C polysaccharide. 
Antonfa van Leeuwenhoek 1987, 53, 557-564 
Chapter III.2 
Immunogenicity of various presentation forms of class 1 outer 
membrane protein of Neisseria meningitidis in mice. 
C. Peeters, 1. Claassen, M. Schuller, G. Kersten, E. Rouppe 
van der Voort, and J. Poolman 
Vaccine in press 
135 

Chapter m.2 
ABSTRACT 
III this study we compare differellt vaccille formulatiolls cOlltaillillg mellillgococcal 
class 1 outer membralle proteill (ParA); purified ParA, outer membral/e vesicles 
(O};fV) alld immulle-stimulatillg complexes (iscom). Bactericidal alltibodies could be 
gellerated by the OAff alld iscom formulatioll but IIOt with purified ParA usillg either 
AIPO, or Quil-A as adjuvallt. O};[V alld iscom formulatiolls revealed similar 
immllJlOgenicity when tested in a dose response mallner, with respect to bactericidal as 
well as OMV-bil/dillg alltibodies. The allti-OMV IgG subclass respol/se il/duced by 
ParA ill OMV formulatioll was foulld il/ all subclasses IgGl, IgG2a, IgG2b, IgG3. 
OMP-iscoms il/duced velY high IgGl allti-OMT' alltibodies but almost I/O IgG3 
respollse. 
Also, OMP-iscoms appeared to be a potel/t il/ducer of al/tibodies directed agaillst 
lillear peptides correspolldillg to slllface exposed loops of ParA. III additioll, iscoms as 
well as purified ParA with Quil-A as adjuvallt (but I/ot with AIPO,) il/duced high levels 
of alltibodies agaillst purified ParA. 11/ SUmI/WIY, il/ additiol/ to the O};[V formulatiol/, 
ol/Iy iscoms cOl/tail/il/g ParA are able to gel/erate al/ al/aml/estic al/d bactericidal 
alltibody respol/se. 
INTRODUCTION 
Neisseria mel/il/gitidis is an encapsulated bacterial species which causes invasive 
diseases such as meningitis with incidences that can sometimes reach epidemic levels. 
Infectious diseases caused by encapsulated bacteria can be prevented by immunization 
with vaccines generating antibodies to the capsular polysaccharides. In contrast to the 
group A and C capsular polysaccharides, the group B meningococcal polysaccharide 
induces poor or negligible bactericidal antibodies in humans (1). One of the 
explanations for this poor immunogenicity is the similarity of poly-a- 2,S-neuraminic 
acid, which composes the B polysaccharide, with sialic acid moieties on human cells 
(2). In addition to the presence of anti-capsular antibodies, bactericidal and opsonizing 
antibodies to noncapsular meningococcal surface antigens have been demonstrated in 
humans after meningococcal disease (3,4). For this reason many investigators have 
chosen to develop a vaccine against group B meningococcal disease based on outer 
membrane proteins (5-7, S, 9,10,11,12,13-15,16). 
A large number of proteins can be identified in the outer membrane (17). Most isolates 
contain the PorA protein, PorB (class 2/3 OMP); Rmp (class 4 OMP), Opc (class 5c 
OMP), and several Opa (class 5 proteins). Many other OMPs have been recognized 
amongst which iron-limitation inducible OMPs, such as LbpA and LpbB, lactofelTin 
binding proteins; FrpB (70 kD), function unknown; TbpA and TbpB, transferrin 
binding proteins. The antigenic heterogeneity of PorA and PorB forms the basis of 
typing of meningococcal strains into subtypes and serotypes, respectively (IS). 
Monoclonal antibodies with il/ vitro bactericidal activity in the presence of 
137 
Immunogenic presentation of viral and bacterial antigens: iscoms and OMV as a model for new vacmes 
complement have been raised against PorA and PorB, of which PorA specific 
antibodies were the most effective (13). In an infant rat passive protection model it was 
demonstrated that antibodies to class I proteins are strongly protective (19). Opa 
proteins have been shown to be very inununogenic, though they do have a high 
variability and are therefore of less interest for vaccine development. Opc protein also 
induces bactericidal antibodies, however most case isolates do not express this protein 
(20). TbpB and FrpB also induce a strong bactericidal antibody response (21,22). Most 
results so far demonstrate potent bactericidal antibodies to be directed against strain-
or type specific epitopes within the various OMPs (PorA, TbpB, FrpB, PorB, Opal. 
Anti-LPS polyclonal and monoclonal antibodies raised in animals have been shown to 
have bactericidal activity (22-24). Also, in sera of patients bactericidal anti-LPS 
antibodies could be demonstrated (25,19). However, LPS is not suitable for vaccine 
development in its natural form. Saccharide-protein conjugates or liposomal LPS are 
currently being investigated as potential LPS vaccines (26,27). 
The first generation of meningococcal OMP vaccines, predominantly containing PorA 
and PorB were derived from wild-type strains and designed to be used in area's 
dominated by a single strain or clone. These vaccines demonstrated efficaciesabove 4 
years of age in the range of 50-80% (5,6,11,28,16). Although antibodies were induced 
no efficacy was demonstrable in infancy (6). The in vitro bactericidal activity was 
found to be strain-specific for the greater part (29) although cross reactivity is observed 
after boosting (12, 20). It is clear from these vaccine studies that OMP vaccines need 
to be improved. One way to improve OMP vaccines lies in the area of vaccine 
formulation. Previously, it was demonstrated that the presentation fonn of PorA was of 
great importance for the generation of bactericidal antibodies (7,30,13). In this study 
we compare three presentation forms of the meningococcalPorA: i) purified OMP with 
AIPO, or Quil-A as adjuvant, ii) OMP in outer membrane vesicle (OMY) formulation 
with intrinsic LPS and added AIPO, as adjuvant and iii) OMP in immune-stimulating 
complex (iscom) (31,32) formulation with intrinsic Quil-A as adjuvant. 
MATERIALS AND METHODS 
Animals 
8 to 12 week-old female NIHlRIVM mice (random outbred strain) were used. They 
were bred and kept at the National Institute of Public Health and Enviroll11lent. 
Antigens 
OMP of Neisseria lIlellillgilidis serogroup B strain HIH-5 (B:-:P1.7,16:L3,8), a PorB-
negative variant of H44/76, was purified basically as described for the purification of 
gonococcal porin protein IE by Teerlink et al. (33). Lyophilized meningococci were 
extracted with Zwittergent 3-14 in 0.5 M CaCI,. The extract was precipitated with 20% 
ethanol and freed from ethanol and CaCI, by repeated dilution and ultrafiltration. 
Further purification was achieved by ionexchange chromatography (DEAE 
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Sepharose) and gel pemleation clu'omatography (Sephacryl S-300). Fractions were 
analyzed by SDS-PAGE, and PorA containing fractions were pooled. The purified 
protein was stored at 4°C with 0.2 % sodium azide (w/v) as a preservative. 
OMP containing iscoms were prepared according to the procedure described for 
gonococcal porin protein IB containing Iscoms (34,35). Briefly, the purified OMP was 
ethanol precipitated and solubilized in octylglucoside (Sigma) in Tris buffered (10 
mM) saline (140 mM) pH 7.4. Solubilized OMP and Quil-A (Spikoside, Iscotec, 
Sweden) were added to lipid micelles of phosphatidylethanolamine type IlIA (Sigma) 
and cholesterol (Sigma). The weight ratio of OMP : Quil-A : Phosphatidyl-
ethanolamine : cholesterol was 2:20:5:5. The micelles were dialyzed against the 
TrisINaCI buffer at 4°C. The Iscoms were purified on a sucrose gradient 10-60% in 
TrisINaCI buffer. and the iscom fraction was dialyzed against TrislNaCl. Incorporation 
of OMP was confilll1ed by SDS-PAGE of the gradient fractions. The iscoms were 
structurally identified by negative contrast electron microscopy. The presence of PorA 
was demonstrated by SDS-PAGE of the OMP-iscom and immunoblotting with 
monoclonals recognizing the Pl.? and P1.l6 epitope. Both monoclonals recognized a 
43 kD protein band in the immunoblot and no degradation products could be 
demonstrated. 
OMV of Neisseria lIIellillgitidis serogroup B strain H44/76 and of a multivalent 
serosubtype Neisseria lIIellillgitidis strain PLl6215 were prepared by deoxycholate 
extraction of felll1entor grown bacteria. OMV were obtained after high speed and ultra 
centrifugation and were subsequently adsorbed to AlPO, (36). 
PLl6215 is a genetically engineered H44/76 strain that expresses three different PorA 
proteins, PI.?,16, P1.5,2 and P1.19,15 and does not express lactoneotetraose, PorB 
and B-polysaccharide (10). 
OMV were structurally identified by negative contrast electron microscopy. A variable 
size of 10-100 11111 was found for these vesicles. The presence of PorA, Rmp, Opa5.5 
and Opc was demonstrated by SDS-PAGE and immmunobiotting. Approximately 30% 
of total protein present in H44/76 OMV was found to be PorA. For PLl6215 OMV, 
approximately 90% of total protein was found to be PorA, with equimolar distribution 
of all tluee PorA subtypes, implying the P1.7,16 OMP to be present at about 30% of 
total protein. Both OMV preparations contained approximately 10% of LPS (w/w 
protein) as was demonstrated with silver staining after SDS-PAGE. 
Immunization scheme 
Groups of 5 to 6 mice were immunized subcutaneously with 0.25 ml solutions of 
variable doses (ranging from 0.33-10 fig or 30 fig) of OMP adsorbed to AIPO, 
(RIVM), OMP with Quil-A, OMP-iscom, H44/76 OMV adsorbed to AlPO, or 
PLl6215 OMV adsorbed to AIPO, in saline. A subcutaneous second immunization 
with the same dose of antigen was given to each animal 28 days after the first 
immunization. Blood samples were collected from the retro-orbital plexus at regular 
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intervals after each immunization. The blood was allowed to clot at room temperature, 
the serum was withdrawn and stored at _20 0 C until use. From evety individual sennll 
collected on day 42 from a given experimental group a 10 III sample was used to 
prepare pooled samples. These pooled samples were used for analysis of antibody 
responses on this day. All other assays were perfol1l1ed with individual serum samples 
of experimental groups in which antibody responses could be detected in pooled 
samples. 
Sernm antibody assays 
Antibody titers to H44/76 OMV , 2996 OMV(B:2b:PI.S,2:L3,8) and purified HIII-S 
OMP were detenl1ined by ELISA as described below. 
Antibody titers to OMV of H44/76 or 2996 and to H1II-S OMP were measured on 
highly activated immunoassay microtiter plates (Flow, Irvine, United Kingdom) 
coated ovemight at room temperature with S Itg/ml of total protein of OMV or 2 Ilg/ml 
of purified class I OMP in 0.01 M phosphate buffer pH 7.4. Plates were washed with 
tap water-Tween 80 (0.03 % (w/v». All plates were then incubated for 2 h at 37 °C 
with three-fold serial dilutions of serum samples in PBS containing 0.1 % (w/v) 
Tween-SO. Binding of specific antibodies was demonstrated with peroxidase 
conjugated goat anti-mouse antibodies (Southem Biotechnology Associates, 
Birmingham, AL), which detect IgM, IgG, IgGI, IgG2a, IgG2b or IgG3, in PBS-
Tween-80 0.1 % (w/v) and skimmed milk powder O.S % (w/v) for 90 min at 37 °C. 
Plates were washed again and incubated at room temperature with 100 It! of the 
peroxidase substrate 3,3',5,S'-tetramethylbenzidine (0.1 mg/ml; Sigma)-O.OI % H,o, 
(Merck) in 0.11 M sodium acetate buffer pH S.5. After 10 minutes, the reaction was 
stopped by adding 100 it! of 2 M H,SO,. The 1\50 was registered on a Biokinetics 
microplate reader EL312e. The data from each plate were analyzed by using the 
KinetiCalc V2.03 calculation programme. All IgG antibody titers were expressed as 
percentages of a reference hyperimmune serum either for H44/76 OMV, 2996 OMY or 
P1.7,160MP. 
Antibody titers towards the serotype-specific variable domains in loop I and loop 4 of 
the P1.7,16 class I OMP were detenl1ined by using a peptide ELISA. Biotinylated 18-
mer peptides corresponding to the amino acid sequence of surface exposed loop I 
(QLTEAQAANGGASQVKV) and loop 4 (YTPAYYTKDTNNNLTLVP) of the 
P1.7,16 class I OMP were bound to avidine coated plates. The ELISA was further 
proceeded as described above. 
SDS-PAGE and Western blotting 
H44/76 OMV preparation was separated on a 12 % SDS PAGE gel at a constant 
amperage of 30 mA/gel for approximately I hour. Sample buffer was added to the 
OMV preparation and the mixture was heated for 5 min. at 100°C. A total protein 
concentration of 10 Ilg protein was loaded on the top of a lane. After running the gels, 
the separated proteins were transferred to nitrocellulose sheets in a BioRad Trans blot 
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semi dry transfer cell at a constant CUlTent of O.S mA/cm' for I hour. The nitrocellulose 
sheet was cut into 4 nun strips. The nitrocellulose strips were washed twice with Tris 
buffered saline 0.01 M, pH 7.2 containing 0.5% (w/v) Tween-SO (TBST). After 
washing, the strips were incubated with a I :500 dilution of pooled serum samples in 
TBST. As controls, strips were incubated with monoclonals recognizing the surface 
exposed loops PI. 7 or P 1.16, class 4 protein, class 5 protein and 5C protein. Subse-
quently, the strips were blocked by incubation in TBST and 0.5 % (w/v) skimmed milk 
powder for I hour at room temperature. After washing, the strips were incubated for I 
hour at roomtemperature with peroxidase labeled goat anti-mouse IgG (Southern 
Biotechnology Associates) diluted 1:10,000 in TBST with 0.5 % (w/v) skimmed milk. 
The strips were washed again and subjected to coloring with substrate. 
Serum bactericidal assay 
Neisseria mellillgitidis serogroup B strain H44/76 (B:15:PI.7,16:L3,S) and the 
recombinant engineered Men B strain AS-6t (B:15:PI.5,2:L3,S) (30) were used in this 
assay. The lyophilized strains were rehydrated with PBS and a small sample of this 
suspension was inoculated onto (gonococcal) GC agar plates containing I % Iso Vita-
leX. After overnight incubation at 37°C in 5 % CO, the colonies were harvested with a 
sterile polyester swab and suspended in Mueller Hinton Broth (MHB) with 15 % 
glycerol. Working seed lots of 1.5 ml were stored at -70°C. A sample of this working 
seed lot was tested for surface expression. To eliminate phase variation a fi'esh aliquot 
was plated on GC agar plates containig IsoVitaleX for each experiment. A scrape was 
taken form the frozen seed lot and streaked onto a GC agar plate with Iso VitaleX. 
After overnight incubation at 37"C in 5% CO, colonies were harvested in 2 ml of 
sterile MHB. Approximately 100-200 III of the stock bacterial cell suspension was 
added to 20 ml of sterile MHB pre-equilibrated at rOOm temperature to yield an A600 
between 0.07 and O.OS. The culture flask was then incubated for approximately 2 hours 
at 37°C with 160 rpm shaking until A600 was between 0.23-0.24. This yielded 
approximately into 1.10' CFU/ml. The bacterial cells were diluted in sterile 50 mM 
phosphate buffer pH 7.2 containing 10 mM MgCl" 10 mM Caq and 0.5 % (w/v) 
BSA (assay buffer) until a concentration of 1.10' CFU/ml was reached (bacterial 
working concentration). 
All mouse sera to be tested were heat inactivated for 30 minutes at 56°C. Pooled sterile 
baby rabbit serum (3-4 weeks old; lot IIS14; Pel Freeze Clinical Systems, Brown 
Deer, Wisconsin) without bactericidal activity against the strains to be tested was used 
as exogenous complement source in this assay. A sterile polystyrene U bottom 96 well 
microtiter plate was used for the micro senlln bactericidal assay. The total volume of 
each well of the plate was 50 III with 25 III of serially diluted serum in assay buffer 
(final starting dilution 1:4), 12.5 III of bacteria, 12.5 III of complement (final 
concentration 20 % (v/v) in assay buffer). Controls included samples with buffer, 
bacteria and complement and samples with serum, bacteria and buffer. A known 
positive senllll sample (either monoclonal or polyclonal was included in each assay; 
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the acceptable limit of variability was 1 well dilution). After all components were 
added to each well of the plate a 10 ftl aliquot was taken of the control samples with 
buffer, bacteria and complement and pipetted onto a dry square formed GC agar plate 
containing I % Iso VitaleX and allowed to run in lanes down the plate. The micro titer 
plate was then incubated for 1 hom at 3rC. The GC agarplate with 1% IsoVitaleX 
was incubated 18 hour at 3rC in 5% CO,. After I h incubation a 7 ftl aliquot was 
taken from each well of a lane using a multichatmel pipet and spotted onto a dlY square 
formed GC agar plate containing 1% IsoVitaleX. After 18 hr incubation at 37°C in 5 
% CO,, the colonies on time zero and 60 min-incubation plates were counted. The 
average number of CFU at time zero was used as 100%. The selUm bactericidal titer 
was reported as the reciprocal of the selUm dilution yielding ~ 50 % killing. 
RESULTS 
Protein composition of the antigens 
The antigen preparations that were used in this study were analyzed on 10% 
polyacrylamide gels in the presence of SOS (Figme I). PL16215 OMV (lane 2) 
contain class three porA's, Rmp, Opa, Opc and trace amounts of an 82 kO OMP. 
H44/76 OMV (lane 3) contain class I, 3,4 and 5 OMP and the 82 kO OMP. In the 
batch of the purified OMP used in this study only one single band with a molecular 
weight of app. 43 kD (PorA) was detected. In OMP-iscom the 43 kD OMP was the 
only protein that could be detected. 
class I 
class 3 
class 4 
class 5 
2 3 4 5 
figure 1: Separation of antigens all 10 % polyaclylamide gel ill the presellce of SDS. Proteills were 
stained with Coomassie Brilliallt Blue. i: marker proteills, 2: PL16215-0MV, 3: H44176 OMV, 4: 
purified meningococcal OMP, 5: OMP-Iscom 
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Primary and secondary antibody responses generated with variolls presentation 
forms of class 1 onter membrane protein 
At day 28 after primary immunization, the highest percentage of responding mice for 
anti-H441760MY IgG antibodies were found in groups of mice immunized with 0.33-
10 ~g ofH44/76 OMV (six out of six) as shown in table 1. 
Preparation and Mean IgO titer SEM 
dose (JIg) 
day 28 day 42 
PLI6215 OMY + AIPOl 
0.33 I± I (116) J± 9 (116) 
1.0 I± 1(2/6) 4± 9 (416) 
l3 3± 3 (316) 24> 3 (6/6) 
10.0 6± 2 (6/6) 41± I (6/6) 
30 8± 2 (6/6) 19-1± 4 (6/6) 
HW76 OMV + AIPOl 
0.33 II± 2 (616) 30± I (6/6) 
1.0 13± 2 (6/6) 45± 2 (616) 
l3 20± I (6/6) 62± 2 (616) 
10.0 22± 2 (6/6) 168± 2 (6/6) 
PI.7,16 + AIPOl 
0.33 N.D. 2± 2 (3/6) 
1.0 N.D. 2± 14(3/6) 
3.3 N.D. I± 2 (116) 
10.0 N.D. I± 2 (116) 
PI.7,I6 + QuI! A 
0.33 N.D. I± 1 (0/5) 
1.0 N.D. I± I (0/6) 
3.J N.D. l± I (0/6) 
10.0 N.D. I± I (0/6) 
P1.7,16 in ISCOM 
0.33 I± I (0/6) 22± 2 (616) 
1.0 2i 3 (516) 137± 2 (6/6) 
3.3 6± 4 (416) 258± 3 (6/6) 
10.0 21 3 (215) 18H 3 (5IS) 
Saline with AIPO~ Ii I (0/6) I± I (0/6) 
Saline with Qui! A I± 1 (0/6) Ii 1(016) 
Saline with ISCO~I empty Ii I (1/6) l± I (1/6) 
Saline Ii 1(0/6) I± 1(0/6) 
table 1: Anti~H44/76 OMV IgG antibody response after immunization with different antigen 
preselllatioll forms of P 1.7,16.Experimental groups of mice were immunized with an illcreasing dose 
of various presentationforms ofPl.7,16. A second injection was given ill a 4 week interval. Individual 
sera were analyzed at day 28 after first immunizatiol/ and at day 14 after secondmy immunization. 
Dala are presented as geometric mean SEM of 5 to 6 individual mice as indicated. IgG antibody levels 
are expressed as percentage of reference serum. The lIumber of responding mice is indicated between 
brackets. N.D. = IIO! dOlle, 
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After a boost immunization, all mice recelvlllg OMP-iscom and H44/76 OMY 
adsorbed to alum had developed IgG antibodies binding to H44/76 OMY. OMP-
Iscoms induced higher titers at low doses of antigen. 
After primary immunization a dose of 1.0-10 fig of IgG PLl6215 OMY or OMP-
iscoms was also sufficient to induce seroconversion in most but not all mice. After a 
boost immunization some mice immunized with the lowest concentrations ofPLI6215 
OMY (0.33 fig and 1.0 llg adsorbed to alum) still did not respond whereas at the higher 
doses of this antigen all mice responded with equally high titers as mice immunized 
with H44/76 OMY. Immunization with purified OMP adsorbed to alum or in the 
presence of Quil-A induced only low IgG anti-OMY antibody titers after a boost 
immunization indicating that no response against surface exposed OMP epitopes had 
developed. 
Anti-H44/76 IgM antibody responses after immunization with the various presentation 
fonns were rather low (data not shown). 
Antibodies to purified class 1 outer membrane proteins and to peptides 
corresponding with the main surface exposed loops of class 1 OMP 
At day 42 , 14 days after boost inm1Unization all groups had developed IgG titers 
against purified OMP as measured in ELISA as shown in table 2. The highest IgG 
response was observed in sera of mice inmlUnized with 3.3-10 llg of OMP mixed with 
Quil-A or I, 3.3 or 10 llg of OMP-iscoms. The highest response against peptides 
mimicking surface exposed loop I and loop 4 of the PI. 7,16 OMP was measured after 
immunization with OMP-iscoms. 
Relatively high anti-OMP IgG antibodies, as compared with OMY immunization, 
could be detected in sera of mice immunized with OMP with added Quil-A, especially 
since these sera did not contain any measurable anti-OMY antibodies (Table I). 
Small amounts of IgG anti-loop I antibodies could be measured in sera of mice 
immunized with H44/76 OMY, PLl6215 OMY and OMP- iscom. A relatively higher 
proportion of IgG anti-loop 4 antibodies could be detected in the same serum samples, 
especially the Iscom fonnulation at a dose of 3.3 ",g. 
Immunization with purified class 1 OMP adsorbed to alull! or in the presence of Quil-
A induced no or low IgG anti-loop I or loop 4 antibodies, again indicating that the 
response measured in these mice is not directed against surface exposed OMP 
epitopes. 
Analysis of IgM antibody levels to class I OMP and to pep tides in pooled serum 
samples of each group showed only limited increase of IgM antibodies as compared to 
the groups of mice immunized with adjuvant alone (data not shown). 
Subclass distribution of anti-H44/76 OMY IgG antibodies induced by the various 
presentation forms 
Immunization with OMP-Iscoms induced remarkebly high titers of anti-OMY IgG I at 
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low doses (1 and 3.3 Jhg) but relatively low titers of all other IgG subclasses tested 
(Table 3). Both OMY preparations induced anti-OMY antibodies of the IgGl, IgG2a, 
IgG2b and IgG3 subclasses. As expected, anti-OMY titers measured in mice 
immunized with purified OMP were low for all subclasses. 
It should be noted that the distribution of the subclass antibodies not only varied 
depending on the dose, but also that a large variation in subclass contribution in the 
anti-H44/76 OMY antibody response was observed among individual mice within one 
experimental group. 
Preparation and Anti-PI.7,16 Anti-loop I Anti-loop 4 
doseUlg) Pl.7 PJ.l6 
PLl6215 OMY + AW04 
0.33 6± 5 (4/6) 2± 2 (4/6) 3, 4 (3/6) 
1.0 2± 3 (2/6) I, 1(0/6) 2± 3 (2/6) 
3.3 35± 3 (6/6) I± 2(J/6) 14, 5 (516) 
10.0 64± 3(6/6) 3± 20 (J/6) 34> 2 (616) 
3. 1l0± 6 (6/6) 4± 3 (3/6) 35, 4 (6/6) 
H44176 OMY + AIP04 
0.33 5± 2 (4f6) 2t 2 (2/6) 4, 4 (4/6) I.. lOt 4 (516) 2± 3 (1/6) 12, 4 (516) 3.3 
10.0 21t 3 (6/6) I± 2 (1/6) 25, 3 (6/6) 47± 3 (6/6) 3± 2 (516) 24, 3 (6/6) 
Pl.7,16 + AlP04 14± 3 (6/6) I 6, 3 (4/6) 0.33 
I.. 41± 11 (5/6) I JO, 7 (516) 
3.3 61± 3 (6f6) I 2, 5 (J/6) 
10.0 69± 2 (6/6) I I, 2 (1/6) 
PL7,16 + Quit A 
I 0.33 21± 3 (5/5) I, 1(0/5) 
I.. 7l, 2 (6/6) 4 I, 1 (016) 
3.3 180± 2 (6f6) 6 I, 1 (0/6) 
10.0 215± 3 (6f6) 3 I, 1 (0/6) 
P1.7,16 in ISCOM 
4± 4 (4/6) 0.33 31± 6 (516) 13, 2 (6/6) 
1.0 280± 2 (6/6) 3t \2 (4/6) 103± 3 (6/6) 
3.3 232± 2 (6.'6) 2± 2 (4f6) 538± 3 (6l6) 
10.0 322± 2 (5/5) 16± 16 (4fS) 31± 11 (4/S) 
Saline I I I 
table 2: /gG antibody response to class I OkfP and to peptides corresponding with the maill sUl/ace 
exposed loop 1 alld loop 4 of class 1 Ok!P. Groups of 5 to 6 mice were immunized twice (4 'week 
interval be/ween immunization) with increasing doses of various antigens preselltation forms of 
P 1.7.1 6. /gG antibody levels to class I OAfP and to peptides corresponding with sw/ace e.\posed loop 
1 (Pl.?) and loop 4 (PI.16) outer membrane protein were determined 14 days after second 
immunization. Data are presellled as geometric mean SEAl alld are expressed as percelltage of the 
standard serum. 
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Prepara~_{~g) IgOl Igma IgG2b IgGJ 
and dose 
PLI621S OMV with AlPO, 
0,33 2± 4 (2/6) 4± 10 (2/6) 4± 5 (3/6) 4± 8 (2/6) 
1.0 7t 3 (5/6) I, 1 (0/6) 6± 7 (3/6) 1± 1(0/6) 
3.3 41± 5 (6/6) I, 1(0/6) IO± 2 (6/6) 4± 9 (2/6) 
10.0 90± 3 (6/6) 10± 18(6/6) 12± 4 (6/6) 20:1: 9 (4/6) 
30.0 34± 8 (6/6) 3t 6 (6/6) 77:1: 4 (6/6) 6± 25 (3(6) 
H44176 OMV with AIPO, 
0.33 4± 3 (4/6) I, 2 (6/6) 18± 2 (6/6) I, 2 (1/6) 
1.0 37± 6 (6/6) 4, 9 (6/6) 34± 2 (6/6) IS± 13 (4/6) 3.3 
10.0 41± 5 (6/6) 1I7t 7 (6/6) 94± 3 (616) 9, 3 (5/6) 90± 3 (6/6) 65, 9 (6/6) 142± 2 (6/6) 108:1: 12 (516) 
PL7,16 with AIPO, 10, 13 (3/6) I, I (1/6) 1± I (1/6) I± 1 (0/6) 0.33 
1.0 20, 18 (SI6) I, 1 (1/6) 2± 3 (116) 4± 7 (2/6) 
3.3 2, 6 (1/6) I, I (0/6) 1:1: 1 (0/6) I± 1(0/6) 
10.0 3t 7 (2/6) I, I (0/6) I± 1 (0/6) I ± 1(0/6) 
PI.7,16 with Qui! A 
0.33 I, 2 (0/5) I, I (O!S) 1± I (OtS) I± 1(015) 
1.0 I, I (0/6) I, 1 (0/6) I ± 1(0/6) I± 1 (0/6) 
3.3 I, 2 (1/6) I, 1 (1/6) 1± 1(1/6) I± 1 (1/6) 
10.0 2, 2 (2/6) 3, 2 (2/6) 1± 1(0/6) I± 1(0/6) 
PI.7.16 in ISeQ}.1 
0.33 17, 4 (5/6) 3, 2 (0/6) 2 ± 2 (2/6) I± 2 (116) 
1.0 IS2± 2 (6/6) S7t 9 (4/6) 12± II (516) 3± 5 (2/6) 
3.3 410± J (6/6) 16± 15 (6/6) 7:1: 4 (616) 2:1: 2 (3/6) 
10.0 70, 9 (SIS) 42:1: 21 (SIS) 20± 6 (SIS) 2± 3 (215) 
Saline witll AIPOI 
I, 1(0/6) I, 1(0/6) I± I (0/6) I± 1(0/6) 
I, I (0/6) I, 1(0/6) 1:1: 1(0/6) I± 1(0/6) Saline witll Qui! A I, 1 (0/6) I, I (0/6) I± 1(0/6) 1:1: I (0/6) Saline witll ISeOM empty 
Saline I, I (0/6) I, 1(0/6) I± I (0/6) I± 1 (0/6) 
rable 3. SlIbclass distriblltioll of allti-H44176 OMV IgG alltibodies ill NIl! mice illduced by differellt 
antigen presentation forms of P 1.7,16. Individual sera of 5 to 6 mice per experimental group were 
analyzed for allli-H44176 OMV IgG alltibodies two weeks after the secolld immunization. Alltibody 
levels are given as geometriC mean SEM and are expressed as percentage of a reference serum 
containing anti-H44176 IgGJ, IgG2a, IgG2b and IgG3 antibodies. Number of res pall ding mice and 
Ilumber Of mice tested after each immullization are indicated. 
Bactericidal activity of antibodies induced by various presentation forms of 
P1.7,16 
Immunization with PLI6215 OMV induced the highest anti -H44/76 bactericidal 
antibody titers at day 42 (Table 4). 
The mean bactericidal titer of antibodies generated after immunization with H44/76 
OMV and OMP-Iscom were comparable. Titers induced with purified OMP 
preparations were low in pooled serum samples. 
An increase in bactericidal activity was measured with an increasing dose of antigen, 
with respect to PLl6215 OMV, saturation was demonstrated with H44176 OMV and 
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OMP-Iscom. To investigate whether the bactericidal antibodies were directed against 
PorA P1.7,16 OMP, pooled serum samples of each of these three groups were analyzed 
for bactericidal activity towards a recombinant engineered group B meningococcus 
strain A8-6t (B:15:P1.5,2:L3,8), expressing PorA (P1.5,2) of strain 2996 (Table 4). 
Bactericidal activity towards this strain could only be demonstrated in sera of mice 
immunized with PL16215 OMY, which contains P1.5,2 PorA in addition to P1.7,16 
PorA. These data demonstrate the PorA specificity of the bactericidal response. 
Antigen preparation fonn and dose H44116 A8-6t (j>g) B;1.5:PI.7,1(i:L3,S B:lS:Pl.S,2:L3,8 
PLJ6215 mtV + AlPO. 
0.33 362± S (6
'
6) 512 
1.0 322± 11 (6'6) 2048 
3.3 9\2± 6(6/6) 2048 
\0 2S80t 2 (6/6) 4096 
30 325t± 2 (6.'6) 2048 
H44I76 QMY + AWO. 
0.33 128± 5 (6
'
6) <16 
1.0 1024± 10(5/6) <16 
3.3 1448± 2 (6/6) <16 \0 S12± 26(5/6) <16 
P1.7,16+AIPO. 
32 0.33 
1.0 57, 19(3/6) 
3.3 32 
\0 64 
P1.7,16+QuiiA 
64 0.33 
1.0 64 
3.3 32 
\0 64 
P1.7,16 in ISCOM 
IOl± to (5/6) 0.33 <16 
1.0 912± 2(6'6) <16 
3.3 JS24± 4(6'6) <16 
\0 1I76± 4 (515) <16 
Saline + AIPO, 32 
Saline + QuilA 32 
Saline + 15CO)'1 empty 32 
Saline 32 <16 
table 4: Bactericidal titers against N.melJil1gititis strain H44176 Gnd A8-6t i1l sera a/mice immunized 
with different anligen presentation forms a/meningococcal OMP, Bactericidal titers are expressed as 
the SEM ± SD oflhe reciprocal dilution yieldillg ill 50% killing of the bacleria. Number ofrespolldillg 
mice is givell ill brackets. Whell pooled sera were tested I/O SD or Illimber of respollding mice are 
shOWl/. 
Ollly mice thaI responded to straill H44176 were allalyzed for bactericidal activity 10 strain A8-6t. 
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figure 2: Reactivity of antisera alld Moabs all Western blots to separated proteillsji'om H44176 OMV. 
Strips 1-9 were incubated with immulle sera raised against the following antigens; J; PL16215 OMV, 
2; H44176 aMI', 3; aMP IVith AIP04, 4; aMP with Qui/-A, 5; OMP-iscom, 6; AIP04, 7; Qui/-A, 8; 
iscom matrix, 9; PBS. lalles 10-14 were incubated with monoclonal antibodies directed against the 
JollolVing meningococcal aMP; IO;«-PI.16, II; «-P1.7, 12; «-class 4 aMP, 13; «-class 5.5 aMP 
alld J 4; «-class 5,1 aMP. Strip 15 was illcubated with goal-allti-mouse IgG HRP conjugate ollly. 
Reactivity of antisera on Western blots to separated proteins frolll H44176 OMY 
The specificity of antibodies in pooled serulll samples (500 times diluted), two weeks 
after second ilmmmization was detennined by Western blotting against H44176 OMY 
(Figure 2), H44176 OMY contain all major OMP that are found in the wild type strain 
PorA, PorB, Rmp, Opa5.5, Ope and 5c and trace amounts an 82 kD OMP (Figure 1). 
As shown in figure 2 after immunization with all different antigen preparations anti-
class 1 antibodies could be demonstrated in sera. Only in mice immunized with H44176 
or PL16215 OMY preparations a response could be demonstrated against the 82kD 
OMP. Although this protein was only present in very low amounts in the OMY 
preparations it induced a strong antibody response, Also a response against a 20 kD 
OMP, most likely H.8, could be demonstrated following immunization with the OMY 
preparations. Only H44176 immunization induced anti class 3 OMP antibodies since 
this antigen is not present in the other antigen preparations. In general responses 
observed in immunoblotting experiments correspond with antibody responses in 
human vaccinee sera after vaccination with H44176 OMY (37). 
Sera from mice innnunized with purified meningococcal OMP and OMP-iscom 
reacted with class 1 OMP but also with class 4, class 5 OMP and the 20 kD OMP , 
These results indicate that the purified OMP fraction and the OMP-iscom contained 
trace amounts of OMP other than class 1 OMP, and that these OMP were 
immunogenic in the presence of adjuvanl. In Westel11 blot no difference could be 
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observed between OMP-iscom or purified OMP in combination with Quil-A. AIP04 is 
a weak adjuvant for class 5 OMP and the 20 kD OMP. Control imlllunizations (AIPO" 
Quil-A, iscom matrix or saline) did not lead to detectable antibody levels. 
DISCUSSION 
In this paper we demonstrate that meningococcal OMV and Iscollls containing 
meningococcal OMP are equally potent inducers of bactericidal antibodies in mice. We 
show that OMP-iscoms induce fourfold higher IgG I titers as compared with OMY 
preparations. IgG2a, IgG2b and IgG3 titers were lower in mice immunized with OMP-
iscoms as compared with OMV preparations. Moreover, innnunization with OMP-
iscoms results in the induction of 15-fold higher IgG responses directed against a 
peptide which mimicks a surface exposed class I OMP specific bactericidal epitope 
(loop 4). 
Anti-OMP antibodies could also be generated by immunization with purified OMP in 
the presence of alum or Quil-A. However these antibodies, did not show complement 
mediated killing and could not bind to OMV. 
Sera raised to either meningococcal OMV and to OMP in iscom demonstrated 
comparable complement mediated killing of meningocci ill vitro, OMV containing 
mainly PorA, being the most potent inducer of bactericidal antibodies. The bactericidal 
activity of antibodies is dependent on the amount, specificity, affinity, subclass and 
ratio of complement activating and non-complement activating antibodies 
(38,39,40,41). OMP-iscom induced mainly IgGl whilst OMV induced antibodies of all 
IgG subclasses. Whether this has been of any influence on the total amount of 
bactericidal activity measured in sera raised to OMP in iscom is not known. The 
correlation between anti-OMV IgG antibodies and bactericidal activity to 
meningococcal strain H44/76, as measured in individual sera of mice immunized with 
either various doses ofPL16215 OMY, H44/76 OMV or OMP-iscom, was rather low 
(0.65,0.29 and 0.47 respectively). The different isotype pattent induced by iscom with 
a preference for the IgG 1 subset suggest a stronger Th-2 type response. 
Bactericidal antibodies generated with OMV might be directed to PorA, PorB, or 
OpalOpc. In innnunoblot (Figure 2) it was demonstrated that all antigen adjuvant 
combinations induced an anti-P1.7,16 response and antibodies directed against Rmp. 
Antibodies binding to other meningococcal OMP (82kD, OpalOpc) were detected in 
pooled sera of mice innllunized with PL16215 OMY, H44/76 OMY and OMP-iscom. 
Anti-PorB antibodies could only be demonstrated after immunization with H44/76 
OMV since this is the only antigen preparation containing these antigens. The 
bactericidal antobodies induced were dependent upon the subtype specific epitopes of 
PorA as demonstrated by the use of isogellic target strains containing P1.5,2-PorA 
instead of P1.7,16-PorA (Table3). A correlation of 0.61 exists between bactericidal 
activity against H44176 and serum IgG reactivity with peptides corresponding with 
surface exposed loop 4 of PorA. Murine PorA specific bactericidal antibodies are able 
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to bind to loop I and loop 4 linear peptides (30). Presumably these sera contain a rather 
large proportion of functional antibodies, reactive with native surface epitopes. 
These findings support the idea that only antibodies to conformational surface exposed 
epitopes are able to show complement mediated killing (7,30). 
Sera raised to meningococcal OMY and to OMP-iscom showed similar reactivities to 
OMY in ELISA and to linear peptides corresponding to surface exposed loops I and 4 
in ELISA. For both presentation forms, antibodies were mainly formed to peptides 
corresponding to loop 4 but OMP-iscoms induced much higher levels of such 
antibodies. Another possibility is that loop 4 is belter recognized by the immune 
system since it is more exposed as compared to loop I and is more exposed in iscoms 
as compared with OMY. These data suggests that the OMP in Iscom is present in an 
orientation that resembles that of the OMP in the bacteria and in vesicle formulation, 
although Iscoms are micellar rather than vesicular structures (35). Kersten et a!. 
demonstrated that the chymotrypsin susceptibility of OMP of Neisseria gOllorrhoeae in 
iscom and in OMY was similar (33). The finding that Iscom vaccines induced much 
higher responses to purified class I OMP and loop 4 as compared to OMY vaccines 
may indicate that incorporation of purified class 1 OMP into Iscom leads to a different 
conformation. Antibodies to the purified class I OMP as observed by Western blot and 
ELISA were found in sera of mice immunized with all antigen presentation forms of 
PI.7,16. Data from ELISA showed that anti-purified OMP antibody responses were 
highest in sera of mice immunized with OMP mixed with Quil-A and OMP- iscom. 
Quil-A was found to have a better adjuvant effect for the induction of an immune 
response to purified OMP as compared to AIPO,. 
OMP-iscom also induced a stronger anamnestic response as compared to OMV. These 
observations confirm results of other studies in which a T-cell independent polyclonal 
Bcell activating character of OMP was suggested (7,40). It is also in line with results 
from clinical trials showing rapid antibody declines and poor boosting responses 
induced by OMV vaccines. However, meningococcal OMP do contain strong T-cell 
epitopes (43, 44). Different activation of T helper cells such as leading to different 
activation ofTh, and Th, cells by AIP04 (OMY vaccines) or Quil-A (iscom vaccines) 
may also explain the difference in isotype distributions and primary responses. 
In conclusion the confonnation and presentation of PorA is important for the induction 
of antibodies able to kill meningococci. The immunogenicity of meningococcal PorA 
in Iscom is comparable to PorA in OMY. The dose of specific antigen (PI.7,16) 
needed to induce maximal immune responses was equal for PL16215 OMY, H44/76 
OMY and P1.7,16 in iscom. The PL16215 OMY was the most potent inducer of 
bactericidal antibodies, OMP-iscom induced a stronger anamnestic response. Both 
OMY and iscom are multimeric presentation fonns and possess intrinsic adjuvant 
activity (Quil-A and LPS respectively). Each of them has advantages and 
disadvantages (4,32,15). A major point in favour ofOMY is that they can be prepared 
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more easily as compared to Iscoms. A possible advantage of iscoms is that they are 
very stable structures when stored frozen or freeze-dried. In our hands' a 
meningococcal OMY vaccine has been stable at 4°C for more than three years without 
loss of structural integrity or immunogenicity in mice. OMY vaccines to Neisseria 
lIIellillgitidis serogroup B strains are being studied in humans at the moment (5,29,20). 
The use of OMP in is com might be an alternative vaccine fonnulation capable to 
induce antibodies with bactericidal activity. 
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Basic knowledge of the mechanisms underlying the effects of adjuvants and adjuvant 
systems, is important for the development of vaccines against several infectious 
diseases for which no effective vaccines are available and against newly emerging 
infectious diseases (Kaufmann, 1997). More efficient antigen presentation fonns are 
therefore required for the presentation of viral, bacterial and parasite antigens (Nossal, 
1997). Also for vaccines which require high amounts of antigen to induce adequate 
immune responses, like rabies vaccine, adjuvation is needed to reduce the cost (Tsarev 
et aI., 1997). In this thesis the evaluation of two different antigen presentation fom1s, 
iscom and OMV, which are both tested in human trials at present (personal 
conullmunication Osterhaus; Peeters et aI., 1996), is described. Each of these 
presentation fonns has its advantages and disadvantages and neither one of them can 
be considered the only and ideal vehicle to present all possible antigens. Not all 
vaccines need to be adjuved or require a specific presentation fonn. Live vaccines in 
general can do without any adjuvant (Bemstein, 1998). Inactivated human polio 
vaccine contains about I fIg formaldehyde inactivated vims of tlu'ee different 
serotypes (Salk et aI., 1982). Without the addition of any adjuvant this vaccine has 
proven to be very efficient and safe (Salk et aI., 1984). In comparisoll p-propiolacton 
inactivated rabies vims contains about 200-300 Ilg viral protein, and is adjuved with 
the classical adjuvant used in humans, Alum (AlOH or AIP04) (van Wezel et aI., 
1978). In rabies vaccine production the amount of RV antigen that can be produced is 
a bottleneck, thus more efficient ways of presentation are urgently needed. Bacterial 
vaccines are usually administered in high doses and adjuvated with alum. Moreover 
some components of bacterial vaccines, e.g. pertussis vaccine, contain LPS which 
possesses high adjuvant activity (Nmmine and Olander, 1991). However, this 
component is also responsible for most of the negative side effects that are observed 
with DPT vaccines. In order to develop better presentation f01111s for non-replicating 
vaccines we studied the mechanisms underlying the innnune stimulating effects of 
both iscoms and OMV. To this end we analysed iscom as a model for viral and 
bacterial antigen presentation and OMV as a model for bacterial antigen presentation. 
In chapter 11.1. a labelling method for RV antigen and RV-iscoms is described which 
enabled us to investigate the localization of these antigens ill vivo after il1llnunization. 
Experiments revealed that two different subsets of macrophages are involved in the 
uptake and handling of these antigens. Labelled ll-propiolacton inactivated RV 
(RV-BPL) was found predominantly in the marginal zone macrophages and the red 
pulp macrophages whereas labelled RV-iscoms were localized in a small subset called 
marginal metallophilic macrophages (MMM). Iscom matrix containing no protein 
antigen but only Quil-A , cholesterol and phospholipids were also found in this 
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pal1icular subset suggesting that either the iscom structure or the presence of Quil-A is 
responsible for this phenomenon. Until now the involvement of this subset in antigen 
uptake (and processing) had not been demonstrated. Targeting to specific APC, such 
as those MMM, is considered to be one of modes of action of adjuvants. Targeting of 
antigens to mucosal surfaces is described in chapter II.2. The specific uptake of iscom 
in M-cells in Peyers patches in the gut was studied ill vitro. M-cells are APC draining 
the gut lumen and are involved in the generation of a mucosal itmnune response. This 
response is not essential for the protection against rabies but is considered imp0l1ant 
for other pathogens. Particulate antigens used as a control like inactivated virus or 
polystyrene microparticles were not taken np at all or very badly in the M-cells in 
Peyers patches. RV-iscom and lactobaccilllls were taken up very efficiently by M-
cells. Attempts to localize the antigens after oral administration were unsuccessful, 
probably due to degradation of the antigens in the stomach or, more likely for lipid 
structures, bile salts in the gut itself. Therefore for oral inm1Unization much higher 
amounts of antigen are required to induce relevant inunune responses (Mowat et aI., 
1993). Again, the findings described in this chapter and chapter 11.1. suggest specific 
targeting of iscom to certain antigen presenting cells. One of the approaches that can 
be used to study the role of these phagocytosing cells ill vitro or ill vivo is the removal 
of these cells fi-om the immune system. In chapter 11.3. a method is described for the ill 
vitro removal of macrophages from (mixed) cell populations. The method, which 
describes the use of chlodronate containing liposomes to eliminate macrophages is an 
adaptation of a method that has been described to kill macrophages ill vivo (van 
Rooijen and van Nieuwmegen, 1984). Murine macrophages are eliminated from 
spleen cell preparations within 4 hours. It is demonstrated that at least ill vitro tlus 
method has no adverse effect on the percentage of B- and T -cells in spleen cell 
populations. Moreover, no direct effect on B hybridoma cells could be measured with 
regard to proliferation or antibody production. In a system where human EBV 
transformed B-cells were used to present antigen to specific T -cells it was 
demonstrated that incubation of either B- or T-cells with chlodronate liposomes did 
neither influence antigen presentation by the B-cells nor the capability of the T-cells to 
proliferate after stimulation. Chlodronate containing liposomes were also used to 
remove spleen and liver macrophages ill vivo. 
The effect of depletion of splenic macrophages on the uptake of, and itmnune response 
against, different presentation fomls of RV antigen is described in chapter \lA. 
RV-BPL and iscom containing RV antigen were used to inununize macrophage 
depleted and control mice. In the absence of phagocytic cells in the spleen, antigen is 
still trapped in the red pulp and to a lesser extent in the peri arteriolar lymphocyte 
sheaths (PALS) for both antigen presentation fonns. The localization pattern in the 
main area of inunune response induction, the follicles, was unaltered after macrophage 
depletion. Functionally, the depletion of splenic and liver macrophages had no 
influence on the induction of specific antibody responses in both RV-BPL or 
RV-iscom immunized mice, even though the latter presentation fonn was clearly 
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associated with specific localization in the MMM. In RV-BPL immunized mice, 
macrophage depletion had no influence on proliferative T-cell responses. However, 
macrophage depleted mice that were immunized with RV -iscom showed a significant 
decrease in proliferative T-cell responses. These results confirm existing ideas on the 
spleen as a physical filter rather than an induction site for humoral responses and shed 
new light on the efficient role of iscom as antigen presenting moieties in relation to 
their specific ill vivo localisation patterns and only partial macrophage dependency. 
One of the possible advantages of using iscom for the presentation of viral antigens is 
their potential to induce MHC class I restricted CTL. In chapter II.5. priming of mice 
for CTL is described after immunization with both RV-iscom and RV-BPL. III vitro 
experiments revealed that these CTL are restricted by MHC class I molecules on the 
surface of the infected target cells. It is a remarkable finding that the inactivated form 
of the RV antigen is able to induce CTL even without the addition of any adjuvant. 
Although this has been described before in the RV system the finding is in contrast 
with results from other authors which indicate that induction of CTL require the 
presentation of antigen in particulate fonn or in the presence of suitable adjuvants. It 
shows that the use of iscoms for this particular antigen has no qualitative advantage, 
although it does have a quantitative effect, with regard to the induction of RV specific 
CTL after immunization. 
A different approach to enhance RV specific responses after vaccination is described in 
chapter II.6. The ill vivo administration of exogenous cytokines TNF -ex, IL-Iex, IL-2 or 
IFN-y on the immune response against rabies vaccine in mice was examined. Each of 
the cytokines increased RV specific IgG responses after primary and secondary 
immunization. IL-2 and IFN-y were very potent and led to an 77 and 50 fold increase 
in PD50 values respectively with a concomitant enhancement of virus neutralizing 
antibodies. When administered together IL-2 and IFN-y synergistically enhanced 
VNAb responses. The timing of cytokine administration proved to be very important 
as it was demonstrated that IFN-y was most effective when administered prior to 
vaccination. When IFN-y was administered 2 -24 hours after vaccination VNAb 
responses and protection were dramatically lowered. 
In chapter III another antigen presenting system is described that is used to present 
meningococcal outer membrane proteins (OMP). Using meningococci manipulated to 
express three different subtypes of the class I OMP, outer membrane vesicles (OMY) 
were prepared. These vesicles are similar to iscoms in that they are a multimeric 
presentation fornl with a built-in adjuvant. The adjuvant in this case is the bacterial 
LPS that is a non11al component of the outer membrane and during the fotmation of the 
OMV is necessaty to maintain the structure and stability of these OMV. Chapter III.I. 
describes the production and characterization of a hexavalent OMY vaccine and its 
immunogenicity in mice. The vaccine described in tltis study lVas tested in a phase I 
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study in humans and is cunently tested in a phase II trial in infants. It was 
demonstrated that the OMV vaccine has no negative side effects and that the subtypes 
incorporated in the vaccine were immunogenic in humans (Peeters et ai., 1996; Rouppe 
van derVoort et ai., 1997b and 1998). 
Neisseria lIlellillgitidis OMP were also incorporated in iscom which made it possible to 
compare iscom and OMV as antigen presenting systems. Chapter III.2. describes the 
immunogenicity of different presentation fonns of (purified) meningococcal class 1 
OMP. In this study OMY and iscoms are compared with soluble OMP using Quil-A 
and AIPO, as adjuvant. It is clear from this study that solubilised neisserial class 1 
OMP are not able to induce a bactericidal antibody response. Both iscom and OMV 
were shown to induce functional antibody resposne although differences in isotype 
distribution were observed. 
Potential of Iscom and OMV based subunit vaccines 
Table 1 shows some aspects of the two antigen presenting moieties studied in this 
thesis, both adjuvant systems have advantages and disadvantages. From this table it 
becomes clear that both adjuvant systems, which are presently being evaluated in 
human trials, have a great potential of becoming routinely applied in human and 
veterinary medicine to combat and contain infectious diseases. Before discussing the 
advantages of both approaches, it should be realized that each suffers from the general 
drawback of non-replicating vaccines, that the amount of the immunizing antigen 
required is relatively high. However, due to the potent and long lasting inunune 
responses that appear to be induced by both presentation fonns, the amount of antigen 
needed is relatively low as compared to that needed for other non replicating vaccines 
based on inactivated viruses and microorganisms alone. 
Production aspects of is com and OMV vaccines 
One of the prerequisites for vaccine production is that production processes can be 
executed under good manufacturing practice (GMP) conditions. 
Antigens to be presented in iscom and OMY are usually produced by biological 
fennentation processes followed by down stream processing (DSP) procedures which 
lead to the final vaccine. When producing iscom vaccines, DSP typically consists of 
extraction and purification of the relevant antigen structures followed by incorporation 
in the iscom matrix. DSP in relation to OMV vaccines consists of extraction of the 
vesicles and purification/concentration which simultaneously removes large amounts 
of (free) LPS. OMY are relatively simple to produce since they can be obtained by a 
simple extraction. Cultivation of viruses and bacteria can be upscaled in fennenters for 
efficient antigen production. 
The observation that lower amounts of antigen induce good immune responses when 
incorporated into iscom could be useful in cases where antigen production is a limiting 
factor. During the fonnation of iscom however usually not all antigen is incorporated 
so this step should be optimized to take full advantage of the lower amount of antigen 
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needed. Optimal incorporation conditions will have to be detelmined for each antigen. 
Antigen production and immunogenicity are limiting factors of the production of RV 
vaccines especially when produced on continuous cell lines. Maybe a switch to iscom 
vaccines could promote the acceptance of cell substrates e.g. baby hamster kidney 
(BHK) cell lines for viral production. In general iscom are of interest where there is a 
limited amount of target antigens that can easily be incorporated or when specific 
immune responses are required that can not be induced otherwise. Large scale 
production of iscom is under development. Upscaling of iscom production is necessary 
if iscoms are to be considered as candidate for pediatric vaccines. A commercial 
veterinalY influenza vaccine has been on the market for several years now, 
demonstrating the potential of this vaccine teclul<ilogy (Mumford et aI., 1994). 
iscom OMY 
Induction of B cell responses 
-biologically active (virus neutralizatioll, bactericidal) + + 
-long lasting + NT 
-also in the presence of pre-existing specific antibody + +INT 
Induction of potent T cell responses 
-MHC class II restricted CD4+ + + 
-MHC class I restricted CD8+ (CTL) + NT 
-also iI/ the presence of pre-existing specific antibody + NT 
Induction of immunity upon local application 
-lIIllcosal imll/unity + NT 
-systemic immunity + NT 
Induction of protective responses + +INT 
Absence of toxicity 
-accepted for registered vaccine + + 
Suitable for large scale production 
-well defined production technology + + 
-very stable vaccine + + 
-sterilefiltratioll possible (0.22fllll) + -
table 1: shows the relevant immunological, toxicological, and economical aspects of is com alld OMV 
based vaccines. NT: not tested. 
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It may not always be necessary to incOl1l0rate the antigen in the iscom stmcture as it 
was shown that influenza antigen in combination with Quil-A matrix elicits equally 
high antibody responses as influenza antigen incol1JOrated in iscom (Lovgren and 
Sjolander, 1996). For primaty responses the amount of Quil-A required was higher 
when antigen and Quil-A were not present within the same stmcture. 
An advantage of iscom is that they are very stable stmctures that can be stored for 
prolonged periods of time when frozen or freeze dried. Another advantage ofiscom is 
that unlike OMY they can be sterilized by filtration (0.22 fun). 
One of the issues in development of OMY vaccines are the DSP requirements. 
Vesicles are easy to obtain but hard to purify. The procedures described in chapter 
III.!. involve high- and ultra-speed centrifugation steps that can be used for large scale 
production. Unlike iscom, OMV are not formed after mixing of individual 
components. Instead they are fonned naturally by some bacterial strains as so called 
blebs. The biological function of these blebs is unknown but it has been speculated that 
the bacteria use blebs to fool the immune system. Blebs may bind antibodies and 
complement and in this way some of the invading pathogenic bacteria can survive in a 
hostile environment. Blebbing can be promoted by the addition of DOC. Treatment of 
bacteria with DOC results in the massive fonnation of OMY and at the same time in 
the complete inactivation of the bacterium. Purification of OMY that form spontane-
ously during the cultivation process would require an additional inactivation step to 
guarantee safety of the vaccine. Temperature inactivation (56°C) works velY well with 
the N.mellillgitidis vaccine strains (data not shown). However it is not known how the 
antigenicity is affected of the antigens present in the OMY, not whether temperature 
inactivation has any influence on stability of the vaccine. With respect to inactivation 
DOC extraction guarantees a safe vaccine. 
Also there are some steps in the described process that are susceptible to microbial 
contamination from the environment. This is of some concem since, unlike iscoms, 
OMY can not be sterilized by 0.22 fun filtration. Therefore these steps should be 
validated or replaced by steps in which the risk for contamination is absent. 
Replacement with other purification methods e.g. ultrafiltration and column 
chromatography is under development and may result in the possibility to produce 
batches of preferably at least 50000 doses each to satisfy the needs of vaccination 
programs. The consistent production of suitable biomass is central to an effective 
production process. Optimization and upscaling of large scale felmentation processes 
are the means to achieve this. Such a process has been described for a group B 
Neisseria mellillgilidis, including a chemically defined medium and event based 
harvest conditions, resulting in consistent production of 5 gil biomass under GMP 
conditions (Fu et aI., 1995). 
Real time stability studies have shown that the experimental OMY vaccines are velY 
stable structures in AIPO, adjuvant. Four years after production these OMV are still 
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similar to the original product with regard to structure (EM), antigen composition and 
immunogenicity in mice. OMV are velY much like the surface of the original 
pathogen. They lack the capsular polysaccharide (CPS) but contain all the OMP and 
LPS. Since not all OMP are relevant for protection it was decided to knock out these 
genes and replace them with class I OMP genes (van der Ley et a!., 1995). In this way 
it was possible to construct vaccine strains that express class 1 OMP but no or 
relatively low amounts of other OMP. 
Studies will have to be initiated to investigate whether OMV can be combined with 
other pediatric (meningitis) vaccines. Other vaccines will most likely be 
polysaccharide-protein conjugate vaccines that are stable as freeze dried preparations. 
It is not k.nown whether OMY can be freeze dried and retain their inullunogenicity. 
T cell responses induced by iscom immunization 
It has been demonstrated in many papers that iscom are efficient inducers of T-cell 
immunity. Both MHC class I and class II restricted reponses can be shown after 
immunization with iscom vaccines. 
Functional class I restricted CTL may add to or may even be necessary for the 
induction of protection against most viruses and against other intracellular pathogens. 
CTL could be demonstrated against a wide variety of pathogens after immunization 
with iscom (Takahashi et a!., 1990; Jones et a!., 1988; Hsu et a!., 1996; Tarpey et a!., 
1996; Heeg et a!., 1991). The induction ofMHC class I restricted CTL appears to be 
associated with the use of Quil-A as an adjuvant (Newman et a!., 1992) since 
liposomes that contain Quil-A and ovalbumin also support the generation of a CTL 
response (Lipford et a!., 1994). The Quil-A containing iscom are targeted to different 
cellular subcompartments involved in the generation of peptide/MHC complexed that 
are recognized by the T-cells (van Binnendijk et a!., 1992; Heeg et a!., 1991; Villacres 
et a!., 1998). Iscom can target the antigens to both endosomal and cytosolic pathways 
for antigen presentation. 
Efficient intemalization of the antigen containing iscom also is dependent on the nature 
of the incorporated antigen. Iscoms containing influenza virus membrane proteins were 
intemalized 50 times more efficiently than ova containing iscom (Villacres et a!., 
1998). 
Within the l' helper subset the generation of either Thl or Th2 type responses can 
detelmine the outcome of infection. Iscom are able to induce both type of responses to 
some extent (Sjolander et a!., 1997; Maloy et a!., 1995; Villacres-Eriksson, 1995). This 
is not always beneficial for the induction of protection, for example in the case of 
vaccination against leisl1ll1aniasis (Sjolander et a!., 1998b). 
After vaccination with influenza virus iscom moderate to strong IL-2, IL-4 and IFN-
gamma responses could be demonstrated (Sjolander et a!., 1997). As demonstrated in 
chapter 11.6. of this thesis, IL-2 and IFN-gamma have a strong positive effect on the 
immune response against rabies vaccine. It is therefore tempting to conclude that the 
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stronger Iymphokine responses after vaccination with iscom vaccines are responsible 
for the higher immune responses. However in IL-4 and IFN-gamma knock out mice 
normal immune responses were observed after both parenteral and mucosal 
immunization with ovalbumin containing iscom (Smith et aI., 1998). 
T -cell responses after immunization with OMY vaccines 
One of the goals of OMV vaccine development was to be able to induce a T-cell 
dependent immune response and memOty for the immunizing antigen. Isotype switch, 
level of inununoglobulin synthesis, affinity maturation and the development of a 
secondary booster response are all T- cell dependent phenomena. To study whether 
vaccine induced T-cell responses were generated two independent approaches were 
followed. In a small scale efficacy study in three human voluteers it was found that 
proliferative T-cell responses could be measured after the first and second 
immunization (Rouppe van del' Voort et aI., 1997b). After a third booster 
immunization no T-cell responses could be measured in any of the volunteers 
vaccinated with the Dutch vaccine. Naess (1998) demonstrated high boostable T-cell 
responses that con-elated well with the development of specific IgG titers in volunteers. 
The differences between the Norwegian OMV vaccine and the Dutch OMV vaccine 
are many. Differences that may be associated with differences in the inunune 
responses are: wild type LPS versus GalE mutant LPS, differences in protein 
composition especially the different amount of Opa and Opc, and the use of AIOH 
instead of AIPO, adjuvant (Table 2). An increase in the presence of CD45RO+ 
(memory) T- cells could be measured as well. Wiertz et al. (1991 and 1996) 
demonstrated that unvaccinated, primed by infection, healthy individuals possess T-
cells that recognize peptides con-esponding to class I and class 5 OMP sequences. If 
other proteins than class I are necessary for the induction of memOlY they should be 
included in the vaccine strain. 
OMV but not purified PorB protein could recall responses in B I 0 mice that had been 
immunized with peptides con-esponding to PorB sequences (Delvig et aI., 1997). In 
experiments in mice OMV derived from HI-5, a meningococcal strain that lacks class 
I OMP, induced T-cell proliferative responses that were even higher than those 
obtained with H44176 OMV immunization (own observations). Further studies are 
necessary to determine the nature of the T-cell response against antigens incorporated 
in OMV. Specificity of the T-cells involved should be studied as well as the question 
whether they belong to the Thl or Th2 subset. Establishment of ill vivo or ill vitro 
measurements of Iymphokine pattems will provide some insight in this matter. In this 
respect the role of (modified) LPS and the way in which it influences responses is 
interesting. LPS or LPS derivatives mainly induce Thl type responses (Johnson et aI., 
1990) in mice wereas aluminum adjuvants are known to induce Th2-type responses 
(Mancino and Ovary, 1980). 
Meningococcal group B OMP are used as canier for peptides and polysaccharide 
antigens to render them T-cell dependent. Proteasomes containing these OMP can 
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serve as carrier as well (Levi et a!., 1995). 
In a recently executed clinical trial in adult volunteers it was demonstrated that OMV 
are immunogenic even without the addition of alum adjuvant but that responses after a 
booster vaccination were higher when the vaccine was absorbed as compared with 
unabsorbed OMV. Absorption of OMV to AIOR reduced pyrogenicity in rabbits. A 
combination of serogroup C polysaccharide and OMV proved to be highly 
immunogenic, even without AIOR (Rosenqvist et al., 1998). 
Contents 
Total protein 
High mol. wt. 
ParA 
Subtypes 
PorB serotype 15 
Rmp 
Opa/Opc 
LPS, inununotype 
Phosholipid 
B CPS 
DOC 
AIP04 
AI(OH), 
Sucrose 
Thiomerseal 
PorA: class I outer Immbrane protein (OMP) 
PorD: class 213 OMP 
Dutch Vaccine 
100 ~g 
2% (80 kD) 
89%·90% 
P1.7,16;5,2; 19, 15 
P1.5 c, I 0; 12,13;7h,4 
absent 
7% 
3% 
10%, GalE (truncated) 
nd 
absent 
11 ~g 
1.S mg 
10 mg 
0.05 mg 
LPS: lipopolysaccharide 
Rmp: class 4 OMP (reduction modifiable protein) 
DOC: deoxycholate 
B CPS: group D capsular polysaccharide 
OpaJOpc: class 5 and class 5-like OMPs 
nd: not determined 
Norwegian Vaccine 
25 ~g 
5% (70 + 80 kD) 
33% 
P1.7,16 
38% 
12% 
15% 
7%, wildtype (L3, LS) 
8% 
< 0.065 l'g 
4 ~g 
1.67 mg 
9mg 
0.05 mg 
fable 2: Vaccine composition of one human dose (0.5 m!) of the Dutch and Norwegian aMV vaccines. 
(with permissiontakenji-om: Meningococcal vaccines. A continllous crusade? (1998) E. ROllppe van 
der Voort, thesis, Free University Amsterdam). 
Induction of protection by iscom 
Protection against a variety of bacterial, parasitic, and viral diseases, can be 
demonstrated after vaccination with iscom vaccines. Comparison with other adjuvants 
demonstrate that responses after iscom vaccination are usually higher, and also 
different with regard to induction of specific cellular immunity (Coulter et al., 1998; 
Rimmelzwaan et al., 1997; Ben-Ahmeida et al., 1993; de Vries et al; 1994). Protective 
levels of innl1unity against influenza virus infection could be demonstrated after 
parenteral or local application (Ghazi et al., 1995; Ben-Alnneida, 1994; Rimmelzwaan 
et al., 1997). 
Cross reactive protection against influenza virus could be demonstrated and was 
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associated with the induction of cross reactive CTL (Sambhara et ai., 1998). 
Protection against measles virus infection, in the presence of preexisting antibodies, in 
macaques was demonstrated (van Bilmendijk et ai., 1997; Osterhaus et ai., 1998). This 
demonstrates that iscom may be attractive candidate vaccines in cases were matemal 
antibodies are present. 
From the data presented in this thesis one may conclude that the adjuvant effect of 
antigen incorporated in iscom is quantitative rather than qualitative when responses are 
compared with an unadjuvated inactivated RV antigen. Less antigen is needed to 
induce immune responses and protection against RV infection. In studies performed 
by Fekadu (Fekadu et ai., 1992) it was shown that RV-iscom are superior for post 
exposure treatment when compared with a widely used human diploid cell vaccine. 
Protection could be induced with glycoprotein containing iscom in mice. 
Iscom vaccination does not allways lead to protection against infection or disease 
(Hulskotte et ai., 1995). After ilmllunization of cats with feline immunodeficiency 
virus iscoms, virus neutralizing antibodies could be demonstrated but the animals were 
not protected against a challenge with the virus (Huisman et ai., 1998). After 
vaccination enhancement of infectivity may be seen illstead of protection (Siebelink et 
ai., 1995) which is probably attributable to virus specific antibodies (Robinson et ai., 
1989; Schutten et ai., 1994). 
Induction of protection by OMY 
A number of efficacy trials with OMV based meningococcal vaccines have been 
conducted since 1987 in Cuba, Brazil, Norway and Chile. Estimated efficacy varies 
between 50% and 83% largely depending upon age (Bjune et ai., 1991; Cassio de 
Moraes et ai., 1992). Bactericidal and opsononizing antibodies, specific for all off the 
OMP, could be demonstrated after immunization with the Norwegian vaccine (Aase et 
ai., 1995; Rosenqvist et ai., 1993, 1995; Sjursen et ai., 1990; Delvig et ai., 1995; 
Guttonllsen et ai., 1993). Complete protection however was not provided by the 
vaccine since some of the vaccinees contracted the disease (Wedege et ai., 1998). 
Immunization with the Dutch vaccine gave rise to class I OMP specific antibodies 
(Rouppe van del' Voort et ai., 1996, 1997a). The vaccine described in this thesis is 
cUlTentIy being tested in infants and children, but no data are available yet on 
protective levels that can be reached. The approach to include multiple subtypes into a 
single vaccine should give a broad coverage against infection with meningococci. 
Recently it was demonstrated that after intranasal administration of the Norwegian 
vaccine persistent local and systemic bactericidal antibodies (Haneberg et ai., 1998a, 
1998b) OMY can be used as adjuvant/canier system for intranasal application as well 
(Levi et ai., 1995). 
Toxicological aspects of is com and OMY based vaccines 
Large scale application of most adjuvants is hampered by toxicological problems that 
may occur after application. As mentioned earlier both iscom and OMV contain 
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adjuvants that are potentially hannfid but may also be essential for their adjuvant 
activity. 
Low doses of Quil-A in iscom are preferable because of the toxic nature of Quil-A. 
Quil-A in matrix or iscom is less toxic than Quil-A in its free fonn (ROIUlberg et aI., 
1995). Mixing of antigen and Quil-A matrix may work well for antigens that have a 
multimeric stl1lcture by themselves (e.g. inactivated vil1lses) (Lovgren and Sjolander, 
1996) but almost certainly will not work with monomeric antigens (peptides or 
recombinant proteins), but it may be an alternative for RV-iscom. For other viral 
antigens (measles vil1ls, HIV) the quality of the immune response may be more 
relevant. 
Quil-A is the unique component that is absolutely necessary for the formation of 
iscom. Quil-A is a mixture of Qllillaia saponins extracted from the bark of the tree 
Qllillaja sapal/aria Malil/a. Purification of Quil-A components has led to the insight 
that it is composed of fi'actions that differ in toxicity and adjuvant activity. Studies by 
Kensil (for review see Kensil, 1995) have led to the widely studied component QS-21 
that can be purified from cl1lde Quil-A. Kersten showed that of the individual fractions 
that can be obtained after separation of crude Quil-A by HPLC only very few peaks are 
able to fonn iscom structures (Kersten, 1990, thesis Utrecht). 
Crude Quil-A was purified in three components and each of these components was 
tested for its ability to fom1 iscom matrix and for toxicological properties. Fractions 
were isolated (QH-A and QH-C) that contribute to the fom1ation of iscoms and have 
low toxicity (ROIUlberg et aI., 1995; Behboudi et aI., 1995,l996,and 1997). An attempt 
to chemically detoxifY QH-B, a Quil-A fi'action with high adjuvant and toxic activity, 
resulted in a fraction with low toxicity but that was unable to fonn classical iscom 
structures (Ronnberg et aI., 1997). Iscoms with a defined quillaja triterpenoid 
formulation named QH703 are presently tested in human trials (Morein et aI., 1998a 
and b). From these results it becomes clear that iscom vaccines with acceptable side 
effects can be realized. 
LPS is an important component of the OMY stl1lcture. It is necessmy for the integrity 
of the lipid bilayer. If too much LPS is removed during down stream processing 
protein aggregates are forn1ed instead of vesicles. These aggregates were found to be 
non immunogenic. On the other hand one would like to develop a vaccine, which is 
intrinsically low in toxicity. It was shown that LPS, when present in vesicles or 
liposomes, has greatly reduced toxicity. OMY demonstrate low pyrogenicity in rabbits 
(Frederiksen et aI., 1991; own observations). Furthennore in a placebo controlled 
clinical trials ordy mild side effects were observed (N0kleby, 1991; and Peeters et aI., 
1996). Studies on the genes that are involved in the biosynthesis of LPS may provide 
insight in how to genetically alter the lipid-A core to render it less toxic while still 
retaining its adjuvant properties. Chemically modified monophosphoryllipid-A (MPL) 
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has a reduced toxicity but high adjuvant activity. It is not known whether this would be 
the same for meningococcal lipid-A which possesses two phosphate groups. Another 
possibility to reduce toxicity might be the addition or removal of one or more fatty acid 
side chains of the lipid-A structure. It remains to be established whether 
meningococcal LPS biosynthesis genes can be altered to result in the of LPS with 
reduced toxicity while still retaining its adjuvant activity. 
It has always been assumed that LPS is an important component of the Neisserial outer 
membrane and hence of the OMV structure. LPS is supposed to be necessary for the 
integrity of the membrane. Recently however viable Neisseria isolates have been 
described that are free of LPS in their membrane (Steeghs et aI., 1998). If however, 
too much LPS is removed during DSP the vaccine no longer contains vesicles but 
merely aggregates of proteins. Since the confomlation of these proteins is not identical 
to the membrane bound can be expected to be lower and less functional. On the other 
hand one will want a vaccine to be intrinsically low in toxicity. It was shown that LPS 
when present in vesicles or liposomes has greatly reduced toxicity. 
The contribution of LPS as an adjuvant in OMV vaccines still has to be established. It 
seems very likely however that the high immunogenicity of antigens in OMV can 
partly be explained by the fact that antigen and adjuvant (LPS) are incorporated in the 
same particle. It has been demonstrated that the length of the carbohydrate chain of the 
LPS has a drastic effect on the bactericidal response to PorA (class 1 OMP) in mice 
(Andersen et aI., 1997a). This demonstrates that adjuvant activity ofLPS in vesicles is 
not detennined by the Lipid-A part alone. Purified meningococcal serogroup B OMP 
that were complexed to group C polysaccharide, a LPS free OMP vaccine, was used in 
a vaccine study in Chile. This vaccine contains no LPS and the proteins are not in their 
natural confonnation. Significant protection could be demonstrated in volunteers 5 to 
21 years of age but not in younger children. The experiments described in chapter III.2. 
of this thesis show that these responses are comparable with the same antigens 
incorporated in iscom with Quil-A as an adjuvant. In these expetiments however OMY 
were adjuvated with alum. Studies involving liposomes containing antigen in the 
absence or presence of LPS can answer these questions. A prerequisite is that 
liposomes can be prepared in which antigen and LPS are incorporated in the membrane 
rather than being captured inside the liposomes. 
In evaluating the role of LPS in OMV vaccines it should be considered that anti LPS 
antibodies play a role in the protection against bacterial infections as well. It has 
therefore been postulated that OMY vaccines should contain various LPS 
immunotypes (Andersen et aI., 1997b). 
Concluding remarks 
Iscom and OMV are interesting candidates for antigen presentation in the development 
of new generations of vaccines. [scoms are more widely studied than OMV and have 
shown a great potential as antigen presentation form for a wide variety of protein 
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antigens. Antigens derived from viruses, bacteria, mycoplasmatales (Abusugra et a!., 
1997) and parasites have been successfully incorporated into iscom (for review see 
Morein., 1998b). Relevant B- and T-cell responses and protection have been described 
against wide variety of antigens in various animal systems. Iscom can induce relevant· 
immune responses in the presence of maternal antibodies (van Bi11llendijk et aI., 1997; 
Osterhaus et a!., 1998a). Polyvalent subunit vaccines incorporating virus, bacterial, 
and parasitical epitopes in the same particle are feasible (Sjolander et a!., 1998a). 
Moreover iscoms are also suitable for mucosal vaccination (Hu et a!., 1998). Side 
effects described are limited and the purification of Quil-A components with low 
toxicity will lead to even safer iscom vaccines (for reviews see Morein et a!., 1998a, 
1998b and Osterhaus et aI., 1998b). 
In view of the above, iscom should be seen as an antigen presentation/adjuvant system 
with great vaccine potential especially for those viral infections and diseases for which 
at present no efficacious vaccines are available. 
OMV vaccines are more restricted in their potential application. In this thesis vaccine 
candidates were studied using homologous expression of membrane proteins in 
N.lllellillgitidis. The literature describes also meningococcal OMP as carrier/adjuvant 
for foreign antigen structures (van de Verg et a!., 1996). Recently it was demonstrated 
that OMV can be used for mucosal vaccination. The induction ofT-ceIl responses has 
been demonstrated but their relevance has to be established. Other bacteria are known 
to produce vesicles and could be used as vaccine strains. Recombinant DNA 
teclmiques could allow the heterologous expression of bacterial, viral and parasitic 
proteins in bacterial OMP. Theoretically in this way OMY could develop into broad 
range vaccine carriers. 
The magnitude and effectiveness of the induced inunune responses varies greatly with 
the choice of adjuvant and antigen, which emphasizes the need to study different 
vaccine/adjuvant formulations. Taken together the results presented in this thesis 
indicate that iscol11 and OMV are serious presentation fonns for new candidate 
vaccines against a number of viral and bacterial diseases. 
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Samenvatting 
Gedurende het hele leven wordt de mens gelnfecteerd met een grote varieteit aan 
microorganismen en virus sen die ziekten, soms met lethale afloop of blijvende 
restschade, kunnen veroorzaken. Ons lichaam beschikt over meerdere 
afweennechanismen om aan deze infecties het hoofd te bieden. Door middel van 
vaccinatie is het mogelijk het im1lluunsysteem op specifieke wijze voor te bereiden op 
de (eventuele) infectie met een pathogeen agens. Ongetwijfeld het grootste succes van 
vaccinatie is het wereldwijd uitbannen van het menselijk pokkenvirus geweest. In 
Nederland is door het grootschalig vaccineren van kinderen op jonge leeftijd het 
voorkomen van de typische kinderziekten fors tel1lggedrongen. Dit proefschrift 
beschrijft studies aan een tweetal "nieuwe" wijzen van vaccinformulering die lllogelijk 
een bijdrage kunnen leveren aan het elimineren van infectieziekten waartegen 
moment eel nog geen effectieve vaccins bestaan. 
Klassieke vaccins bestaan vaak uit verzwakte of "gedode" microorganismen of 
virussen die een inunuunrespons opwekken die uiteindelijk leidt tot bescherming. De 
huidige strategieen binnen de vaccinontwikkeling zijn er op gericht steeds betel' 
gedefinieerde antigenen in gezuiverde vortn te gebruiken in vaccins, om zodoende in 
staat te zijn gericht innnuunresponsen te stimuleren. Een algemeen nadeel van deze 
aanpak is dat deze zogenaamde sub-unit vaccins meestal slecht werkzaam zijn, tenzij 
er stoffen aan toegevoegd worden die het immuunsysteem extra stimuleren. Stoffen die 
in staat zijn op deze wijze te helpen bij een immuunrespons noemt men adjuvantia 
(afgeleid van het Latijnse woord ad}lIvare dat helpen betekent). Gezuiverde sub-unit 
vaccins worden slecht herkend door het inunuunsysteem omdat ze "te klein" zijn. Door 
meerdere sub-units in een deeltje te brengen kan de immuunrespons verbeterd worden. 
De antigeenpresentatiesystemen die in dit proefschrift beschreven worden, 
combineren, in hetzelfde deeltje, meerdere sub-units en een adjuvant. De onderzochte 
lllultilllere presentatievortnen zijn imllluun-stimulerende complexen (iscom) en 
buitenmembraan vesikels (OMY). 
In hoofdstuk 11.1. wordt een methode besclneven om geinactiveerd hondsdolheid 
(rabies) vitus (RY) en iscoms zichtbaar te maken in weefselcoupes met behulp van een 
fluorescentiemicroscoop. Hierdoor werd het Illogelijk te bestuderen welke cellen er 
kort na immunisatie betrokken zijn bij de opname en verwerking van de antigenen in 
deze vaccins, in muizen. Het bleek dat er twee verschillende sOOlten Illacrofagen in de 
milt een 1'01 spelen. Opvallend was dat iscoms, ook als ze geen antigeen bevatten, 
vool1lamelijk teruggevonden werden in de zgn. marginale metallofiele Illacrofaag 
(MMM), een celtype waarvan tot dusverre geen betrokkenheid bij de opname en 
verwerking van antigeen was aangetoond. Het sturen van de antigenen naar specifieke 
celpopulaties is een van de mogelijke werkingsmechanislllen van adjuvantia. Een 
goede bescherming tegen pathogene microorganismen statt op de plaats waar deze het 
lichaam binnen treden. Yaak zijn dat de slijlllvliezen van de neus, longen en dann 
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(mucosa). Technisch gezien is dit een grensvlak tussen binnenkant en buitenkant van 
het lichaam. Deze slijmvliezen beschikken over een eigen innnunologisch 
afweersysteem met daarin specifieke cellen die betrokken zijn bij de opname van 
(vreemde) antigenen. 
In hoofdstuk II.2. wordt beschreven hoe iscoms in de daml opgenomen worden door 
zgn. M-cellen. De opname van iscoms geschiedt veer efficienter dan de opname van 
andere (in grootte vergelijkbare) paliikel antigenen (RV en polystyreenbolletjes). 
Aileen lactobacillell werden op vergelijkbare wijze opgenomen in de M-cellen. De 
bovengenoemde experimenten ondersteunen het mogelijk gebmik van iscom voor 
orale vaccinatie. 
In hoofdstuk II.3. wordt een methode beschreven om il/ vitro macrofagen te 
elimineren. Aangetoond werd dat de beschreven methode, die gebmikt maakt van 
liposomen die gevuld zijn. met een voor macrofagen toxische stof (chlodronaat 
liposomen), geen effect heeft op het percentage B- en T-cellen. Ook werd aangetoond 
dat de B- en T-cellen na behandeling functioneel blijven voor wat betreft 
antilichaamproductie, antigeen presenterende capaciteit en antigeen specifieke 
proliferatie. 
Om te bestuderen of de fagocyterende cellen die in hoofdstuk II.l. bescln'even zijn van 
belang zijn voor de ontwikkeling van de immuunrespons werd de boven beschreven 
methode toegepast om il/ vivo lever en milt macrofagen te elimineren. In hoofdstuk 
II.4 werd aangetoond dat de depletie van de macrofagen geen invloed had op de 
localisatie van RV antigeen of iscom in de follikels in de milt. Antigenen werden nog 
steeds weggevangen in de rode pulpa en de periarteriolaire Iymfeschede. Er was geen 
invloed te meten op de specifieke antilichaam respons. Er was weI een significante 
afname te meten van de proliferatieve T-ce1 responsen na immunisatie met iscom in 
muizen die met chlodronaat liposomen behandeld waren. Deze resultaten ondersteunen 
geldende ideeen dat de milt met name een filterende functie heeft en geen rol in de 
inductie van de humorale immuunrespons. 
In hoofdstuk II.S. wordt beschreven dat zowel immunisatie met RV-iscom alsook met 
geinactiveerd rabies vaccin in staat zijn RV specifieke cytotoxische T-cellen (CTL) op 
te wekken. Met behulp van depletie experimenten werd aangetoond dat deze CTL 
MHC klasse I gerestricteerd zijn. De bevinding dat geinactiveerd rabies vaccin CTL 
activiteit kan opwekken is niet nieuw echter immunisatie met RV-iscom is efficienter, 
dwz er is mindel' antigeen nodig, voor het opwekken van CTL activiteit in vergelijking 
met rabies vaccin. De conclusie uit deze studie is dat iscom voor dit specifieke 
antigeen geen kwalitatief betere respons geeft maar weI een kwantitatief voordeel. 
Deze bevinding is van belang omdat voor de huidige rabies vaccins antigeenproductie 
een beperkende factor is. 
Een andere benadering om de respons tegen RV te versterken is beschreven in 
hoofdstuk II.6. De in vivo toediening van cytokinen TNF-a, IL-Ia, IL-2 en IFN-y op 
de immuunrespons tegen rabies vaccin werd bestudeerd. Elk van de cytokinen had een 
positief effect op de RV specifieke IgO respons. IL-2 en IFN-y bleken het meest 
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effectief met respectievelijk 77 en 50 voudige verhoging van de beschennende waarde. 
De adjuverende werking van IL-2 en IFN-y werd versterkt als zij beiden gelijktijdJg 
toegediend werden. Het tijdstip waarop deze cytokinen werden toegediend bleek 
cruciaal. IFN-y was het meest effectief als het voor de vaccinatie werd toegediend. 
Wanneer IFN-y 2 tot 24 uur na het rabies vaccin werden toegediend namen 
beschenning en de specifieke antilichaamproductie af. 
In hoofdstuk III wordt een ander antigeen presentatie systeem beschreven dat gebruikt 
wordt om Neisseria mellillgitidis serogroep B (een van de veroorzakers van 
hersenvliesontsteking) buitenmembraan eiwitten te presenteren. Van gemanipuleerde 
meningoccocen werden OMV gemaakt die gefonnuleerd werden tot een vaccin. Deze 
OMV hebben met iscom gemeen dat zij meerdere copieen van het antigeen bevatten en 
een ingebouwd adjuvant, in dit geval het bacteriele lipopolysaccharide (LPS). LPS is 
een nomlaal bestanddeel van de bacteriele buitenmembraan. 
Hoofdstuk II!.!. beschrijft de productie en karakterisering van een hexavalent OMV 
vaccin dat beschenning kan bieden tegen zes verschillende varianten (subtypen) van 
meningococcen B. Het vaccin dat in dit hoofdstuk beschreven wordt is inmiddels in 
diverse klinische studies getest. Een van de beschenning inducerende antigenen werd 
tevens ingebouwd in iscom waardoor het mogelijk werd de beide antigeen presentatie 
structuren te vergelijken. 
In hoofdstuk 1I!.2. worden iscom, OMV en gezuiverd antigeen met Quil-A en AlP04 
als adjuvant vergeleken in een studie in muizen. AIleen iscom en OMV konden 
beschennende antilichamen opwekken in muizen. Gezuiverde antigenen wekten wei 
een specifieke antilichaamrespons op, maar deze antilichamen waren niet in staat om 
ill vitro meningococcen te doden. Deze resultaten geven aan dat in iscom en OMV de 
betreffende antigenen in de juiste conformatie aanwezig zijn om een fUllctionele 
immuunrespons op te wekken. 
De resultaten in dit proefschrift geven aan dat zowel iscom als OMV serieuze 
presentatie vonnen zijn voor nieuwe kandidaat vaccins tegen een groot aantal virale en 
bacteriele infectieziekten. 
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Nawoord 
Nawoord 
He, he, eindelijk. Boekje klaar. 
Natuurlijk was me dit niet gelukt zander de steun van een aantal mensell. Vele mensen hebben 
op de een of andere wijze hun steentje bijgedragen maar een aantal van hen wil ik hier 
persoonlijk bedanken. 
In het bijzonder bedank ik natnurlijk mijn promotor Ab Osterhaus. Ab, samen met jou ben ik 
aan dit onderzoek begonnen en sarnen met jou heb ik het uiteindelijk ook afgerolld. Ook na je 
vertrek naar Rotterdam bleef je me bij iedere gelegenheid eraan herinneren hoe belangrijk het 
was om het proefschrift af te ron den. Ieder keer opnieuw was je bereid de draad weer op te 
pakken om zodoende weer een stukje verdeI' te komen. Bedankt voor je enthousiasme en je 
inspirerende begeleiding tot aau het einde. Ik vrees de laudatio die je gaat uitspreken. De 
bie11jes moetje maar een keel' terug komen halen. 
In de tweede plaats mijn co-promotor Jan Poolman. Jan, dankzij jOllW inbreng heb ik ingezien 
dat er tegell de diverse bacteriele infectieziekten ook nog het cell en ander gedaan moest 
worden. De samenwerking met LVM was voor mij de stimulans om vaccincontrole, met name 
ontwikkeliug, echt leuk te gaan vinden. Ik vind het jammer dat de afstaud te groat geworden 
is om zo nl! en dan billnen te lopen en te filosoferen over de nieuwe ontwikkelingen en 
mogelijkheden. 
"Broertjes zijn onbetaalbaar". Eric, jij had er meer last van dan ik dat mijn boekje niet afwas. 
Jjj was mijn "worst nightmare". Met grote regelmaat wist je me te herinneren dat mijn 
afrondingscoefficient voor verbeteril1g vatbaar was. Het aantal uitstaande etentjes is tot 
astronomische hoogten gestegen. De diverse "promoticboekjcs" die je voor me gemaakt hebt 
zijn inmiddels aan de vergetelheid ptijsgegeven. 
De directie en het management vau het RlVM wil ik bedanken omdat ze mij de gelegenheid 
gegeven hebben, naast mijn reguliere werk, aan dit proefsclllift te werken. De collega's 
biunen het RIVM met wie ik samengewerkt heb wil ik bedanken voor de prettige sfeer en de 
openheid van de discussies. Adrie en Ruud, dankzij jullie inzet verliepen aile 
proefdierexperimenten gesmeerd. 
Aile mensen met wie ik heh samengewerkt in de periode dat ik eerst in Rijswijk en daama 
Leiden bij TNO experimenten uitgevoerd heb wil ik bedanken, in het bijzonder Marjan van 
Meurs. Ik hoop wei dat TNO inmiddels een bewakiugssysteem heef! voor vriezers. 
De collega's van QC-EH\V, in willekeurige volgorde, Duco, Petra, Hellk, Marianne, Klaas, 
Hans, Lydia en Simone. Bedankt voor de fijne samenwerking en de rust die jullie me gegeven 
hebben am het boekje af te ronden. Sommigen van jullie hebben er lVat meer last van gehad 
dan anderen dat ik een aantal weken illco11lunicado was. Nu gaan we er weer samen tegen aan. 
Jolanda, jon wil ik speciaal bedanken. JOUIV multi-inzetbaarheid en je vennogen am mij op te 
jagen zorgen ervoor dat alles altijd lVeer op tijd klaar is. 
Pa en ma, bedankt. 
Eva, Hugo, Judith, vanaf nu gaan we weer leuke dingen doen in het weekend. Het 
eerstvolgende project wordt de glijbaan. Lieve Vera, bedankt voor je steun. Samen hebbenlVe 
deze berg overwonnen. Ik weet zeker dat we samen in staat zijn aile bergen te nemell en daar 
kijk ik vol verlangen naar uit. 
Iva. 
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